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I. INTRODUCTION 
 
Breast cancer is by far the most common 
cancer among women and after lung cancer the 
most lethal, accounting for 22% of all cancer deaths 
(1) . The vast majority of deaths are caused by the 
effects of metastasis, i.e. stage IV disease. The 
lifetime odds of getting breast cancer now stand at 
1 in 8, double the risk of 1940 (2).  
The most common clinical question in 
breast cancer concerns the risk of systemic 
recurrence after definitive primary therapy. This 
risk estimation is aimed at defining the need for 
systemic adjuvant therapy and patient prognosis. 
The classical basis of prognosis in breast cancer 
patients is the clinical and pathological Tumor 
Node Metastasis (TNM) staging, with the presence 
or absence of lymph node involvement being the 
most important prognostic indicator in primary 
breast cancer. Histologic grading, patient age with 
age under 35 being associated with poorer outcome 
and α-estrogen receptor (αER) and progesteron 
receptor (PR) assessment are not strong predictors 
of prognosis, but confer a modest effect on 
outcome, independent of tumour size and nodal 
status (3,4,5,6). Ongoing efforts to harness novel 
prognostic markers are aimed at fine tuning of 
prognosis in both node positive and node negative 
patients.  
The second most frequently asked question 
is whether information can be obtained to predict 
which therapy might be particularly advantageous. 
In this regard, the value of intracellular αER and 
PR status for predicting response to hormonal 
treatment is well documented (7).  
Given both the prognostic and particularly 
the predictive value of αER and PR in human 
breast cancer, several  analogs of estrogens and 
progestins have been radiolabelled and evaluated in 
vivo for receptor binding affinity and selectivity. 
Few of these ligands, however, reached the clinical 
stage. These include halogenated  substituents of 
estradiol and vinylestradiol (8,9,10). The clinical 
potential of these ligands has been recently 
reviewed (8). Overall, currently available data in 
humans do not substantiate a quantitative 
relationship between uptake of these estradiol 
radiolabelled agents and the content and binding 
characteristics of αER  
Recent major advances made possible by 
the development of new investigational techniques 
have broadened the interest from the intracellular 
αER and PR receptor to cell surface receptors and 
their cognate ligands that are upregulated in breast 
carcinoma and participate in the aberrant growth of 
breast cancer. These cell surface  receptors are 
subdivided in 3 superfamilies : (1) proteins formed 
of a core structure of seven transmembrane α-
helical sequences with intracellular coupling to 
trimeric G-proteins, the so called G-protein coupled 
receptors (GPCR’s) ; (2) large glycoproteins which 
generally possess a single transmembrane sequence 
and tyrosine kinase activity grouped into 4 families 
(see figure 2) on the basis of sequence homology of 
their kinase domains, their structure and the 
structural similarity of their ligands, the so called 
Tyrosine Kinase Receptors (TKR’s); and (3) 
molecules which span the cell membrane once but 
do not have kinase activity, the non-tyrosine kinase 
receptors (NTKR’s). The final common pathway 
for most of these receptor systems is activation of a 
kinase cascade culminating in activation of  
extracellular-signal-regulated kinase (ERK). This 
serine/threonine kinase translocates into the cell 
nucleus where it propagates the mitogenic signal by 
way of phosphorylating and activating appropriate 
transcription factors to induce the expression of 
genes necessary for initiating the cell division cycle 
(see figure 1) (11,12,13,14). The increased 
knowledge on the biological properties and the 
relationship of these potential oncogenic receptor 
systems to the clinical behaviour of breast cancer 
has led to the development of novel therapeutic 
strategies and could provide an impetus for the 
development of novel radioligands.  
 
II. WHY NUCLEAR MEDICINE TO ASSESS 
CELL SURFACE RECEPTOR EXPRESSION 
WHEN OTHER METHODOLOGIES ARE 
ALREADY AVAILABLE? 
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Different methodologies, respectively 
northern blotting, ligand binding assays (LBA’s), 
immunohistochemistry (IHC), reverse trancript 
polymerase chain reaction (RT-PCR) and in situ 
hybridisation (ISH), each with a great variation in 
cut-off values have been used to assess cell surface 
receptor status leading to conflicting data (vide 
infra) e.g. prognostic value of HER-2/neu. As the 
size of the average tumour continues to decrease 
due to a more performant screening, blotting and 
ligand binding assays requiring bulk tumour 
homogenates are no longer possible in most  
patients. Thus IHC, ISH and RT-PCR will become 
more and more important. These techniques suffer 
from several drawbacks (15). Semiquantitative 
analysis of immunohistochemically stained tissue 
sections is operator dependent, requiring both 
judgement and experience of the observer, and 
resulting in a suboptimal reproducibility. Also, 
most antibodies recognise more than one molecule 
or epitopes. ISH is labour intensive and requires 
high sensitivity of the probes used. RT-PCR may 
lack specificity due to false priming. Most 
importantly, none of these techniques estimates 
receptor functionality.   
In contrast with these techniques and their 
shortcomings nuclear medicine offers several 
potential advantages. These include the in vivo 
whole body assessment capability for visualising 
“functional” receptor expression, the fact that 
radioligands are not subject to animal variation as is 
the case in antibody production, the absence of 
errors of sampling and tissue manipulation, as well 
as preparation, and the ability to address the 
intrinsic heterogeneity of receptor expression. 
However, to demonstrate these potential 
advantages, radioligands with very high tumour to 
background ratio’s will be needed to 
counterbalance the inherently low resolution and 
related partial volume effect of our gamma camera 
systems. As agonist- GPCR or - TKR complexes 
are internalised with the ligand being trapped in 
lysosomes, the emphasis should be on agonist 
radioligands for this entrapment will prolong the 
residence time of the ligands, resulting in higher 
tumour to background ratio’s than can theoretically 
be obtained with antagonists (16,17). Consequently, 
radiolabelled peptides, the naturally occurring 
agonists of GPCR’s, TKR’s and NTKR’s are more 
likely to yield high tumour to background ratio’s 
when compared to radiolabelled murine 
monoclonal antibodies which are not internalised . 
 
III CELL SURFACE RECEPTORS 
UPREGULATED IN HUMAN BREAST 
CARCINOMA  
 
STAGING AND FOLLOW-UP 
 
GPCR’s upregulated in human breast 
cancer specimens when compared to the 
surrounding normal breast tissue include the gastrin 
releasing peptide receptor (GRP-R), vaso-active 
intestinal peptide receptor (VIP-R) and 
somatostatin receptor (SS-R). Reported incidences 
of GRP-R, SS-R, specifically subtype 2, and VIP-R 
are 71%, 36-80% and 100 % respectively (18-23). 
Ligand binding to these receptors activates a G-
protein, which in turn activates or inhibits an 
enzyme that generates a specific second messenger. 
Depending on the subtype, GPCR’s stimulate 
mitogen activated protein kinases (MAPK’s) by 
increasing phosphatidylinositol turnover leading to 
activation of proteinkinase C and Raf or via Gβγ 
subunits, depending on their ability to stimulate 
phospholipase C resulting in activation of Ras (see 
figure 1.) (24).  
Upregulated TKR’s in breast cancer are 
shown in figure 2 (indicated in bold). The highest 
reported incidences are those of  PDGFb-R (platelet 
derived growth factor-b receptor, 86-100%), 
VEGF–R (vasoendothelilal growth factor receptor, 
KDR subtype, 100%),  IR (insulin receptor, > 80 
%) and IGF1-R (insulin-like growth factor-type 1 
receptor,  50-90%) (25-35). Significantly lower 
values were reported for the c-erb-B family, 
respectively 20-58 %, 17-30 %, 19-21 % for 
subtype 1 (EGF-R or epidermal growth factor 
receptor), 2 (HER-2 neu) and 3, and for the FGF-R 
(fibroblast growth factor receptor) subfamily, 32 % 
, 22 % and 4 % for subtype 4,1 and 2 (36-50). 
Unlike GPCR’s, which interact directly with an 
associated protein, TKR’s are linked indirectly to 
Ras via two proteins, growth receptor binding 
protein 2 (Grb2) and Son of sevenless (Sos) (see 
figure 1) and, with the exception of the type II 
subfamily, activated by ligand induced 
dimerization.  
NTKR’s upregulated in breast cancer 
include amongst others the leukemia inhibitory 
factor receptor (LIF-R) and the interleukin-2, 3, 5, 6 
and 11 receptors (IL-2,3,5,6,11 R) (51-57). 
Reported incidences for the interleukin family vary 
from 53-100 %, the highest incidence being 
reported for the beta subunit of the IL2-R 
(100%)(53). For LIF-R this value is 80 % (51). 
Contrary to CPCR’s and TKR’s, NTKR’s use 
multiple signalling pathways, the best known of 
which is the Jak-STAT pathway, a very rapid 
cytosol-to-nuclear signaling pathway.   
 
Thus, given their high reported incidence of 
expression in human breast cancer, radioligands 
guided against PDGFb-R, VEGF-R , VIP-R and 
IL2-R (beta subunit) seem to be of particular 
interest for staging. However, several facts need 
consideration. First, reported data have almost 
exclusively been obtained on primary tumour tissue 
and no extensive data on variability of receptor 
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expression between different nodal or metastatic 
lesions for these receptors are available. Second, 
specifically for VIP-R, the potential for 
overestimation of lymph node involvement due to 
high physiological VIP-R expression in lymph 
nodes, in the CD3 zone around lymphoid follicles, 
was stressed by Reubi (23,57). Finally, whether or 
not the degree of amplification of these receptors 
holds steady throughout the course of disease and is 
similarly amplified in subsequent metastases as has 
been suggested for HER-2neu and EGF-R,  a 
prerequisit for follow-up, needs to be resolved. 
Knowledge on these issues can only be obtained 
non-invasively by means of receptor radioligand 
scintigraphy . 
 
PROGNOSIS ASSESSMENT  
 
In terms of prognosis, the most thoroughly 
investigated cell surface receptors in breast 
carcinoma are HER-2/neu(c-erb-2) and EGFR and 
to a lesser extent IGF-1 R and IR. 
Using gene amplification, evidence for a 
role for HER-2/neu as a predictor of poor disease 
free survival and overall survival in node positive 
patients was first provided by Slamon et al. in 1987 
(58). Attempts to replicate these results however 
have had mixed success, with some studies 
observing that HER2-neu gene amplification was 
an independent predictor (59,60) and others failing 
to find any useful information (61-65). Using IHC, 
similar results were obtained with only one out of 
more than ten studies in node negative patients 
showing that HER-2/neu overexpression was an 
independent marker of poor prognosis (66-76). The 
role of EGFR and other cell surface receptors such 
as IR and IGF1-R, as prognostic factors in breast 
carcinoma is less well studied and even more 
controversial. Particularly for EGFR, multiple 
techniques have been used with great variation in 
the cut-off points used to define high and low risk 
subsets. In most, but not all, of these studies EGFR 
failed to be an independent predictor of disease free 
survival or overall survival in node positive breast 
carcinoma patients when mutivariate analysis was 
done (77). Of interest, a number of these papers 
found EGFR to have prognostic value in node 
negative breast cancer (78,79). Finally, a number of 
studies, using a variety of methodologies, suggest 
that IR and IGF-I R are independent favorable 
prognostic factors strongly related to disease free 
time in node negative breast cancer (80). 
Thus, in general, it seems that untill 
additional validation studies are done with a well-
standardized technique for measuring these 
receptors, the use of cell surface receptors in 
defining prognosis remains controversial and not-
usefull in clinical routine. In this regard, the 
availability of a technique able to assess 
“functional” receptor status is a more than exciting 
prospect. On theoretical grounds such a technique 
is likely to be more adequate. Importantly, 
estimates of receptor expression by means of 
nuclear medicine should be expressed as a 
continuous and reproducible variable as much 
prognostic information is lost or poorly presented 
by simple dichotomy or point scoring systems. This 
will require a rigid, uniform and standardized 
acquisition and processing protocol. Large numbers 
of patients in well defined disease stages, uniformly 
treated should be included in these studies to ensure 
that the results will be statisitically significant. It 
will then be possible to perform subset analysis and 
arrive at meaningfull conclusions. With increasing 
economic pressures and regulation, results obtained 
will need to be included in large, prospective 
intergroup studies comparing the accuracy of all 
available methodologies as is e.g. currently the case 
for the different immunohistochemic methods 
described for HER-2 neu expression. This will not 
be an easy task given the fact that nuclear medicine 
has no antecedents in this field and the use of 
radioactivity is to our disadvantage. 
 
PREDICTION OF RESPONSE TO THERAPY  
 
The need for prediction of response to a 
certain therapy in patients suffering from breast 
carcinoma is twofold. First, the classical assessment 
of response, based on volumetric changes, as 
defined by the Union International Contre le Cancer 
(UICC) response criteria, require an observation 
period of 2-6 months. Thus, with the exception of 
response to hormonal treatment which can be 
predicted with an accuracy of 60-70 % based on 
αER and PR status, non-responders are deprived of 
a potentially beneficial alternative treatment option 
for several months. Second, with an increasing 
number of patients receiving adjuvant therapy, the 
availability of a test that can predict successfull 
adjuvant therapy is becoming increasingly 
important as this treatment aims to cure patients.  
Recent direct and indirect evidence suggests that 
assessment of cell surface receptor status might 
offer at least a “partial” solution to both problems. 
A. Response prediction to conventional 
treatment modalities  
Adjuvant chemotherapy : The relationship between 
HER-2/neu expression and success of adjuvant 
doxorubicine containing chemotherapy was initially 
observed in several retrospective studies. These and 
more recent studies differ in type of chemo-
hormonal agents used for adjuvant treatment for 
breast cancer, in techniques and scoring systems 
used for HER-2/neu overexpression and in 
evaluation and interpretation of data (81). Examples 
of these subtleties and discrepancies in 
interpretation and evaluation are  the two large, 
recently published reports from the Cancer and 
Leukemia Group B (CALBG) 8541/8869 and the 
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National Surgical Adjuvant Breast and Bowel 
project (NSABP) B11. CALBG 8869 evaluated the 
relationship between HER-2/neu expression and 
dose response to doxorubicine (30 mg/m2 vs. 40 
mg/m2 vs. 60 mg/m2 per cycle) in a total of 992 
patients (82). The effect of dose intensity of 
doxorubicine on survival and disease-free survival 
was evident only in the HER-2/neu-positive group. 
Unlike the CALBG study, the NSABP-11 study 
provided a comparison of  a treatment regimen plus 
or minus doxorubicine and, therefore, a direct test 
of an interaction between doxorubicin and HER-
2/neu expression (83). In this trial, HER-2/neu 
overexpression was related to improvement in 
outcome to the same dose of doxorubicin 30 mg/m2 
at the lower end of the dose response curve in 
CALBG 8541. The interaction between 
doxorubicin treatment and HER-2/neu 
overexpression was statistically significant for 
disease free survival  and distant disease free 
survival. Thus it appears that response to 
doxorubicin-based adjuvant therapy depends on 
HER-2/neu status. However, a consenus on the 
most reliable, most reproducible and most 
predicitive method to determine HER-2/neu status 
is still mandatory.  
Neoadjuvant chemotherapy : Archer et al. 
evaluated the relationship between HER-2/neu 
expression and the ability of anthracycline-based 
neoadjuvant chemotherapy to induce apoptosis of 
tumour cells (84). The assessment of apoptosis was 
made through an apoptosis index defined by 
terminal deoxynucleotidyl transferase-mediated 
dUTP-biotin nick end-labelling (TUNEL). Their 
results demonstrated that this apoptotic index 
increased significantly less in nine patients with 
HER-2/neu overexpressing tumours than in 230 
patients with HER-2 negative tumours (34 % versus 
245 % respectively). 
Adjuvant endocrine treatment : Data regarding 
HER-2/neu expression and response to adjuvant 
tamoxifen are conflicting. Whereas the Naples 
GUN trial demonstrated that HER-2/neu expression 
implies a diminished response to adjuvant 
tamoxifen (85), the CALBG 8541and the NSABP 
B-11 trials did not demonstrate this interaction. 
These discordant findings likely relate to the use of 
different antibodies and different scoring systems 
for HER-2/neu expression assessment and suggest 
the need for reliable and reproducible 
methodologies to determine HER-2/neu expression. 
Ongoing intergroup studies by the North Central 
Cancer Treatment Group (NCCTG) and the 
NSABP trialists are now including prospective 
analysis of HER-2/neu expression by different 
methodologies while analyzing the role of 
trastuzumab (vide infra)  in an adjuvant setting. 
Endocrine treatment in  metastatic disease : In a 
series by Neskovic et al. in 106 newly diagnosed 
patients, a high EGF-R status was found to be 
highly predictive for non-response to endocrine 
treatment in metastatic breast cancer patients (86).  
B. Response prediction to novel treatment 
modalities 
Currently designed cytostatic anti-cancer strategies 
interfering with the autocrine/paracrine cell surface 
receptor/hormone loops, include blocking 
monoclonal antibodies, peptide hormone 
antagonists, peptide/toxin fusion proteins and 
inhibitors of signal transduction. 
Blocking monoclonal antibodies: Trastuzumab or  
muMAb 4D5 (Herceptine R), a murine monoclonal 
antibody against the extracelullar part of HER-
2/neu given concomitantly with first line 
chemotherapy for metastatic  breast cancer  
improves time to progression (7.6 vs. 4.6 months) 
and overall response ( 48% versus 32 %) when 
compared to chemotherapy alone in a phase III 
multinational study evaluating 469 patients (87). 
The one year survival data increased significantly 
with the addition of Herceptine (68 % vs. 79 %, p < 
0.01). Patient eligibility in this study was 
determined by testing tumour specimens for 
overexpression of HER-2 neu by means of IHC 
using a 4 point scoring system ( 0-3+).  Only 
patients with tumour score 2+ and 3+, the currently 
FDA approved patient group for Herceptine 
treatment, were included. Retrospective analysis 
suggested that the beneficial effect of Herceptine 
therapy was inferior in patients with a 2+ level of 
HER-2 protein expression when compared to 
patients with a 3+ level. Other studies suggest that 
patients with untreated or chemotherapy refractory 
metastatic breast cancer may also benefit from 
monotherapy with Herceptine (88,89). The major 
side effect of Herceptine is cardiotoxicity which 
becomes particularly relevant when combined with 
anthracycline (90). Specific guidelines for 
monitoring cardiac function in these patients are yet 
to be developped.  
Other potential blocking antibodies are 
2A11 and C225 which respectively recognise GRP 
and EGFR blocking their biological activity in both 
in vitro and in human in vivo studies (91,92). Yang 
et al. demonstrated that the assessment of GRP-R 
status using IHC allowed  prediction of growth 
inhibition of several breast carcinoma cell lines to 
2A11 treatment (93). Several other potential 
blocking antibodies against e.g. PDGF and VEGF 
have been descrided and are currently under 
evaluation  in tumour cell lines and xenograft 
models (94,95). 
Peptide hormone antagonists : Currently, several 
GPCR antagonists are being tested in phase I 
clinical trials e.g. the (Arg6,D-Trp,9, MetPhe8) 
substance P analogue which may prove usefull for 
treating breast carcinoma patients. Of interest, 
several papers demonstrate downregulation of 
EGF-R following effective administration of GRP-
R antagonists in animal tumour models suggesting 
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the tumour promoting effect of GRP involves 
transactivation and upregulation of EGF-R (96). 
Peptide hormone/toxin or chemotherapy fusion 
proteins : Another possibility is to utilise peptide 
hormones to vehiculate toxic compounds to tumour 
cells. As such recombinant diphteria toxin 
(DAB389)/EGF, IL-2 etc…hybrids, receptor or SP 
fusion proteins and hybrid doxorubicin 
/bombesin(GRP) hybrids have been constructed to 
selectively kill tumour cells expressing the 
corresponding receptor (97,98). The possible value 
of these agents in therapy will not only depend on 
their receptor specific targeting potential, but also 
on the toxicity on normal cells expressing these 
receptors. Thus selectivity of these agents can be a 
problem. 
Inhibitors of signal transduction : Finally, anti-
growth factor therapy can be accomplished by 
inhibiting molecules, involved in growth factor 
receptor signal transduction. Some of these 
molecules are close to or have already entered 
clinical trials, respectively : .(1) molecules such as 
tyrphostins, quinazolines and 2-substituted 
aminopyrido(2,3-d) pirimidones which can 
selectively inhibit tyrosine kinases including EGFR 
and PDGFR and TKR inhibitors against VEGFR-2 
(Flk-1/KDR) and basic FGFR acting as novel 
antiangiogenic anticancer agents, (2) Peptidyl 
phosphotyrosine analogs designed to bind at the 
Grb2 SH2 site inhibiting Grb2 binding to activated 
TKR’s, (3) farnesyl transferase inhibitors, blocking 
anchorage of Ras to the plasma membrane thereby 
prohibiting its activation and (4) modulators of 
proteinkinase C (PKC) which is particularly 
upregulated in node-negative breast carcinoma 
patients (99-103). Growth inhibition in vitro and in 
vivo by these agents is associated with 
downregulation of the targeted receptor on its cell 
surface.   
 
To maximize the benefit from new 
treatment paradigms, objective markers of 
therapeutic success are mandatory. From the data 
presented, it may be deduced that characterization 
of cell surface receptor systems in breast carcinoma 
will become increasingly important for therapy 
response prediction. With this regard, based on 
available data, targeted radioligands against HER-
2/neu and EGFR are of major interest. When 
compared to IHC , RT-PCR and ISH, the potential 
for whole body assessment will be a major 
advantage as clinicians prefer information on all 
lesions over information on only one lesion.  
Whether or not therapy response 
prediction will be feasible by means of one single 
scanning examination  remains to be proven. In 
general, high ligand uptake, indirectly reflecting 
receptor functionality and number may allow 
separation of responders from non-responders. 
Imaging prior to treatment should be sequential as 
an increase of tumour to background ratio’s from 
early to late images reflects ligand internalisation 
and thus receptor functionality. However, in  some 
tumours, levels of receptor expression are not 
proportional to the level of signaling. Low receptor 
levels with high signaling may occur as a result of 
breakdown of normal cellular asymmetry and 
spatial seggregation of the receptor and its ligand. 
For instance, EGFR’s are predominantly located on 
the basal part of the cell membrane of epithelial 
cells protecting them from overstimulation by high 
concentrations of circulating EGFR binding 
ligands. As such, receptor redistribution with a 
minor increase in apicocellular receptor number  
may result in a major upregulation of signaling 
loops. In this group of tumours, more accurate 
information on response to treatment could be 
obtained by repeating the scintigraphic examination 
shortly after treatment as effective treatment would 
result in downregulation of the functional receptor 
probably from as early as one week post-treatment.  
Efficiency of GPCR targeted treatment could also 
be visualised by means of sequential EGFR or other 
TKR visualisation before and after treatment, given 
their transactivation of these receptor pathways.  
 
IV. CONCLUSION :  
 
Nuclear medicine has the potential to significantly 
alter treatment planning and monitoring by offering 
therapy response prediction or early response 
assessment in patients suffering from breast 
carcinoma as well as prognostic information, by 
means of visualising cell surface receptors. For this 
purpose radioligands, preferably peptides, with high 
tumour to background ratio’s and rigid, uniform 
standardized protocols will be needed. The main 
cell surface receptors of interest are the TKR’s , 
with a specific role for  EGF-R and HER2-neu, 
followed by the GPCR’s. To guarantee their place 
in clinical practice these ligands will need to be 
evaluated in large muticenter studies requiring 
collaboration from various nuclear medicine centers 
and the respective clinicians involved in the 
management of patients suffering from breast 
carcinoma.   
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Figure 1 : 
Ligand binding to the tyrosine kinase receptor generally results in receptor dimerization and autophosphorylation of cytosolic tyrosine 
residues which serve as docking site for the src homology 2 (SH2) domain in the growth receptor binding protein 2 (Grb2). The two SH3 
domains in Grb2 then bind Son of Sevenless (Sos), a guanine nucleotide exchange factor, thereby bringing Sos clouse to membrane bound 
Ras. Ras is an intracellular switch protein that cycles between an inactive GDP-bound form and an active GTP-bound form. Binding of Sos 
to inactive Ras causes a large conformational change that permits release of GDP and binding of GTP. Thus activated Ras binds to the N-
terminal domain of Raf, a serine threonine kinase which subsequently binds to and phosphorylates MEK, a dual-specificity protein kinase 
that phosphorylates both tyrosine and serine residues. 
MEK than phosphorylates and activates MAP kinase (MAPK) which subsequently phosphorylates many different proteins, including nuclear 
transcription factors, that mediate cellular responses. 
Ligand specfic binding to a G-protein coupled receptor leads to dissociation of GDP, which is replaced by GTP, bound to the α-subunit of 
the heterotrimeric G-protein. Subsequently Gα.GTP dissociates from Gβγ.   Depending on the subtype, G-protein coupled receptors stimulate 
phospholipase C to release inositol (1,4,5)triphosphate(1,4,5)P3) and diacylglycerol (DG), which cause the release of intracellular Ca2+ and 
activate protini kinase C, either via Gα.GTP or via Gβγ subunits. Through Pyk2 and Src, G-protein coupled receptors are linked to the MAPK 
pathway.  
Eph 
Elk 
Eck 
Eek 
Erk
FGFR1 
FGFR2 
FGFR3 
FGFR4
PDGFRa 
PDGFRb 
c-kit 
c-fms 
IR 
IGF-1 R 
IRR 
c-erbB1 
c-erbB2 
c-erbB3 
c-erbB4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 
Figure 2 shows the different tyrosine kinase receptor (TKR) families. Upregulated TKR’s in breast cancer are indicated in bold. 
Abbreviations of relevance are explained in the text on staging and follow-up. 
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  3
THESIS OUTLINE 
________________________________________________________________
 
As early as 1936 Lacassagne proposed that if breast 
cancer was caused by a special hereditary 
sensitivity to estrogen, then the development of an 
estrogen antagonist could prevent the disease. 
Unfortunately, estrogen antagonists did not exist at 
that time and there was no therapeutic target. It was 
only in 1962 that the target was found by Jensen 
and Jacobson, who described the specific binding 
and retention of radiolabeled estradiol in estrogen 
target tissues. Jensen subsequently proposed the α 
estrogen receptor (αER) as the mechanism to 
modulate estrogen activity, leading to the 
development of numerous reversible and non-toxic 
endocrine deprivation treatment modalities of breast 
cancer. Even now, novel drugs targeted at blocking 
or reducing αER stimulation are about to enter the 
clinical stage including pure antiestrogens, potent 
and specific aromatase inhibitors and long acting 
preparations of LHRH analogues. Given the well 
documented value of intracellular αER status in 
human breast cancer for predicting response to 
these hormonal treatment modalities, several 
analogs of estrogens have been radiolabelled and 
evaluated in vivo for receptor binding affinity and 
selectivity. Few of these ligands however reached 
the clinical stage Unfortunately, available data on 
these halogenated substituents of estradiol and 
vynilestradiol in patients suffering from breast 
cancer fail to substantiate a relationship between 
uptake of these ligands and the content and binding 
characteristics of tumoural αER status as well as 
with outcome to hormonal treatment. As the 
mainstay of adjuvant- as well as palliative hormonal 
treatment for breast cancer is the anti-estrogen 
tamoxifen, assessment of radiolabelled tamoxifen 
uptake by means of nuclear medicine imaging 
might predict more accurately outcome to 
conventional hormonal treatment. 
Recent major advances made possible by the 
development of new investigational techniques 
have broadened the interest from the intracellular 
αER receptor to cell surface receptors and their 
cognate ligand that are upregulated in breast 
carcinoma and participate in the aberrant growth of 
breast cancer. The increasing amount of knowledge 
on the role of these cell surface receptors in 
proliferative signal transduction has led to the 
development of novel cytostatic anti-cancer 
strategies interfering with these autocrine/paracrine 
cell surface receptor/hormone loops. One of the 
many studied ligand/cell surface receptor systems 
in breast carcinoma is the gastrin releasing peptide 
(GRP)/ gastrin releasing peptide receptor 
(GRP/GRP-R) pathway which may effectively be 
blocked by the murine monoclonal antibody 2A11.  
 
This thesis describes the basic development of and 
the first methodological and clinical studies with 
123Iodine–dimethyl-N,N-tamoxifen (ITX) and 
99mTc RP527, radioligands for single photon 
emission tomographic imaging (SPECT) of human 
breast cancer, respectively targeted against the αER 
and GRP-R.  
In part I the available data on radiolabelled estradiol 
derivatives to predict response to hormonal 
treatment in breast cancer patients are reviewed and 
studies with ITX described, considering both 
technical and clinical aspects. 
In part II the rationale for GRP-R imaging in human 
carcinoma, including breast carcinoma, is reviewed 
and studies with 99mTc RP527 described, also 
considering technical and clinical aspects (phase 
I/II trials).  
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PART I : ESTROGEN RECEPTOR IMAGING IN BREAST CARCINOMA 
__________________________________________________________________________________________ 
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ABSTRACT 
 
Several radiolabelled steroidal and non-
steroidal estradiol derivatives of which the tumoral 
uptake is believed to relate quantitatively to the 
content and binding characteristics of the αER 
receptor in the target tissue have been synthesized and 
their imaging potential and clinical usefulness 
evaluated in vivo in humans. Due to the use of 
different methodologies and cut-off values for 
measuring αER positivity, the use of both 
quantitative PET and semiquantitative SPECT, and 
the difference in patient populations studied, direct 
comparison of these data is not possible. Individual 
data however fail to substantiate a direct relationship 
between these radiolabelled estradiol derivatives and 
αER status in keeping with recent pathophysiological 
findings demonstrating 1) estradiol sequestration and 
retention through other than αER mediated, either 
membrane or non-membrane related, mechanisms and 
2) an inverse relationship between estradiol uptake 
and local biosynthesis through aromatisation and 
interconversion in αER positive tumours. 
Additionally, given the discovery of very high 
affinity αER-like binding sites  (Kd, dissociation 
constant, < 0.1 nM), and the potential for 
underestimation of αER Kd when using ligand 
binding assays, at least part of radiolabelled estradiol 
derivative uptake reflects tumoral perfusion rather 
than the ligand-receptor binding process.  
However, the reduction in cellular uptake, 
membrane sequestration and local biosynthesis of 
estradiol following tamoxifen treatment in αER 
responsive tumors should allow early therapy 
prediction through rapid sequential radiolabelled 
estradiol scintigraphy with higher accuracy than 
conventional αER estimations as supported by recent 
data.  
 
 
I. INTRODUCTION 
 
Breast cancer is the most common malignant 
tumour among women comprising an estimated 24 % 
of all cancer cases, corresponding to an estimated 
184,300 new cases per year in the European 
Community (1). Because of its propensity to 
metastasise, even before the disease can be detected 
clinically or by screening mammography, breast 
cancer remains the most lethal cancer for women, 
accounting for 18 % (58,000/ year) of all cancer 
deaths (2).  
     Based on three main lines of evidence : (a) the 
ability of estrogens to generate mammary tumours in 
rodents, (b) epidemiologically derived risk factors 
such as the protective effect of ovariectomy and 
increased risk of breast cancer in young women given 
diethylstilbestrol to prevent abortion and (c) the 
mitogenic effect of estrogens on established breast 
cancer cell lines and efficacy of antiestrogens in 
treating established breast cancer, estrogens are 
believed to be the major adverse factor in human 
breast cancer (3,4,5,6,7). Consequently, numerous 
modalities of endocrine therapy, primarily aimed at 
estrogen deprivation with comparable spectra of 
activity, either ablative, additive or antagonistic, have 
been developped (8,9,10). The main mechanism of 
action of these cytostatic agents which are now 
largely used for adjuvant or palliative purposes, either 
alone or in combination with chemotherapy, is 
believed to be a block of division of estrogen 
dependent tumour cells with arrest in the G0 or G1 
phase of the cycle (11,12). Of these agents, the 
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principal and most frequently used is the anti-
estrogen tamoxifen.  
   Tamoxifen is used both in an adjuvant setting as 
well as for treatment of metastasized breast 
carcinoma. Whereas older studies such as the NATO- 
and Scottisch trial favored the systematic use of 
tamoxifen treatment in an adjuvant setting (13), a 
recent meta-analysis by the Early Breast Cancer 
Collaborative Study Group failed to demonstrate a 
beneficial effect on disease free and overall survival 
of adjuvant tamoxifen in estrogen receptor (αER) 
negative patients (14). Consequently, the most recent 
1998 Sankt-Gallen Conference Consensus advised 
against the use of adjuvant tamoxifen in αER 
negative patients, whatever their menopausal status. 
   Indications for tamoxifen treatment in patients with 
distant metastases include αER positivity, limited 
tumoral burden and the absence of life threatening 
conditions. Typical patients are those with soft tissue 
or bone metastases in the absence of liver 
involvement. If the hormonal receptor status is 
unknown, the choice for tamoxifen treatment is based 
on several prognostic factors such as age, disease free 
period, performance status and distribution and 
number of metastases.  
   Prediction to first line hormonal tamoxifen therapy 
in metastasised disease is based on αER 
measurements and the UICC (Union International 
Contre le Cancer) criteria. Since Jensens’ work (15) 
correlated response to adrenalectomy with the αER 
status of neoplastic tissue, similar observations have 
been made for all available hormonal treatments : the 
presence of αER, especially in high concentrations is 
associated with high rates of responsiveness, whereas 
the absence of αER’s or very low levels generally 
predicts failure (16,17,18). Most of the data on the 
clinical utility of αER content have been generated 
using biochemical ligand-binding assays (LBA’s) 
(19,20,21,22), such as the dextran-coated charcoal 
assay (DCA). Since the first report of its independent 
prognostic significance almost two decades ago (21), 
the assessment of αER status using LBA’s has been 
validated repeatedly and is generally regarded as the 
standard by which other methods are assessed. LBA’s 
are, however, technically challenging, expensive and 
require a relatively large amount of fresh frozen 
tissue. The development of highly specific 
monoclonal antibodies and immunohistochemistry 
(IHC) techniques to localise αER’s provided the 
potential to overcome most of the difficulties inherent 
to LBA’s (23,24,25,26). Compared with LBA’s, IHC 
is easier to perform, less expensive and applicable to 
a wider variety of samples. As with LBA’s, the 
ultimate usefulness of αER status assessment by IHC 
resides in its ability to predict responsiveness to 
therapy and clinical outcome. Most of the studies 
evaluating the clinical relevance of αER 
measurements by IHC have reported statistically 
significant relationships with clinical outcome. Direct 
comparison of these studies is, however, difficult as 
many different antibodies, detection systems with 
unequal sensitivities and specificities, and arbitrary 
calibrated definitions of αER positivity were used. 
Also, the majority of these studies evaluated patient 
populations of mixed clinical stage and treatment 
status, making it nearly impossible to separate the 
prognostic from the predictive implications of their 
results. Despite these largely unresolved issues, most 
laboratories today assess αER status almost 
exclusively by IHC on routine archival tissue 
samples.  
Results of the role of αER , measured using 
either LBA’s or IHC, as a predictive index of 
sensitivity to hormonal therapy have been 
summarized in several overviews (27,28,29,30). 
Whereas 60-70% of all breast cancers are αER 
positive tumours, only 50-60 % of these are 
associated with an objective response to ablative 
therapies. In contrast less than 10 % of the αER 
negative tumours are associated with objective 
response to ablative therapies. Thus, response to 
endocrine treatment can be predicted with an 
accuracy of 60-70%. While this is an improvement 
over random allocation, the issues of why 50 % of 
αER positive  tumours fail to respond and yet 10 % of 
αER negative tumours do respond still need to be 
resolved. Potential causes of discordancy between 
αER status and therapy response include sampling 
errors, tumoral heterogeneity, alteration of the 
antiestrogen ligand or the αER receptor, and 
antiestrogen cellular efflux (31,32).   
    The UICC criteria used to define objective 
remission, stabilization or progression are in general 
based on morphological imaging and hence on 
volumetric changes, with a significant reduction in 
volume usually ensuing at the earliest 2-3 months 
following effective treatment. Specifically for 
assessment of response to treatment of osseous 
metastases  the UICC criteria require sclerosis of lytic 
lesions as a sign of regression. However, some 
patients will have evidence of sclerosis in lytic 
lesions before starting therapy. Additionally, 
radiological evidence of response to successful 
therapy is often not evident for 6 months and may be 
delayed for more than 1 year (33,34). 
    Given the inaccurate predictive value of current 
αER measurements and the application of the UICC 
criteria, roughly 40-50 % of patients on first line 
hormonal treatment are deprived for at least  2-3 
months of a potentially beneficial other treatment 
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option. Accordingly, better methods for predicting 
clinical response to antiestrogen therapy are needed. 
In this regard several radiolabeled steroidal and non-
steroidal estradiol derivatives of which the tumoral 
uptake is believed to relate quantitatively to the 
content and binding characteristics of the αER 
receptor in the target tissue have been synthesized and 
their imaging potential and clinical usefulness 
evaluated in vivo in humans. This review is an 
attempt to place the available data in the perspective 
of recent pathophysiological findings. 
 
II. ER RADIOLIGANDS FOR IN VIVO 
IMAGING 
 
Over the last 20 years, several halogenated 
derivatives of estradiol, vynilestradiol (steroidal) and  
hexestrol (non-steroidal) have been synthesized (35-
52). Few of these agents however reached the clinical 
stage (figure 1). These include substituents of 
estradiol halogenated at the 16β position and 
vynilestradiol derivatives halogenated at the 17-
position, either in cis (Z) or trans (E) position . Most 
of these receptor radioligands (RRLs) fullfill the 
following three requirements : 1) high specific 
activity ( radioactivity per unit mass of the RRL, > 
1Ci/mmol), as receptors are saturable systems with 
limited uptake capacity in vivo,2) high receptor 
affinity with low non-specific binding, and 3) 
appropriate metabolic and clearance characteristics 
(53,54,55,56). Because of the high specific activity 
available with RRL’s and the concern regarding 
excessive dosimetry to humans, Kd ( dissociation 
constant) as a measure of affinity of the ligand to the 
receptor  should be in the range of 0.1-50 nM.  If 
affinity is too high ( Kd < 0.1 nM), the rate limiting 
step becomes a measure of flow rate or membrane 
transport, rather than the ligand-receptor binding 
process. If affinity is too low (Kd > 50 nM), the 
signal to noise ratio may be significantly decreased 
due to the large amount of unbound free tracer in 
circulation and tumour visualization may merely 
reflect vasculature or blood volume in the tissue of 
interest (57). Low non-specific binding and 
appropriate metabolic and clearance characteristics 
are required to obtain optimal tumor to background 
ratios allowing depiction of tumoral lesions .  
 
    In terms of uptake, Scharl et al. (63) using an 
indicator dilution technique that allowed monitoring 
of blood-tissue exchange of radioactivity in a 
continuous manner in anesthesized surgically 
prepared pigs with by-passed liver circulation. This 
technique showed rapid extraction of 125-
iodoestradiol (IES) for most organs including the 
lungs, central nervous system, intestines and spleen 
…after intra-arterial injection in vivo. However, 
within minutes the organs released the 125-IES in its 
original chemical form back into the vascular system, 
with the exception of αER rich tissues and the 
kidneys which retained the 125-IES in its original 
form ( although in the kidneys a nonpolar metabolite 
also accumulated). In humans, McNeil et al. (64) and 
James et al. (65), showed that following  infusion of 
tritiated estradiol and estrone into patients both are 
taken up and concentrated within the breast. The 
accumulation was selective but variable, being more 
marked in breast cancer tissue than in normal tissue 
and especially associated with estradiol. 
Concordingly, Duvivier et al. reported on the 
existence of a positive arterial-venous gradient for 
estradiol in the blood irrigating mammary tumours 
(64-6).  
 
III.  UPTAKE AND RETENTION OF 
ESTRADIOL AND RADIOLABELLED 
ESTRADIOL DERIVATIVES :   PASSIVE 
INFLUX AND  αER BINDING ? 
 
Levels of estradiol range from 0.2-1.7 
(mean: 0.4) pmol/g tissue and 0.2 - 0.5 (mean: 0.3) 
pmol/g respectively in pre- and postmenopausal 
normal glandular breast tissue compartments of 
mastectomy specimens. Breast adipose tissue also 
displays levels of estrogens markedly in excess of 
those in peripheral plasma but these consist mainly of 
estrone. For many of glandular breast tissue samples, 
tissue to plasma ratio’s tend to be higher than unity. 
In breast carcinoma, levels of estradiol tend to be 
higher than those found in normal breast tissue, 
ranging from 0.25 - 0.4 (mean: 0.7) and 0.15 - 4.0 
(mean: 0.75) pmol/g in pre- and postmenopausal 
women respectively. Furthermore, the levels in blood 
circulation exceed those in plasma by varying 
amounts, the excess differing enormously and 
sometimes reaching more than 100-fold 
(58,59,60,61). This striking and enormous variation 
in concentration of estrogens between different 
specimens of breast tissue relates only in part to 
menopausal status and the differences between 
normal and carcinomatous tissue (60). The reasons 
for such high concentrations of estrogen in breast 
tissue have been subject to substantial investigation, 
the results of which point towards either active 
biosynthesis within the breast and/or active uptake of 
steroid hormones form the circulation against a 
concentration gradient.   
The mechanisms by which this selective 
retention or uptake occurs are not well known. In 
general, estradiol uptake is believed to occur in a 
passive way with subsequent binding to αER’s. 
Theoretically, the high degree of lipophilicity  of  
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estradiol and radiolabelled derivatives could result in 
sequestration in adipose tissue and the plasma 
membrane of cells. Thus, the presence of significant 
amounts of adipose, stromal and epithelial tissue 
could partly account for the ability of breast tumours 
to retain estradiol or its radiolabelled derivatives. On 
the other hand, loss of either the stromal or adipose 
component of a tumour, or a reduced degree of 
vascularization, might be expected to also reduce a 
tumour’s apparent ability to retain estradiol or its 
derivatives. This however does not explain the 
reduced accumulation in several in vitro cell line 
models and the high uptake of estradiol in tumoral 
tissue relative to a predominantly fatty tissue 
background. Retention of radiolabelled estradiol in 
estrogen target tissues through specific binding on the 
αER target was first reported by Jensen et al. (67). 
The number of αER’s per cell is limited to 
approximately 10000 which translates to 1000 fmol 
(10-15 mol) receptor sites per mg of cytosolic proteins, 
corresponding Kd values are measured in the 
subnanomolar range (68,69). Recent discoveries 
,however, suggest that in addition to αER binding, 
active membrane related sequestration through steroid 
binding protein receptors (SBPR), high affinity 
binding sites other than αER and intracellular 
estradiol depot formation  are involved in the 
retention or uptake of estradiol .  
Active membrane related uptake or binding : 
Specific membrane receptors for sex steroid binding 
protein (SBP) were first described in human decidual 
endometrium and in hyperplastic prostate (70). 
Binding to these receptors, which are part of the G-
protein receptor family is time-dependent, specific, 
saturable and occurs with  high affinity (71). The SBP 
/SBPR interaction followed by the binding of 
estradiol to the complex protein/receptor causes a 
significant increase of the intracellular levels of 
cAMP ( figure 2) and a significant reduction of both 
estradiol induced cell proliferation and estradiol 
mediated increase of progesterone receptors. The 
interaction, however, does not increase the amount of 
estradiol entering estrogen responsive cells (72)  
rather  it “captures” an additional quantity of the 
hormone at the outer surface of cells.  In humans, 
cytoplasmatic SBP, exclusively found in epithelial 
cell cytoplasm, is present in half of non-invasive 
breast carcinomas, particularly in those that are highly 
differentiated, and in 67.5 % of invasive tumors 
regardless of subtype and differentiation (73). SBP 
receptors are present in  a higher percentage of αER 
positive tumours (75%) than in αER negative tumors 
(37%). Thus membrane sequestration of estradiol is 
likely to occur preferentially in hormone responsive 
tumors. 
Non αER intracellular estradiol binding sites  :  
Monje et al. detected specific and saturable 
(3H)17β-estradiol binding sites of high affinity (Kd= 
0.36nM) in uterine rabbit microsomes at higher 
concentration than in cytosol (370 + 98 vs. 270 + 87 
fmol/mg protein, respectively) (74). Use of 
monoclonal antibodies against the transactivation heat 
shock protein recognition and steroid binding 
domains of the nuclear estrogen receptor ( 67 kDa), 
revealed lower concentrations of the αER in 
membranes and the presence of five additional 
immunoreactive proteins of 57, 50, 32,28 and 11 kDa 
which were absent in cytosol. Moreover the antibody 
against the steroid binding domain was as effective as 
an inhibitor for cytosolic and membrane specific 
radioligand binding.  Similarly, in humans, Lopes et 
al. (75) demonstrated the presence of microsomal 
estrogen binding sites (Kd = 0.1-0.6 nM) likely 
related to cytosol ER recycling. Furthermore  these 
authors showed that the magnitude of estradiol 
binding to microsomes depends on the ER positivity 
of the tumors.  
    A second ER form , respectively βER, found to 
bind estradiol with a comparable Kd to αER was 
recently described (76,77,78). Its role in breast cancer 
aetiology and cancer biology, however, remains to be 
proven as  available data suggest that the amount of 
βER relative to αER in breast carcinoma is minor and 
most studies on βER have been based upon mRNA, 
rather than protein expression (79,80,81,82). 
    Additional high affinity binding  sites, other than  
αER and βER, but bearing ER characteristics were 
recently described by Masamaru et al. (83) Using 
osmotic minipumps to continously infuse 3H-
estradiol at rates producing serum concentrations 
ranging from pre- to postmenopausal levels for two 
weeks in oophorectomized Sprague-Dawley rats 
bearing nitrosomethylurea-induced mammary 
tumours, these authors were able to demonstrate a 
very high affinity, estrogen target tissue specific, 
estradiol binding component with a Kd two orders of 
magnitude lower (0.35x10-12) than determined with 
standard in vitro techniques. A second estradiol 
binding component with the expected αER Kd in vivo 
of 1-10x-10 M was also present. Estradiol bound to 
both classes of binding sites could be displaced with 
DES within a 6hr period. Additionally, whereas tissue 
to blood ratio’s were low in brain and muscle tissue 
(3:1), the ER-containing tissues, uterus and NMU-
induced mammary tumors, concentrated 3H-estradiol 
with maximal tissue:plasma gradients of 346:1 and 
32:1 respectively, when estradiol was infused at a rate 
of 1 ng/hr. However, when estradiol was infused at a 
rate of 750 ng/h, these gradients fell to 4:1 and 2.5:1 
respectively, indicating that tissues concentrate 
estradiol to a greater extent at a low than at a high 
circulating estradiol level. Thus, it may be that the 
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actual binding estradiol affinity in target tissues in 
humans in vivo , especially at low estrogen 
concentrations, is much higher than  usually 
estimated from standard, in vitro αER assays. Siiteri 
et al. (84) came to a similar conclusion regarding in 
vitro measurements of the estrogen receptor. Siiteri 
noted that the free fraction of estradiol present under 
in vitro conditions is underestimated because of the 
high concentrations of additional low affinity 
estradiol binders in tissue. Using isodialysis 
techniques to measure actual amounts of free 
estradiol under in vivo incubation conditions, Kd 
values for the αER were 2-fold lower than with the 
use of conventional in vitro methods.  
Estradiol depots 
In vitro, when incubated with estradiol, human 
mammary tumors have the ability to synthesize long 
chain fatty acids esters linked to estradiol at the 17-β 
position, the so called lipoidal estrogens (E-L). E-L 
remain exclusively in the cytosol and can behave as 
long acting estrogens because of their slow hydrolysis 
resulting in release of estradiol (85). The enzyme 
responsible for formation of E-L ,  fatty acylCoA: 
estradiol-17β acyl transferase, is present in both αER 
positive and αER negative tumours. Its contribution 
to estradiol retention however is likely low as 
suggested by available data presented by Adams et al. 
(86). These authors found that following exposure to 
5nM tritiated estradiol, extensive and specific binding 
of estradiol to αER in MCF-7 and ZR-75-1 cell lines, 
occurred before appreciable synthesis of E-L was 
evident and the maximum level of E-L attained was 
only 3-9 % of the amount of estradiol bound to αER.  
 
In summary, it is unlikely that uptake of radiolabeled 
estrogens merely reflects binding to αER and cellular 
uptake, sequestration and retention through other 
mechanisms, either membrane or non-membrane  
related, have to  be considered. Additionally,  given 
the discovery of the existence of very high affinity 
αER-like binding sites ( Kd < 0.1 nM), and the 
potential for underestimation of αER Kd when using 
LBA’s, part of cellular radiolabeled estradiol 
derivative uptake may reflect tumoral perfusion rather 
than binding to receptors.  
 
 
IV IS THE AMOUNT OF RADIOLABELLED 
ESTRADIOL UPTAKE CONCORDANT WITH 
αER STATUS AND COULD IT BE USED TO 
PREDICT  RESPONSE TO HORMONAL 
TREATMENT ? 
 
Besides enhanced uptake from blood, in situ breast 
carcinoma estradiol synthesis in postmenopausal 
women contributes significantly to the high 
intratumoral estradiol concentrations found in about 
70 % of breast carcinoma patients (87,88). Both in 
vitro and in vivo studies have shown that breast 
tissues have the capacity for estrogen biosynthesis 
and interconversion through respectively, 
aromatisation of androgens to estrogens and 
(predominantly) interconversion of estrone to 
estradiol (figure 3) (89,90,91).  Although activities 
are low, they are comparable to those in other 
peripheral tissues and in vivo represent pmol amounts 
of estrogen being produced locally within the breast.  
The enzymes responsible for aromatisation and 
interconversion, respectively aromatase and sulfatase, 
have been detected in both αER-positive and αER-
negative tumors (92,93,94). However, aromatisation 
and interconversion seem more likely to be of 
biological significance in αER-positive tumors. In 
both pre- and postmenopausal women, the activity of 
sulfatase is 50-200 times higher than that of 
aromatase (95,96).  
    Using dual isotope techniques, Reed et al. (97) 
showed that in postmenopausal women with breast 
cancer the extent to which endogenous estrogens 
derived either from uptake or from in situ production 
is very variable between different individuals. It 
seems that certain breast carcinomas obtain all 
estrogens from uptake, and others from in situ 
synthesis, wbut that the majority acquire estrogens 
from both sources. Consequently, no significant 
correlation between tumor in vitro aromatase or 
sulfatase activity and endogenous estrogens has been 
reported (98,99). In vitro as well as in vivo 
experiments suggest that both enzymes are under the 
control  of estrogen in ER-positive cells, allowing 
protection of αER against excess estrogen (100,101). 
For instance, tumor cells deprived of estradiol adapt 
by increasing their level of aromatase, developing the 
capability to become more sensitive to estrogen 
precursors. Thus αER positive tumors displaying high 
local estradiol biosynthesis are likely to show a low 
estradiol uptake and vice versa. Finally, Yue et al. 
(102) demonstrated that tumors deprived of estradiol 
have the ability to adapt to estradiol deprivation to 
allow them to be responsive to four log lower 
amounts of estrogen than when studied under wild 
type conditions.  
Thus it seems that the tumoral need of 
estradiol to effectuate a biological effect is highly 
variable intertumoral and can vary over time 
intratumoral, depending on local environmental 
conditions. The local estradiol needs are provided 
through both uptake as well as local biosynthesis 
,which, in αER positive tumors are inversely related. 
Consequently, a lack of concordance between 
radiolabelled estradiol uptake and αER status is to be 
 18
expected and the predictive value of radiolabelled 
estradiol uptake for tamoxifen therapy response is 
likely to be limited. 
    Available data on imaging of radiolabelled 
estradiol derivative uptake in human breast carcinoma 
for measuring αER status in vivo are limited to 
halogenated estradiol 17β and vynilestradiol 
derivatives. Direct comparison of these data is not 
possible (table 1) owing to the  use of different 
methodologies and cut-off values for  measuring αER 
positivity, the use of both quantitative PET and 
semiquantitative SPECT, and differences in patient 
populations studied. Individual data, however, fail to 
substantiate a direct relationship between estradiol 
RRL uptake and αER status in keeping with 
pathophysiological findings. 
    Bromoestradiol : Using a pinhole collimator at 1 hr 
after injection of 150 mCi 16α-77Bromoestradiol-17β 
Katzenellebogen et al. were able to visualise DMBA-
induced mammary adenocarcinoma in mature female 
Sprague-Dawley rats (103). The average uptake ratio 
in their series was 6.27 and tumour uptake could be 
selectively depressed ( to an average ratio of unity) by 
treatment with excess estradiol. Biodistribution 
studies in the same rats showed that 16α-
77Bromoestradiol-17β was predominantly cleared 
through the liver and intestines and to a lesser extent 
urinary. Extrapolation of rat data to humans, taking 
into consideration the slower clearance half-time and 
increased urinary excretion of estrogens in humans, 
suggested an effective whole body dose of 0.03 
rad/mCi with the primary critical organs being the 
lower large and upper large intestine, dose received 
being 0.43 rad/mCi and 0.34 rad/mCi. In a small 
feasability study on eight patients, four of which 
suffered from primary and four from metastatic breast 
carcinoma, McElvany et al. found three abnormal 
scintigrams in patients with primary breast 
carcinoma, two of which were  biopsied and found to 
be estrogen receptor positive. By contrast two 
patients with advanced tumours on antiestrogen 
therapy showed negative results and one abnormal 
scan was obtained in an αER positive patient with 
chest-wall metastases (104). No uptake of tracer was 
seen in the single αER-negative primary tumour. 
However, despite the use of a diverging high energy 
collimator, a low tumour to background contrast was 
obtained due to high scatter from the 521 keV peak 
(23 % abundancy) of activity residing in the  liver, 
gallbladder and intestines.  
    Iodoestradiol : Given the identical in vivo 
behaviour in female Sprague-Dawley rats of 16α-
77Bromoestradiol-17β and  16α-(125I or 123I) 
iodoestradiol-17β and the favorable imaging 
characteristics of 123I, subsequent studies were 
performed using 16α-123 iodoestradiol-
17β (105). Preston et al. presented SPET data on 28 
breast carcinoma patients acquired 2 h following the 
injection of 50 µCi/kg of 16α-123 iodoestradiol-
17β (106). SPET imaging demonstrated eight of nine 
histologically proven breast cancers, four of which 
were ER positive, three ER negative and two of 
undetermined  ER status. There was one false 
negative of unknown ER status. Four of four 
metastases and six of six known axillary nodes were 
visualised. Initially there were 12 “false-positive “ 
axillary nodes and two “false positive” scans showing 
mediastinal involvement. However, with clinical 
follow-up, 2 of 12 axillae and 1 of 12 mediastina 
were found to contain cancer of sufficient volume to 
be detected by common radiographic techniques. 
More consistent results were reported by Schober et 
al. in a series of 21 women, 14 of whom were 
suffering from breast carcinoma and 7 from benign 
breast tumours (107). Following the injection of 111 
MBq of 16α-123 iodoestradiol-17β  and acquiring 
data up to 24 h pi., 7 out of 9 ER positive ( > 10 
fmol/mg tissue) tumors were visualised whereas all 
12 ER negative , including the 7 benign diseases, 
were not. In 42 patients with known ER receptor 
status out of a group of 62 patients, an overall 
sensitivity of 66 % (20/30) and specificity of 92 % 
(11/12) was found by Scheidhauer et al. in a 
multicentre study using  16α-123 iodoestradiol-17. 
Tumour to non-tumour ratios in this series varied 
from 1.3 - 2.1(108) .  Finally, in  a series of 29 
women undergoing diagnosis for primary or recurrent 
breast carcinoma, using 16α-123 iodoestradiol-
17β   Kenady et al. found that scintigraphic detection 
was most noteworthy in patients with chest wall 
tumors and inflammatory breast cancer (109). 
Agreement between readers was 98 % for true 
negative readings and 94 % for true positive readings, 
but only 60 % for false positive and false-negative 
readings. However, data on the  sensitivity and 
specificity when  compared to ER status in this series 
were lacking.  
    Fluoroestradiol :  Because of the unique ability of 
PET to quantify tracer distribution in vivo, 16α-18 
fluoroestradiol-17β (FES) was introduced as an agent 
for in vivo ER receptor imaging (110). Additionally, 
because PET provides substantially greater contrast 
than is possible with conventional nuclear medicine 
imaging techniques, its use with 18F offers potential 
diagnostic advantages. FES has shown specific 
activity, highly selective ER binding in vitro, and 
high affinity for ER-positive target tissues (eg. uterus 
and mammary tumours) in animal models (111). In 
clinical studies, FES has most extensively been 
studied as a radiopharmaceutical for breast carcinoma 
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imaging. Mintun et al. performed PET imaging in 15 
patients suffering from primary breast cancer. In the 
nine patients in whom the αER status was known ,a 
correlation of 0.96 (p < 0.001) between (a) non-
specific binding and partial volume effect corrected in 
vivo uptake of 18-FES expressed as percentage of the 
dose injected per mL x 10-4 and (b) αER 
concentration (fmol/ mg protein)(112). This high 
correlation, however, is likely an overestimation as 
the linear regression line in this series was fully 
determined by the two patients with the highest αER 
receptor concentration. The mean regional tumoral 
activity expressed as % ID/ mL.10-4 was 1.86+ 2.21. 
In a subsequent study by the same group on 16 
patients with clinical or radiographic evidence of 
metastatic disease, metastatic lesions within the 
regions imaged on PET studies were identified by 
other imaging studies in 14 out of 16 patients (113). 
The pre-therapy PET images with FES demonstrated 
accumulation of the radiopharmaceutical in the lesion 
or lesions of 11 of these 14 patients (79%) and in 53 
of 57 lesions (93%). Two false positive findings were 
due to radiation fibrosis and an insufficiency bone 
fracture. Unfortunately, in vivo regional uptake 
values expressed as % ID/ml were not systematically 
available. Based on the available data in a small 
subgroup of 7 patients the correlation between 
pretherapy % ID/mL uptake vs. ER status ( r = 0.36, p 
= 0.43) was much poorer than the initial results 
presented by Mintun et al. in primary tumors. The 
higher overall uptake values in this series (% ID /mL 
10-3)  is likely due to the later imaging (110 min pi. 
vs. 90 min in the series by Mintun et al.). Dehdashti 
et al.  in a series of 53 patients ( 32 patients with 
primary breast tumours and 21 with clinical or 
radiological evidence of distant metastases or disease 
recurrence) found a good overall agreement 88% 
(35/40) between in vitro ER assays and FES-PET % 
ID/mL (114). It is of interest that all 5 cases of 
disagreement were positive on in vitro ER but 
negative on FES PET ( SUV values < 1.0). Only one 
of these patients was treated with hormonal therapy 
and she did not respond. Finally, when multiple 
tumor sites were assessed in a given patient, 
concordance was present in 85 % of lesions which is 
in agreement with the level of concordance obtained 
using in vitro ER determinations. Mortimer et al. 
assessed the value of FES in women with breast 
cancer for predicting response to systemic therapy 
(115). Results of FES-PET were related to ER status. 
Cancers were considered functionally hormone 
sensitive if the SUV of the lesion on FES-PET was > 
1.0 and hormone resistant if FES SUV was < 1.0. In 
this series, all 20 ER- tumours were also FES-. 
However, of the 21 ER+ tumours, 16 were FES+ and 
5 were FES-. Thirteen patients were treated with 
hormone therapy, and 8 (61%) responded to that 
therapy. Only 1 of the 5 patients whose tumours were 
ER+ but FES- received hormone therapy, and this 
treatment resulted in disease stabilization only. When 
compared with the in vitro assays of ER status, FES-
PET had a sensitivity of 76 % and specificity of 100 
%.  
     Vynilestradiol derivatives: Iodine (125I) labelled 
vynil derivatives of estradiol were first reported by 
Hanson et al. (116). Synthesis of such derivatives 
involves formation of the two stereoisomers : 20E and 
20Z iodovynil estradiol. The most promising of both 
agents turned out to be the E stereoisomer, showing 
rat uterus to blood ratios of 19 and 16 at 1-2 h post 
injection, declining to 7 by 4 h post injection. Both 
agents however suffered from a high plasmatic 
protein binding which is likely the reason why human 
results with these agents were never reported. In 
contrast, 11β-methoxy iodovynil estradiols (MIVE) 
have a low plasmatic binding (117) . In a comparative 
analysis by Foulon et al. performed in 21-day-old 
mice, the trans-isomer (E) showed the highest affinity 
for αER’s ( Kd = 16 x 10-10 M) with uterus to blood 
ratios being 15-fold higher for this derivative (118) . 
However, as shown by Rijks et al. the cis- isomer has 
a higher uterus-to-fat ratio and a higher in vitro 
affinity for dimethylbenzanthracene-induced rat and 
fresh human mammary tumour ER (119). To date, for  
breast carcinoma imaging purposes, only the cis- 
isomer has been injected in humans. Cis- MIVE was 
injected into 19 women, 8 of whom were referred for 
initial evaluation of breast cancer and 11 for 
postoperative follow-up (118).  Nine  of  the latter 
patients suffered from bone metastases. The primary 
tumor  ( size : 8-10 mm) was visualised in 2/4 pts 
with high αER concentrations ( 162-455 fmol/mg) 
and was not detectable in 4 pts with low αER 
concentration ( 6-32 fmol/mg). Axillary lymph node 
metastases were detected in 2 patients and bone 
metastases in 4 out of the nine patients with such 
metastases. Rijks et al. (120) reported on their results 
obtained using cis-MIVE in 25 patients, 12 with 
primary breast cancer and 13 with metastases evident 
from other imaging modalities. Planar imaging 
showed uptake in 11 of 12 primary carcinomas and in 
9 out of 13 metastasised patients. αER IHC data 
available in 10 of the 12 primary cancers and in 11 
out of 13 metastasised patients were concordant with 
cis-MIVE imaging in all 10 primary and in 10/11 
metastasised patients. In a series of 13 patients 
reported by Nachar et al. who had been referred for 
cis-MIVE scintigraphy because of abnormal 
mammography or a suspect mass at physical 
examination, 5 out of 10 histologically proven breast 
carcinoma showed specific tracer uptake. In eight 
breast carcinoma patients a good agreement with in 
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vitro ER determination was found whereas in 2 
patients scan results were false positive (121).  
 
 
V  CAN WE VISUALISE THE EFFECT OF 
TAMOXIFEN TREATMENT ON ESTRADIOL 
UPTAKE BY BREAST CARCINOMA? 
 
Following the administration of tamoxifen, several 
extra- and intratumoral mechanisms  are responsible 
for a reduction of estradiol uptake and intratumoral 
retention occuring in hormone-dependent, but not in 
hormone-independent, breast carcinoma tissue. 
    Extratumoral : In a series of 64 postmenopausal 
patients by Bertolissi et al. (122) an increase of 44 % 
(p = 0.000) in SBP concentration 30 days following 
the initiation of tamoxifen treatment was found, 
baseline values being 62.1 + 3.3 nmol/L. Similarly, 
Rose et al.  (123) demonstrated an increase in 
immunoreactivity of SBP blood concentration (p < 
0.001) in 22 patients treated with tamoxifen for 3-36 
weeks when first sampled, compared with 27 patients 
who were not receiving tamoxifen therapy. In the 
series by Rose et al., tamoxifen also produced a 
reduction in the percentage non-protein bound 
estradiol (p < 0.001) and percentage albumin-bound 
estradiol (p < 0.01), the two biologically available 
fractions, and a corresponding increase in the 
percentage SBP-bound estradiol (p < 0.01). As shown 
by Fortunati et al.  the increase in estradiol bound 
SBP and its inability to bind to SBP receptors will 
result in a decrease of tumoral estradiol membrane 
sequestration. In postmenopausal women on 
tamoxifen treatment Lonning et al. further 
demonstrated a fall in plasma estradiol level ( mean 
reduction of 11.9%, p< 0.05) possibly due to a 
reduced ovarian excretion of testosteron  as evidenced 
by a  mean fall in plasma FSH and LH values of 45.5 
% and 48.1% (respectively p< 0.0001 for both)(124) .  
    Intratumoral : As shown by Pasqualini et al. and 
others, in hormone dependent breast carcinoma cell 
lines, tamoxifen and a variety of other molecules can 
block sulfatase activity (125,126,127).  
    In summary, tamoxifen treatment results in a 
decrease of absolute and free or bioavailable plasma 
estradiol as well as in  an increase in SBP bound 
estradiol, resulting in a reduction of cellular uptake 
and membrane sequestration. Additionally, tamoxifen 
treatment decreases intratumoral estradiol synthesis 
resulting in a higher occupation of αER’s by 
tamoxifen  and consequently a reduced availability to 
the free fraction of estradiol. Theoretically, this 
should also result in a decreased uptake of 
radiolabelled estradiol derivatives following initiation 
of tamoxifen treatment initiation compared with 
baseline uptake. 
    Available data, although limited, support the 
usefulness of sequential radiolabelled estradiol 
derivative imaging for the purpose of predicting 
response to treatment as early as one week following 
treatment initiation, in keeping with 
pathophysiological data. 
    Dehdashti et al. (128) reported on the potential 
usefullness of consecutive FES imaging to predict 
responsiveness to antiestrogen therapy in patients 
with αER-positive metastatic breast cancer. Eleven 
postmenopausal women were included and underwent 
FES PET before and 7-10 days after initiation of 
tamoxifen therapy. There were seven responders and 
4 non-responders on clinical follow-up ( 3-24 
months). Responders had higher baseline SUV’s 
when compared with non-responders (> 2.2 vs. < 1.7 
) and the degree of ER blockade by tamoxifen was 
greater in responders ( mean SUV decrease 2.7 + 1.7) 
than in non-responders (mean decrease 0.8 + 0.5). 
     Comparable data were presented by Bennink et al. 
(129) using Z-MIVE to predict response or non-
response to anti-estrogen treatment in metastasized 
patients. Among 23 patients treated with tamoxifen 
(40 mg daily) who underwent Z-MIVE scintigraphy 
prior to and 3-5 weeks after initiation of tamoxifen 
treatment, the 18 who showed complete blockage of 
αER activity responded to treatment. On the other 
hand, the 4 patients showing a mixed response and 
the single patient showing no blockage of ER showed 
progressive disease despite antiestrogen treatment. 
Patients with ER blockage had a significantly longer 
progression free interval ( mean value + SEM, 12.7 + 
1.7 vs. 1.6 + 0.6 months, p < 0.001) (128). 
 
VI CONCLUSIONS: 
 
Available data in humans do not substantiate a 
quantitative relationship between uptake of estradiol 
radiolabelled agents and the content and binding 
characteristics of αER, in accordance with recent 
pathophysiological findings in breast carcinoma.  
    The tumoral need of estradiol to bring about a 
biological effect is highly variable intertumorally and 
can vary over time intratumorally, depending on local 
environmental condition. The local estradiol needs 
are provided through both uptake as well as local 
biosynthesis which in αER positive tumors are likely 
inversely related. Thus a lack of concordancy 
between estradiol uptake and αER status is to be 
expected, and the predictive value of estradiol uptake 
for tamoxifen therapy response is likely to be low, in 
accordance with available data.  
    In agreement with pathophysiological findings, 
early therapy prediction is likely feasible through 
rapid ( prior to and one week following treatment 
initiation) sequential radiolabelled estradiol 
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scintigraphy, the accuracy of which seems higher than 
conventional αER measurements (cfr. Dehdashti et 
al. and Bennink et al.)  
    Additional significant advantages of radiolabelled 
estradiol scintigraphy as compared to conventional 
αER measurements which have to be taken into 
consideration are : 1)  its non-invasive character and 
whole body assessment capability, 2) the fact that the 
receptor is not a biological product, which means that 
its production is not subject to animal variation as is 
the case in antibody production, 3) the more 
favourable biodistribution of the small labelled 
molecules which derives from their ability to often 
pass different biological barriers by mere diffusion, 4) 
the absence of errors of sampling and tissue 
manipulation as well as preparation and 5) the ability 
to address the intrinsic heterogeneity of receptor 
expression and estradiol uptake between the primary 
tumor and metastatic or recurrent lesions. 
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Figure 1. Structures of estradiol (A) and cis-methoxy iodovynilestradiol (MIVE) (B). Clinically used halogenated substituents 
for estradiol include 16a Bromo-, Iodo- and Fluoroestradiol. 
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Figure 2. 
Sex hormone binding protein (SBP) is an allosteric protein with two binding sites, one for steroids and the other for the SBP 
receptor (SBPR). Binding of a steroid to free SBP induces a change in the SBP membrane-binding domain that non-
competitively inhibits SBP from binding to SBPR’s. SBP/SBPR interaction followed by binding of a steroid to the 
SBP/SBPR complex however cause an increase in intracellular cAMP (Steroids 1999; 64: 100-106). 
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Figure 3. 
Aromatisation of androgens (∆ 4-androstenedione and testosterone) to estrogens (estrone and estradiol). 
 
 
 
 
 
____________________________________________________________________________________________________ 
Authors   Tracer  Nb of breast  M0/M+ ER status  cut-off for 
     Carcinoma pts  assessment ER positivity 
____________________________________________________________________________________________________ 
 
McElvany et al., 1982 BES  8  4/4 LBA  > 10  
Preston et al., 1990  IES  28  NA NA  NA 
Schober et al., 1990  IES  14  NA LBA  > 10 
Scheidhauer et al., 1991 IES  30  19/11 LBA  > 10 
Kenady et al., 1993  IES  29  NA LBA  > 3 
Mintun et al., 1988  FES  13  13/0 LBA  > 3 
Dehdashti et al., 1995  FES  53  32/21 LBA  > 3 
Mortimer et al;, 1996  FES  43  26/17 LBA  > 3 
Ribeiro-Barras et al., 1992 cis-MIVE  19  10 /9 LBA  > 6 
Rijks et al., 1997  cis-MIVE  25  12/13 IHC  -/+ 
Nachar et al., 1999  cis-MIVE  10  10/0 LBA  > 9 
 
___________________________________________________________________________________________________ 
 
BES = 16 α 77bromoestradiol , IES = 16 α 123iodoestradiol, FES = 16 α 18fluoroestradiol, MIVE = methoxy 123iodovynilestradiol, Nb = number, pts= patients,  
MO = non-metastasised, M+ = metastasised, LBA = ligand binding assay, units are in fmol/mg cytosol protein,  
IHC = immunohistochemistry, - = negative staining  and + = positive staining. 
 
Table 1. 
Methodological and population characteristics of available data on radiolabelled estradiol derivative imaging in patients 
suffering from breast carcinoma. 
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ABSTRACT 
 
This study reports on the distribution and 
radiation dosimetry of 123I-labelled trans Z-
iodomethyl-N,N-diethyltamoxifen (123-ITX), a 
promising radioligand for prediction of therapy 
efficacy of unlabelled tamoxifen in human breast 
carcinoma. Whole body scans were performed up 
to 24 h after iv. injection of 123-ITX ( µ:146 MBq, 
range: 142-148 MBq) in 5 female volunteers, four 
with and one without thyroid blockade. Blood 
samples were taken at various times up to 24 after 
injection. Urine was collected up to 24 h after 
injection allowing calculation of renal clearance 
and interpretation of whole-body clearance. Time 
activity curves were generated for the thyroid, 
heart, brain, breasts, liver and gallbladder by fitting 
the organ-specific geometric mean counts, obtained 
from regions of interest. The MIRD formulation 
was applied to calculate the absorbed radiation 
doses for various organs. The images showed rapid 
hepatobiliary excretion, resulting in good imaging 
conditions for the thoracic region whereas imaging 
of the abdominal region was impeded due to 
extensive bowel activity. The breast to non-specific 
uptake ratio increased over time. 123-ITX was 
cleared both by the kidneys and the gastrointestinal 
tract. At 50 h p.i. the mean excretion in the urine 
was 89.4 % ( sd : 5.7%) . If the thyroid was not 
blocked, it was one of the critical organs. The 
highest absorbed doses were received by the 
excretory organs, i.e. the urinary bladder wall, the 
lower and upper large intestine, and the gallbladder 
wall. The average effective dose of 123-ITX was 
estimated to be 0.0084 mSv/MBq. The amount of 
123-ITX required for adequate tumoral uptake 
imaging results in an acceptable effective dose to 
the patient. 
 
INTRODUCTION 
 
Estrogen deprivation therapy is effective in 
only 50-60 % of estrogen receptor positive (ER+) 
and in 5-10 % of estrogen receptor negative (ER-) 
advanced breast tumors (1,2,3,4,5). Therefore if 
potentially beneficial chemotherapy is not to be 
unnecessarily delayed it is important to be able to 
predict the likelihood of response to endocrine 
therapy prior to treatment initiation. By comparison 
with estrogen receptor status, the value of other 
markers eg. HER-2/neu, EGF-R, cathepsin D..., for 
this purpose is less proven and controversial (6). 
The reason why only 50 % of ER+ and yet 10 % of 
ER- breast carcinoma respond to estrogen 
deprivation is unclear and the causes of primary 
resistance remain to be resolved. Although 
treatment is typically successful initially, most 
estrogen dependent tumors will eventually resume 
growth, ultimately resulting in the death of the 
patient (7). Irrespective of whether resistance is 
primary or acquired, it is important to determine its 
cause (which is likely multifactorial) as a greater 
understanding of the mechanisms involved will 
lead to strategies by which resistance may be 
circumvented. In addition to the development of 
appropriate cell line models and xenograft systems 
(8,9,10), radiolabelled anti-estrogen derivatives that 
retain their anti-estrogen activity , allowing in vivo 
assessment of tumor uptake and washout, may 
facilitate progress in this area. 
Yang et al. introduced trans-1-(4-(2-
diethylaminoethoxy)phenyl)-1,2-diphenyl-5-mesyl-
1-pentene (iodomethyl-N,N-diethyltamoxifen ,ITX) 
as an ER specific anti-estrogen for breast cancer 
imaging . In studies of human breast MCF7 breast 
tumor cell growth, MIC50 values were 11 µm for 
tamoxifen and 2.4 and 6.3 µm for the cis and trans 
isomers of ITX respectively (11). In mammary 
tumor bearing rats, ITX showed a tumor uptake 
value of 0.26 + 0.17 % (injected dose/gram tissue). 
Upon priming tumor-bearing rats with estradiol, 
this value increased to 0.48 + 0.11 at 6 hours, the 
mean estrogen receptor density as determined by 
the  (3H) estradiol receptor assay being 7.5 
fmol/mg protein. ITX scintigraphy of rabbits 
primed with diethylstilbestriol (DES, 1 mg/day, for 
3 days, administered subcutaneously) clearly 
visualized the uterus which was no longer visible 
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after blocking with 15 mg DES. The uterus to 
background ratio was 9.6 (12).  
Prior to 123-ITX injection in patients 
suffering from breast carcinoma, we studied its 
biodistribution and dosimetry in female 
postmenopauzal healthy volunteers as required by 
our local Ethics committee. 
 
 
PATIENTS AND METHODS 
 
Radiopharmaceutical synthesis 
 
Trans-(123-I)iodomethyl-N,N-diethyl 
tamoxifen was prepared using a modified procedure 
described by Cherif et al. 20 mCi 123-I (13), 
dissolved in 40 µL 0.01 M NaOH, was added to 
trans-mesyl-N-diethyltamoxifen (1 mg) in 200 µL 
acetone. The reaction mixture was heated at 80 ° C 
for 20 min. After cooling to room temperature, the 
product was purified by RP-HPLC (ethanol : 
acetate buffer pH 5.0, 70:30 v/v , flow rate 1 
mL/min, detection : UV 254 nm and NaI(Tl). The 
fraction containing 123-ITX (Rt = 13.0 min) was 
isolated, filtered through a 0.22 µm membrane filter 
into a sterile and pyrogen free vial and diluted with 
physiological saline up to 10 mL. The specific 
activity amounted to 5 + 0.7 Ci/mmol. The 
radiochemical yield was approximately 65% and 
the radiochemical purity exceeded 98%. 
 
Volunteers 
 
This study was approved by the local 
ethics committee and performed according to good 
clinical practice. Five healthy, postmenopauzal 
female volunteers (mean age : 56 yrs, range : 50-61 
yrs) were included in the study. To limit 
accumulation of free radioactive iodide in the 
thyroid following injection, with the exception of 
one patient (nb 1), the volunteers were pretreated 
with potassium iodide (10 % solution) orally, taken 
as two daily doses , two days before and one day 
after injection of 123-ITX ( mean:146 MBq, range: 
142-148 MBq) . The total dose of potassium iodide 
administered was approximately 300 mg. In the 
remaining patient (no. 1), the effect of no thyroid 
block was investigated. 
 
Imaging 
 
Volunteers were positionned supine with 
their arms alongside their body. Dynamic and 
whole body images were performed using a triple 
headed gamma camera (Irix, Picker, USA), 
equipped with low-energy high resolution parallel-
hole collimators. The maximum useful peak energy 
of these collimators is 160 keV, with a 
corresponding septal penetration of 1.5%.  A 15% 
energy window was centered at 159 keV. 
Immediately following injection of 123-ITX, planar 
images of the abdominal region were recorded 
every minute during 30 minutes (matrix size 
64x64). Whole body planar images were acquired 
1, 2, 4, 6 and 24 h following injection in all 
patients, and up to 48 h for the first patient. 
Acquisition was performed simultaneously in 
anterior, posterior and left lateral position with a 
scan speed of 11 cm/min. Matrix size was 
256x1024 pixels. 
 
 
Blood sampling and urine collection 
 
Blood samples were taken at 15s, 30s, 45s, 
1m, 1m15s, 1m30s, 2.5m, 7.5m, 10m, 12m, 15m, 
20m, 25m, 35m, 50m, 90m, 3h55m, 5h55m, and 
23h55m following injection of the tracer. Urine was 
collected up to 24 h p.i. in three intervals, 
respectively from 0-6, >6-12 and >12-24 h p.i.. 
From each blood sample and the three urine 
collections, duplicate 1 mL aliquots were assayed 
for 123-iodine radioactivity in an NaI(Tl) counter 
(Cobra, Canberra Packards Instruments Company). 
Total blood volume and consequently activity was 
calculated using a total blood volume based on 
body weight and height (14). Total urinary 
radioactivity was determined by multiplying 0.5 
mL urine activity by the total urine volume at each 
interval. Measurements were corrected for physical 
decay and the total amount of activity was 
expressed as a percentage of the injected activity 
(% IA).  
 
Dosimetry 
 
Image analysis 
 
For quantification of radioactivity uptake 
after injection of 123-ITX,  ROI's over the total 
body and organs of interest were drawn on the 
earliest images and the shapes and sizes. i.e. 
number of pixels , were kept constant over all 
subsequent images. Correction for non-specific 
uptake was performed by using a region over the 
shoulder. For each ROI, i.e. each organ, the 
geometric mean ,corrected for physical decay, of 
total anterior and posterior counts was calculated. 
The total body geometric mean activity, calculated 
on the first image (1 h p.i. ) was taken as the total 
injected activity, considering that no urine was 
excreted prior to the first whole body scan. The 
activity in the total body and different organs was 
expressed as the percentage of the injected activity 
(% IA) calculated by the following equation : 
(geometric mean counts in organ or total 
body)/(geometric mean counts in first total body) x 
100. 
 
Dosimetric calculations 
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For each individual , time-activity curves 
were generated for the  thyroid, heart, breasts, liver 
and whole body. Two routes of excretion were 
considered, i.e. urinary and faecal. Urinary bladder 
and intestinal residence times were estimated using 
the dynamic bladder model of Cloutier et al (15) 
and the gastrointestinal kinetics model as adopted 
in the ICRP 30 report (16). Activity leaving 
through the kidney-bladder pathway was assumed 
to accumulate in the urinary bladder with a voiding 
interval of 4.8 h (representing a rate of 5 times a 
day, typical for a normal adult). Of the activity 
excreted by the liver, 30 % of the activity was 
assumed to flow into the gallbladder, which 
empties its contents every 6 h in the small intestine. 
Activity in the intestines was assumed to pass 
through the various segments of the GI tract at 
standard rates, the mean transit time being 4 h for 
the small intestine, 13 h for the upper large 
intestine, and 24 h for the lower large intestine. As 
the specific uptake in organs and tissues was low, 
the accuracy of the 5 data points in time was not 
sufficient to enable a real compartmental model 
analysis with a reliable determination of the 
transfer coefficients. Instead, source organ 
residence times were determined accurately from 
integration of the best unweighted multiexponential 
fit to the experimental data. Target organ radiation 
doses were calculated applying the MIRD 
methodology (17) for the normal female adult using 
the MIRDOSE software package (18,19).  
 
RESULTS 
 
None of the subjects suffered from adverse events. 
Whole body images of one subject 
showing the biodistribution of radio-activity upon 
injection of 123-ITX at different time points post-
injection are presented in figure 1. 
Dynamic imaging of the abdomen during 
the first 30 min following injection in two subjects 
showed a fast and early elimination of 123-ITX by 
the kidneys. Although the kidneys were not 
systematically visualized, there was activity in the 
urinary bladder, confirming prompt urinary 
excretion through the renal system. The assays of 
blood samples showed that the elimination of 
activity from the blood was initially fast. The total 
blood activity at 10 min p.i. was lower than 33 % of 
the activity measured at 1 min p.i. and 
progressively decreased thereafter. The whole body 
images obtained between 1 and 6 h p.i. show most 
of the activity to be distributed in the bladder, liver, 
gallbladder and intestines, reflecting the known 
urinary and hepatobiliary excretion of steroids. 
Uptake in the lungs and brain was low. Although 
123-ITX is of potential interest for myocardial ER 
imaging, no significant myocardial uptake was 
seen. There was a diffuse uptake and retention of 
radioactivity in the normal breast tissue, with the % 
IA remaining practically constant during the 
scanning period. Uptake in the other oestrogen 
target tissues, the uterus and ovaries, could not be 
analysed due to overlying intestinal activity. 
Although they were of low quality due to low 
counting statistics, images acquired 24 h p.i. 
showed most of the remaining activity distributed 
in the intestines. 
Biological radioactivity distribution data at 
various times after injection of 123-ITX and time-
activity curves for the whole body, various organs 
and blood are presented in Table 1 and fig.2 
respectively (the data are averaged over all five 
subjects and expressed as % IA). 
The mean cumulative total measured 
urinary excretion at 6, 12 and 24 hours was 32.2% 
(SD 7.7% ),  46.2% (SD 9.6% ), and  60.8% (SD 
9.4% ) respectively (Table 2). The residence times 
calculated from the exponential fits for the various 
organs was highest for the remainder of the body in 
all subjects (n=5), followed by the urinary bladder 
(n=5) and the upper large intestine (n=4) (Table 3). 
In all subjects, the bulk of the activity injected was 
eliminated via the kidneys as evidenced by the 
calculated 50-day elimination of 89.4% (SD 5.7% ).  
The mean radiation dose estimates (and standard 
deviation) calculated on the basis of the subjects’ 
time-activity curves, are shown in Table 4. In the 
subject in whom the thyroid was not blocked, the 
thyroid was one of the critical organs, with an 
absorbed radiation dose estimate of 0.199 
mGy/MBq. In the other healthy volunteers, the 
organs receiving the highest absorbed doses were 
involved in the excretion of 123-ITX. On average , 
the highest dose was received by the urinary 
bladder (4.76E-02+0.75E-02mGy/MBq) followed by 
the the lower large intestinal wall (2.49E-02+1.15E-
02 mGy/MBq), the upper large intestinal wall 
(2.00E-02+0.90E-02 mGy/MBq), the gallbladder 
wall (12.18E-03+6.00E-03 mGy/MBq) and the small 
intestine (6.85E-03+2.55E-03 mGy/MBq). The dose 
received by the ovaries and uterus was 2.98E-
03+0.41E-03 mGy/MBq. The estimated mean 
effective dose for the female adult was 8.44E-
03+1.51E-03 mSv/ mBq. 
 
DISCUSSION 
 
For receptor tracers to be used in tumor 
imaging, three requirements must be met (a) high 
specific receptor affinity, with low non specific 
binding ; (b) high specific activity (> 1 Ci/ mmol), 
since receptors are saturable systems with limited 
uptake capacity in vivo ; and (c) appropriate 
metabolic and clearance characteristics. Early 
attempts to place an iodine atom on the aromatic 
ring of tamoxifen resulted in either low affinity or 
low specific activity analogues (20). Placing a 
chlorine atom on the aliphatic side chain of 
 31
tamoxifen resulted in an analogue with a higher 
affinity than that of tamoxifen (21,22). 
Unfortunately, there is no existing cyclotron-
produced isotope for chlorine. Replacing chlorine 
for a iodomethyl grou, however, yields a high 
specific activity analogue with a high binding 
affinity, 123-ITX (11,12).  
Injection of 123-ITX in Sprague-Dawley 
and Fisher 344 rats showed high liver (6.764%+ 
0.056% injected dose/g tissue at 1 h) and lung 
(2.835%+ 0.1596% injected dose/g tissue at 1 h) 
uptake as well as progressively increasing tumor to 
blood ratios reaching an optimum at 24h p.i (12). 
These findings imply that delayed imaging may be 
required in order to increase the 123-ITX tumour to 
tissue ratio and clear the high amounts of drug 
taken up by the liver and lung, allowing better 
depiction of 123-ITX uptake by tumours. The 
present study, however,shows low lung retention 
and rapid hepatobiliary excretion of the 
radiopharmaceutical, resulting in excellent imaging 
conditions for the thoracic region  even at early 
time points (1h) post injection. The differences in 
biodistribution between rats and humans may de 
due to species differences in metabolism, e.g.a 
more rapid biliary clearance in man .  
In addition to a predominant urinary 
excretion, 123-ITX was also cleared 
enterohepatically, resulting in a high accumulation 
of radioactivity in the abdominal region that 
impeded image interpretation. As 123-ITX is 
structurally similar to Chloro-tamoxifen α(Cl-
TAM), the metabolic pathway of 123-ITX in the 
liver is probably dependent on the cytochrome 
P450 3A subfamilly-mediated demethylation and 
hydroxilation (possibly by an as yet undetermined 
cytochrome P450 isoenzyme), followed by 
glucuronidation and biliary excretion (23). 
The MIRDOSE sotfware provides a 
calculation of the effective dose as defined in the 
ICRP 60 (24). Based on the effective dose of 8.44 
E-03 ( SD 1.51 E-03 mSv/ mBq) obtained in our 
study, both patients and volunteers could easily be 
investigated with 185 Mbq 123-ITX, allowing 
planar and single photon emission tomography 
imaging. The corresponding effective dose of 1.56 
mSv is one third of the reported average effective 
dose per patient from nuclear medicine procedures 
in Europe (25). The dose received by the volunteers 
was significantly lower than the 5 mSv upper limit 
average effective dose of Category IIa of the World 
Health Organisation and Category IIb of the ICRP 
report(26, 27). From the distribution data for the 
four healthy female volunteers with the thyroid 
blocked, the mean radiation dose estimate for the 
thyroid was 4.70E-03 mGy /MBq. In the subject 
without the thyroid blocked, the radiation dose 
received by the thyroid was 1.99E-02 mGy/MBq, 
adding significantly to the effective dose 
equivalent. Thus blocking the thyroid will result in 
a significant reduction of the radiation absorbed 
dose in clinical studies. Also, since the highest dose 
is received by the bladder wall, frequent voiding 
will reduce the absorbed dose to the urinary bladder 
wall.  
The results of this study further 
demonstrate that 123-ITX is a pharmacologically 
safe radioligand (no adverse events were seen). The 
lack of a pharmacological effect was expected since 
only a tracer amount, 10 ng, was injected. This 
amount occupies only a small percentage of the 
human ER’s. 
In conclusion, the biodistribution of 123-
ITX in five healthy female postmenopausal 
volunteers demonstrated low lung and liver uptake 
allowing early imaging of the thoracic region, with 
a favourable dosimetry. 
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Table 1. Biological radioactivity distribution, expressed as percentage of the injected activity (%IA), in the total body, 
various organs and blood at different time points after injection of 123-ITX 
 
__________________________________________________________________________________________ 
Organ  Time points 
  ___________________________________________________________________________ 
  1 h  2 h  4 h  6 h  24 h 
  ___________ ____________ ___________ ___________ ____________ 
  AVG SD AVG SD AVG SD AVG SD AVG SD 
___________________________________________________________________________________________ 
Total body 100 - 93.3 2.1 77.2 8.8 65.3 10.6 41.6 7.3 
Heart  1.5 0.2 1.0 0.2 0.7 0.2 0.4 0.1 0.1 0.1 
Liver  5.4 1.9 3.3 0.7 2.4 0.7 1.1 0.8 0.3 0.6 
Gallbladder 2.1 1.6 1.9 2.0 1.3 0.8 0.7 0.6 0.3 0.4 
Breast  0.5 0.3 0.4 0.3 0.4 0.2 0.3 0.2 0.1 0.2 
Thyroid(a) 0.1 - 0.2 - 0.2 - 0.2 - 0.1 - 
Blood (b) 20.9 4.2 16.1 3.1 12.2 1.3 6.1 3.3 0.5 0.2 
___________________________________________________________________________________________ 
a, thyroid activity for only one subject. 
c, blood data are for five subjects at each time point. 
 
 
 
 
 
Table 2 . Cumulative measured and predicted excretion fractions (%IA) for 123-ITX 
_________________________________________________________________________________________ 
  URINE        FAECES 
_______________________________________________ ______          _______________ 
  0-6 h  0-12 h  0-24 h  50 d  50 d 
_________________________________________________________________________________________ 
subject 1  26  40  54  86.2  9.7 
subject 2  40  54  68  86.9  8.7 
subject 3  41  58  73  83.0  9.1 
subject 4  29  44  58  96.4  2.3 
subject 5  25  35  51  94.3  4.7 
____________________________________________ ___________________________________ 
mean  32.2  46.2  60.8  89.4  7.0 
SD   7.7   9.6   9.4   5.7  3.1 
________________________________________________________________________________________ 
 
 
 
 
 
Table 3. Residence times (h) for 123-ITX for each source organ 
________________________________________________________________________________________ 
Organ   Subject 
   _____________________________________________________________    
   1 2 3 4 5 AVG SD 
________________________________________________________________________________________ 
Breasts   0.025 0.017 0.019 0.015 0.065 0.028 0.021 
Gallbladder contents  0.045 0.047 0.032 0.012 0.086 0.044 0.027 
Lower large intestine  0.505 0.505 0.574 0.146 0.219 0.389 0.193 
Small intestine  0.320 0.320 0.364 0.093 0.139 0.247 0.122 
Upper large intestine  0.619 0.619 0.702 0.179 0.268 0.452 0.269 
Heart Wall  0.053 0.057 0.061 0.081 0.052 0.061 0.012 
Liver   0.219 0.241 0.154 0.244 0.164 0.204 0.043 
Thyroid   0.021 _ - - - - - 
Urinary bladder contents 0.697 1.080 1.000 0.940 0.825 0.908 0.150 
Remainder                 11.200 8.780 8.100       10.900       10.100 9.816 1.341 
______________________________________________________________________ 
AVG, Average ;  SD, standard deviation 
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Table 4. Radiation absorbed dose estimates (mGy/MBq) for 123-ITX 
________________________________________________________________ 
 
Target organ   AVG   SD 
________________________________________________________________ 
 
Adrenals    2.98E-03  0.41E-03 
Brain    1.83E-03  1.58E-03 
Breasts    1.80E-03  1.25E-03 
Gallbladder wall   2.18E-03  6.00E-03 
LLI wall    2.49E-02  1.15E-03 
Small Intestine   6.85E-03  2.55E-03 
Stomach    2.98E-03  0.41E-03 
ULI wall    2.00E-02  0.90E-02 
Heart wall   4.10E-03  0.78E-03 
Kidneys    2.98E-03  0.41E-03 
Liver    2.34E-03  0.54E-03 
Lungs    2.98E-03  0.41E-03 
Muscle    2.98E-03  0.41E-03 
Ovaries    2.98E-03  0.41E-03 
Pancreas    2.98E-03  0.41E-03 
Red marrow   2.98E-03  0.41E-03 
Bone surfaces   2.98E-03  0.41E-03 
Skin    2.98E-03  0.41E-03 
Spleen    2.98E-03  0.41E-03 
Thymus    2.98E-03  0.41E-03 
Thyroid,b   4.70E-03  1.98E-03 
 
Urinary bladder wall  4.76E-02  0.75E-02 
Uterus    2.98E-03  0.41E-03 
Total body   3.17E-03  0.34E-03 
Effective dose equivalent,a,b   8.77E-03  0.93E-03 
Effective dose,a,b   8.44E-03  1.51E-03 
 
________________________________________________________________ 
 
LLI, lower large intestine ; ULI, Upper large intestine 
a Units of effective dose and effectiove dose equivalent are mSv/MBq 
b Whole body effective dose , effective dose equivalent and thyroid dose were 
calculated excluding subject 1. 
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Figure 1. The anterior whole-body images obtained from subject 1 at 1, 2, 4, 6 and 24 h after intravenous administration of 123-ITX. 
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Figure 2. Time-activity curves for the total body, various organs and blood, calculated from direct measurements of counts in organ-specific 
ROIs or in blood. The physical decay-corrected data, expressed as % IA, are averaged over the five subjects, except for the thyroid (only one 
subject no.1). The error bars represent 1 SD. 
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ABSTRACT 
 
A high-performance liquid chromatographic 
procedure for the quantitation of 
[123I]Iodomethyl-N,N-diethyltamoxifen (ITX), 
a radioligand for human breast cancer imaging, 
in human plasma is described. Separation was 
effected on a RP-C18 column, using a mixture 
of acetonitrile-water-triethylamine (70/30/0.5, 
v/v). ITX was rapidly cleared from human 
plasma and metabolites appeared as early as 
7.5 min p.i. Quantitative assessment of 
metabolites in plasma over time allowed 
recalculation of the ITX plasma time-activity 
curve. Implications of ITX metabolite 
formation for breast tumour imaging are 
discussed. 
 
INTRODUCTION 
 
Although initially tamoxifen was 
earmarked for treatment of α estrogen receptor 
(αER) positive metastasised breast tumours 
with response rates of 40-50%, surprisingly 
and contrary to expectations up to 10% of 
patients with αER negative tumours also 
responded to tamoxifen therapy. The 
metabolism of tamoxifen with formation of 
various metabolites which may have different 
agonist/antagonist profiles is at least partially 
responsible for its in vivo capacity to achieve 
this effect. Unfortunately, in the course of 
treatment, sooner or later, all patients 
eventually develop resistance to tamoxifen 
therapy (2).   
The issues of why 50% of αER positive 
tumours fail to respond and yet 10% of al αER 
negative tumours do respond as well as the 
causes of acquired resistance still need to be 
resolved (4). In addition to the development of 
appropriate cell line models and xenograft 
systems, radiolabelled anti-estrogen 
derivatives that retain their anti-estrogen 
activity, allowing in vivo assessment of 
tumour uptake and washout, may help to 
elucidate the causes of resistance to tamoxifen 
(3,5,8). 
Trans-1-(4-(2-diethylaminoethoxy)phenyl)-
1,2-diphenyl-5-mesyl-pentene-1 
(iodomethyl-N,N-diethyltamoxifen, ITX) is an 
αER specific radiolabelled anti-estrogen for 
breast cancer imaging that has shown specific 
uptake in breast tumour cell lines and human 
tumours in vivo in both animals and humans 
(1,6,9,10). With the goal of optimizing the 
imaging protocol for depiction of ITX binding 
breast lesions and semiquantitative assessment 
of tumour ITX uptake, we investigated the 
clearance properties and metabolite formation 
of ITX in human plasma in vivo. This 
particularly as labeled metabolites not only 
complicate quantitative analysis but also 
provide an image background that can make it 
difficult to identify ITX binding lesions that 
are small or display low ITX binding. 
 
METHODOLOGY 
 
Chemicals 
 
ITX was produced by reaction with 
n.c.a. Na[123I]iodide and purified by RP-HPLC 
(1).  Acetonitrile (HPLC quality was 
purchased by Lab-scan (Dublin, Ireland)). 
Triethylamine (analytical-reagent grade) was 
obtained from Sigma (Bornem, Belgium). All 
other chemicals were of analytical grade and 
purchased by Aldrich (Bornem, Belgium). 
 
Equipment 
 37
 
The isocratic HPLC system consisted 
of a Shimadzu LC-8A pump (Shimadzu, 
Tokyo, Japan), an UV detector PU 4025 (Pye 
Unicam, Cambridge, UK), a syringe injector 
equipped with a 750-µL loop (Valco 
Instruments, Eke, Belgium) and a Waters 745 
automatic integrator (Millipore, Waters, 
Milford, MA, USA). The eluate was collected 
in fractions with a Redifrac fraction collector 
(Pharmacia, Brussels, Belgium). All 
radioactivity counting was performed with a 
Cobra one-channel γ-ray spectrometer 
equipped with a 3 x 3 in. NaI(Tl) detector and 
an automatic sample replacer (Canberra, 
Meriden, CO, USA) (1in. = 2.54 cm). All 
radioactivity measurements were corrected for 
physical decay and geometry. 
 
Chromatographic conditions 
 
An Econosil 10-µm RP-C18 column 
(250 x 10.0 mm I.D.) (Alltech, Laarne, 
Belgium) was used. The mobile phase 
consisted of a mixture of 
acetonitrile/water/triethylamine (70/30/0.5 
v/v).  The flow rate was set a 5.0 mL/min.  UV 
detection was achieved at 254 nm.  The 
sensitivity of the UV detector was set at 0.5 
A.U.F.S. A stock standard solution of ITX 
(0.1µmol/750 µL) was prepared in methanol 
and stored at ambient temperature. 
 
Human plasma analysis 
 
There was informed consent from all 
participants and the Medical Ethics Committee 
of the Ghent University Hospital approved all 
human experiments. Five healthy 
postmenopausal female volunteers (mean age: 
56 years, range: 50 – 65 years) were injected 
i.v. with 148 MBq (range 141 MBq – 152 
MBq) ITX by a rapid bolus injection. At 
different time points (varying between 15 sec 
and 2 h) venous blood samples were taken. 
Plasma was obtained by centrifugation at 1000 
g for 3 min. A 500 µL plasma sample was 
transferred into an eppendorfcup and counted 
for radioactivity. 
At four preset time points (5, 20, 35, 
50 and 90 min post injection) 750 µL of 
acetonitrile was added to the 500 µL plasma 
samples. The mixture was vortexed for 1 min 
and centrifuged at 3000 g for 3 min. After 
centrifugation 1100 µL of the supernatant was 
separated from the pellet. Radioactivity was 
determined in the pellet and the supernatant. A 
750 µL amount of the supernatant was 
resolved by the chromatographic procedure. 
The eluate was collected with the fraction 
collector at time intervals of 0.5 min and 
fractions counted for radioactivity. Blank 
plasma samples were spiked with 1 µCi ITX 
and treated identically. 
 
RESULTS 
 
Validation of the method 
 
The retention time of ITX was 12.5 
min. (k’ = 4.0; hold-up time was determined 
with water). The extraction yield was 
calculated by the following formula: 
sampleplasmaµL500inActivity
1.2/1.1)RSN(ant  supernat1100µLinActivity =×
RSN is the correction factor for the 1100 µL of 
supernatant, which is isolated, compared to the 
total volume of 1200 µL after addition of 
acetonitrile. 
The extraction yield of ITX from blank plasma 
samples spiked with 1 µCi was > 93% (S.D. 
1.5%, n = 4). The stability of ITX during the 
extraction was controlled by HPLC. The 
radiochromatograms of the spiked blank 
plasma samples showed only one peak with 
the same retention time as ITX, indicating that 
no degradation took place during the extraction 
procedure. The relative proportions of 
unchanged ITX were calculated by the 
following formula: 
columntheoninjectedityradioactivofamounttotal
ITXcontainingityradioactivofamount  
In all cases > 98% (S.D. 0.9%, n = 4) of the 
present activity remained as ITX. Control 
radioactivity measurements of the HPLC 
column, demonstrated that no radioactivity 
was retained by the analytical apparatus. 
 
Human plasma analyses for ITX 
 
The initial high concentration of 
radioactivity in the plasma (average 254 
nCi/mL, S.D. 73 nCi/mL) between 1 and 1.5 
min p.i. was followed by a rapid decrease, due 
to an immediate extraction of radioactivity 
from the blood by peripheral organs e.g. the 
liver. At later time points (between 7.5 and 35 
min post injection) an increase of radioactivity 
in the plasma was observed in all volunteers 
(from 90 nCi/mL ( S.D. 32 nCi/mL) to 128 
nCi/mL( S.D. 8.5 nCi/mL)). The extraction 
yield for all plasma samples under these 
conditions was higher than 96%.  
Fig. 1 shows an HPLC 
radiochromatogram (at 20 min p.i. of ITX) 
representative for the separation of ITX and its 
radioactive metabolite. The radioactivity in the 
plasma, represented by unchanged ITX 
decreased from 75% (S.D. 2.5%, n = 5) at 5 
 38
min p.i. to 19% (S.D. 1.8%, n = 5) at 90 min 
p.i. (Table 1 and figure 2). A logarithmic 
relationship between the amount of authentic 
ITX versus time was observed. The equation is 
expressed as: 
)08.0(8020% timeeI ×−×+=  
This equation is used to correlate the time-
activity plasma curve. The corrected curve 
could be fitted to an open, two compartment 
model with T1/2 for the distribution phase of 
0.85 min (S.D. 0.25 min) and T1/2 for the 
elimination phase of 46.2 min (10.3 min).  The 
equation could be written down as: 
)2b(2a)1b(1a tete ×−×+×−×  
The individual values for a1, a2, b1 and b2 are 
shown in table 2.  The corrected time-activity 
plasma curve for patient # 4 is shown in figure 
3. 
 
DISCUSSION 
 
ITX was rapidly cleared from human 
plasma according to a two-compartmental 
model with polar metabolites appearing as 
early as 7.5 min p.i., dominating by 20-90 min 
p.i. As shown by Jacolot et al., the 
metabolisation of tamoxifen occurs 
predominantly in the liver via cytochrome P-
450 enzymes located in the microsomes (4). 
The major metabolic pathways for tamoxifen 
in humans involve demethylation, deamination 
and hydroxylation of key positions on the 
phenyl groups of tamoxifen (8). Demethylation 
of the tertiary amine results in the major 
metabolite accounting for 95-100% of all 
tamoxifen serum metabolites, namely N-
demethyltamoxifen. As ITX is structurally 
similar to tamoxifen, it can be expected that 
ITX shares much of its pharmacokinetic 
behaviour. However, although the position of 
the CH3I group does not interfere with the 
demethylation proces, the radioactive 
metabolite found in the volunteers cannot be 
N-demethyl ITX. As N-demethyl ITX is more 
polar than ITX its HPLC retention time should 
be reduced when compared to ITX which was 
not substantiated by our data. Although 
deaminated and hydroxylated ITX derivatives 
are theoretically possible, biodistribution and 
dosimetry data in humans showing 
visualisation of the thyroid over time point 
towards free iodine. As iodine is polar and 
negatively charged, with the exception of the 
thyroid, it has only limited access to the 
intracellular space. Furthermore it has no 
affinity for αER. However, it will increase 
background activity owing to its presence in 
blood and extracellular space e.g. abdominal 
due to liver and stomach uptake, as well as in 
the intracellular space in the neck, due to 
thyroidal uptake. 
As previously demonstrated in the 
human biodistribution and dosimetry study on 
ITX (7), liver uptake of ITX is rapid. This may 
explain why metabolites appear in blood in 
significant quantities as early as 7.5 min p.i. 
Metabolites dominate by 20-90 min p.i. and 
the blood metabolite curve declines only 
slowly after 20 min. Given the early blood 
disappearance of ITX and the slow decline of 
metabolites, from the standpoint of imaging 
and quantifying ITX tumour uptake, delayed 
imaging is unlikely to yield better results than 
imaging starting at 15-30 min p.i. 
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Table 1 
Unchanged ITX (%) in human plasma at different time points after i.v. injection of 148 MBq ITX (n = 5 for all 
time points). 
 
Time 
(min) 
Unchanged ITX 
(%) 
S.D. 
(%) 
5 75 2.5 
20 34 3.9 
35 25 1.6 
50 22 2.3 
90 19 1.8 
 
 
 
 
 
 
 
 
Table 2  
Corrected time-activity plasma curve parameters for human volunteers after i.v. injection of 148 MBq of ITX, 
according to an open two compartment model. 
 
 # patient 1 # patient 2 # patient 3 # patient 4 # patient 5 
a1 729 694 1364 203 201 
b1 0.76 1.11 4.21 0.96 31.8 
a2 65.0 93.5 43.1 76.4 79.4 
b2 0.017 0.029 0.011 0.023  
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Figure 1  
Representative HPLC radiochromatogram of a human plasma sample at 20 min after i.v. injection of ITX. The leftt 
peak represents polar metabolites. The right peak represents original ITX. 
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Figure 2 
Amount of authentic ITX after i.v. injection of 148 MBq in humans.  The curve represents the mean of five 
patients.  The fitted curve is also given. 
 
 
0
50
100
150
200
250
300
0 20 40 60 80 100
Time (min)
A
ct
iv
ity
 (n
C
i/m
L)
radioactivity
fitted curve
radioactivity corrected for metabolites
 
 
 
 
 
 
Figure 3  
Time activity plasma curve of ITX versus time in patient 4. The corrected values for the amount of authentic ITX 
are also given. 
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ABSTRACT 
 
As the mainstay of hormonal treatment for 
breast cancer patients (bcp) is tamoxifen (TAM), 
assessing uptake, retention and eventually efflux of 
123Iodine-labelled tamoxifen (ITX) in vivo by means 
of scintigraphy could help to increase our 
understanding of tamoxifen’s action and the 
mechanisms involved in resistance to the drug. This 
in turn could provide new targets for the design of 
therapeutic agents which can both effectively 
antagonise the alpha-estrogen receptor (α-ER) 
dependent growth pathway, as well as circumvent or 
prevent the emergence of inevitable resistance to the 
drug. 
17 bcp were included in the study and 
divided in 2 groups. Group 1 (n, number of patients = 
7) included untreated, histologially confirmed 
primary bcp, group 2 (n = 10) included TAM-
resistant metastatic bcp, off hormonal treatment for at 
least 6 months. All bcp underwent whole body planar 
and tomographic (SPECT) imaging 30 min and 4-5 h 
pi. of 185 MBq ITX. Processed images were 
reviewed for the presence or absence of focally 
increased uptake at sites of known lesions from 
clinical or radiological findings. ITX uptake was 
quantified as the ratio of tumour lesion uptake to non-
specific, contralateral breast or axillary uptake (T/N) 
on SPECT images. αER and progesteron receptor 
(PR) status was determined using 
immunohistochemistry. 
In 4/7 bcp of group 1, all αER+ve/PR+ve, 
ITX uptake was clearly depictable. In 2 of these 
patients, involved axillary lymph nodes were also 
visualised. T/N ratios consistently increased over 
time. The remaining αER+ve/PR-ve and αER-ve/PR-
ve tumours failed to show ITX uptake. In bcp of 
group 2, known tumour lesions in bone (n = 6), lung 
(n = 2) liver (n = 1) or liver and bone ( n = 1 ) failed 
to take up ITX. 
As PR positivity, reflecting αER 
functionality, in addition to αER positivity increases 
the likelihood of response to endocrine treatment, the 
lack of ITX uptake in αER+ve/PR-ve and αER-
ve/PR-ve tumours may prove advantageous for 
predicting response to TAM treatment. The data 
presented further favor decreased intra-tumoral 
tamoxifen accumulation as a pathway for acquired 
resistance to tamoxifen in patients suffering from 
breast carcinoma.  
 
INTRODUCTION 
 
The precise mechanisms of resistance to 
tamoxifen and triphenylethylenes in general remain to 
be established. Based on currently available data, it 
seems most likely that the critical events driving 
response and resistance to tamoxifen are related to 
activities regulated through the alpha-estrogen 
signaling (αER) pathways.  
The predictive value of breast tumour αER 
status, either assessed by ligand binding assays 
(LBA’s) or immunohistochemistry (IHC) is well 
documented in both the adjuvant- and palliative 
setting (1-6).  However, in the palliative setting, 
response to hormonal therapy is seen in only 50-60 % 
of αER positive patients with metastasized breast 
cancer and yet in 10 % of αER negative patients (4-
6). This means that αER status is a good, but certainly 
not fully reliable parameter for predicting outcome to 
hormonal treatment in patients with breast carcinoma.  
While a loss of αER expression may not be the 
primary resistance mechanims to triphenylethylenes, 
when it occurs this loss is associated with acquired 
resistance. However, it appears that most tumours that 
acquire resistance in the clinic do so in the face of a 
continued expression of αER. Postulated mechanisms 
for triphenylethylene resistance in the presence of 
αER are (a) post-receptor alterations including 
changes in cAMP and the phosphorylation pathways, 
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or changes in coregulator and transcription factor 
interactions that affect the transcriptional activity of 
the αER, (b) changes in growth factor 
production/sensitivity of paracrine celle interactions 
or (c) pharmacological changes in the anti-estrogen 
itself, including altered uptake and retention or 
metabolism of the antiestrogen (7).  
In vivo imaging of radiolabeled tamoxifen 
tumour uptake, retention and eventually efflux could 
help to increase our understanding of tamoxifen’s 
action and the mechanisms involved in resistance to 
the drug. This in turn could provide new targets for 
the design of therapeutic agents which can both 
effectively antagonise the αER-dependent growth 
pathway , as well as circumvent or prevent the 
emergence of inevitable resistance to the drug in vivo. 
This manuscript reports the first results of 
ITX ( 123iodomethyl-N,N-diethyl tamoxifen) 
imaging in patients suffering from breast carcinoma. 
In this feasibility study , using planar and SPECT 
imaging, primary and known metastatic, either 
resitant or non-resistant to hormonal treatment, breast 
tumor lesions in different types of tissue were 
investigated for the occurrence of accumulation of 
ITX. In previously untreated patients, ITX uptake was 
related to tumoral αER and PR receptor status as 
assessed by immunohistochemistry. 
 
MATERIALS AND METHODS 
 
Patients 
 
Seventeen women (mean age : 54 yrs,   range 
: 35-72 yrs  ) were included in the study.  
Group 1 (table 1) consisted of 7 patients with a 
primary presentation of breast carcinoma, either 
proven by biopsy or strongly suggested by clinical 
and/or radiological findings, with clinically 
macroscopic disease. In all of these patients, 
histopathological diagnosis of breast cancer was 
established.  
Group 2 consisted of 10 women suffering 
from metastatic breast cancer either proven by biopsy 
or strongly evident from clinical, radiological 
(computed tomography (CT), magnetic resonance 
(MRI), or ultrasound (US))and/or bone scintigraphic 
findings. All of these patients eventually acquired 
resistance to tamoxifen in the course of their 
treatment and were off tamoxifen treatment for at 
least 6 months at the time of imaging. Additionally, 
none of these patients had been recently treated by 
chemotherapy, or radiation therapy.  
Informed consent according to institutional 
guidelines was obtained from all patients. The Ethical 
Board of the University Hospital Ghent approved of 
the application of the tracer to humans. 
 
Radiopharmaceutical synthesis 
 
Trans-(iodine-123)iodomethyl-N,N-
diethyltamoxifen (ITX) was prepared using a 
modified procedure described by Cherif et al. 20 mCi 
123I, dissolved in 40 µL 0.01 M NaOh, was added to 
trans-mesyl-N-diethyltamoxifen (1 mg) in 200 µl 
acetone. The reaction mixture was heated at 80°C for 
20 min. After cooling to room temperature, the 
product was purified by RP-HPLC (ethanol:acetate 
buffer pH 5.0, 70:30 v/v, flow rate 1 ml/min, 
detection: UV 254 nm and NaI(Tl)). The fraction 
containing 123-ITX (Rt=13.0 min) was isolated, 
filtered through a 0.22-µm membrane filter into a 
sterile and pyrogen-free vial and diluted with 
physiological saline up to 10 ml. The specific activity 
amounted to 5+0.7 Ci/mmol. The radiochemical yield 
was approximately 65% and the radiochemical purity 
exceeded 98%. 
 
Imaging studies 
 
All patients were pretreated with 300 mg 
potassium iode orally to block thyroid uptake of free 
radioactive iodide. Imaging was performed after a 
single intravenous injection of approximately 185 
MBq ITX. For patients of group 1, the injection was 
given in the arm opposite of the known breast lesion 
to avoid false positive uptake in axillary lymph nodes. 
Patients were positionned supine, and at times of 
imaging of the  thoracic region and breasts, with the 
arms raised alongside the head unless impossible due 
to physical constraints. Whole body images, planar 
spot images and tomographic images were performed 
using a triple headed gamma camera (Irix, Picker, 
USA) equipped with low energy high resolution 
collimator. The peak energy used was 159 kev, with a 
15 % window. The usefull peak energy of the 
collimators used is 160 keV with a septal penetration 
of 1.5 %. For all patients, whole body images , spot 
images and SPECT (single photon emission 
computerized tomography) mages, were performed 
between 15-30 min and 4-5 h postinjection . Anterior 
and posterior whole body images were acquired 
simultaneously using a scan speed of 11.4 cm/min 
and a 256 x 512 pixels matrix size. SPECT images 
were acquired over 15 minutes by 40 views of 20 
seconds per detector (60 angles; 3°angle; matrix size : 
128x128). Transversal, coronal, and sagittal slices 
were reconstructed iteratively using OSEM (ordered 
subset expectation maximization, 6 subsets and 1 
iteration) and postfiltered using a Butterworth filter 
(cut off frequency 0.8, order 7). 
 
Data analysis 
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All studies were reviewed by two 
experienced observers familiar with the known 
normal biodistribution of 123-ITX in healthy 
volunteers. One of the observers was blinded to the 
clinical information and the findings of the other 
imaging modalities, but both were blinded with 
respect to the αER and PR status. Images were 
reviewed for the presence or absence of focally 
increased uptake at sites of lesions known from 
clinical findings and/or other imaging modalities, and 
for possible additional spots of uptake. Disagreements 
were resolved by consensus. 
Quantification of abnormal 123-ITX uptake 
was performed using a region of interest method. 
ROI’s were drawn over areas with increased 123-ITX 
uptake visualised on SPECT images ie. the tumors. In 
patients with primary breast carcinomas, the 
nonspecific uptake in breast tissue was estimated by 
drawing a similar ROI in the contralateral breast. For 
patients with metatastatic lesions, nonspecific uptake 
of the radioligand was determined by assigning ROI’s 
in visibly non affected comparable tissue. For each 
ROI, the average counts per pixel was calculated. For 
each lesion, the 123-ITX uptake was quantified as the 
ratio of total lesion uptake to nonspecific uptake 
(T/N). 
 
In vitro αER and PR determination 
 
In all patients, routine immunohistochemic 
assessment of αER and PR was performed on 
formalin-fixed paraffin-embedded tissue sections of 
the original primary tumor using commercially 
available antibodies.  
 
RESULTS  
 
Following injection of ITX, + 1 nmol, none 
of the patients experienced adverse effects. Images 
showed low uptake and retention of ITX activity in 
the lungs in all patients. In keeping with the normal 
biodistribution data in healthy female volunteers, 
whole body images showed most activity distributed 
in the liver, gallbladder, and bowel, reflecting the 
hepatobiliary excretion of triphenylethylenes. 
Although there was no kidney-activity depictable, 
there was activity in the urinary bladder, suggesting 
prompt renal excretion of ITX. Low lung retention 
resulted in excellent imaging conditions for the 
thoracic region. Assessment of abdominal activity 
however was occasionally impeded due to bowel 
activity. There was diffuse and homogeneous 
accumulation of radioactivity in the normal breast. 
Uptake in the brain was low.  
Patient data of group 1 are shown in table 1. 
In 4 out of seven patients presenting with 
primary breast carcinoma ITX uptake was clearly 
depictable (see table 1 and figure 1) on SPECT 
images, but not always on planar images amongst 
others due to overlap with liver activity. All 4 patients 
suffered from  αER+ve/PR+ve breast tumours. In two 
of these patients, involved axillary lymph nodes were 
also depicted on ITX imaging. T/N ratio’s 
consistently increased over time. The remaining 
αER+ve/PR-ve and αER-ve/PR-ve tumours failed to 
show ITX uptake. 
In patients of group 2, known tumour lesions 
either in bone (n, number of patients = 6), lung (n=2), 
liver (n=1) or liver and bone (n = 1) failed to take up 
ITX . 
 
 
DISCUSSION 
 
Yang et al. introduced ITX as an αER 
specific anti-estrogen for breast carcinoma imaging 
(8). In studies of human breast MCF 7 breast tumor 
cell growth, MIC 50 values were 11 µm for tamoxifen 
and 2.4 and 6.3 µm for the cis and trans isomers of 
ITX respectively. In mammary tumor bearing rats , 
ITX showed a tumor uptake value of 0.26 + 0.17 % 
(injected dose/gram tissue). Priming tumor bearing 
rats with estradiol, this value increased to 0.48 + 0.11 
at 6hours, the mean estrogen receptor density as 
determined by the (3H) estradiol receptor assay being 
7.5 Fmol/mg protein. ITX scintigraphy of rabbits 
primed with diethylstilbestrol (DES) ( 1mg/day, 3d, 
sc.) clearly visualised the uterus which was no longer 
visible after blocking with 15 mg DES. The uterus to 
background ratio was 9.6. Analysis of the 
biodistribution and dosimetry of ITX in female 
postmenopausal healthy volunteers demonstrated that 
ITX is pharmacologically safe and allows early 
imaging of the thoracic region, due to low lung and 
liver uptake, with a favourable dosimetry (9). This 
study reports on the uptake of ITX in patients 
suffering from primary untreated and metastatic 
tamoxifen resistant breast carcinoma.  
  
Primary, untreated breast carcinoma 
 
The majority of tamoxifen and its 
metabolites are bound to serum and only 2-5 % is in 
the “free” unbound state limiting the amount of 
bioavailable drug to the tumour (10). Nevertheless, 
reported intratumoural levels of tamoxifen and its 
metabolites following steady state are 5-7 fold greater 
when compared to serum or plasma levels, implying 
accumulation against a concentration gradient 
(11,12). In patients treated for less than 2 weeks with 
a dose of 30 mg tamoxifen /day, a significant 
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difference in the intra-tumoural tamoxifen 
concentration between αER+ve and αER-ve tumours 
was observed (450.1 + 75.3 ng/gm and 120.9+49.9 
ng/gm, respectively; p = 0.04) (13). However, 
following at least two weeks therapy, approaching 
steady state conditions, no significant difference was 
found, with both αER+ve and αER-ve tumours 
accumulating high intra-tumoural concentrations. 
Thus, both αER+ve and αER-ve breast tumours 
progressively accumulate tamoxifen but αER+ve do 
so much more rapidly. The use of a bolus injection of 
ITX and consecutive imaging should allow for this 
difference in αER related uptake kinetics, with higher 
expected uptake values for αER+ve tumours, to 
emerge visually. However, as the apparent 
distribution volume for tamoxifen is + 50-60 liters/kg, 
implying extensive tissue binding related to its 
lipophilic characteristics, a high background activity 
may be anticipated (14). In this regard, in a study 
from patients receiving 40 mg/day for at least 30 days 
(ie. steady state), tamoxifen an its metabolites were 
found to accumulate in non-malignant human tissues 
10-60 fold above serum levels expressed as ng/gm 
wet weight tissue to ng/ml serum (15). Nevertheless a 
depictable ITX uptake when compared to background 
activity was seen in 4 αER+ve/PR+ve patients but not 
in the remaining αER+ve/PR-ve and αER-ve/PR-ve 
tumours. As shown in the Early Breast Cancer 
Trialists meta-analysis, whereas αER positivity 
confers a 50 % response rate to front-line endocrine 
therapy, associated PR positivity, reflecting αER 
functionality, increases the likelihood of favorable 
response to endocrine treatment by 20-30 % (16). In 
contrast, patients who are αER and PR negative have 
a less than 5 % response rate to endocrine treatment. 
Consequently, the lack of discernible ITX uptake 
when compared to background activity in 
αER+ve/PR-ve tumours may prove advantageous for 
patient response prediction to tamoxifen treatment. 
Hypothetically, the lack of rapid ITX uptake in 
αER+ve/PR-ve may be explained by a lower affinity 
of tamoxifen to non-functional αER. 
Till now, the precise mechanism for 
intracellular uptake and retention of tamoxifen and 
related derivatives such as ITX remains unclear. 
Given the high degree of lipophilicity of tamoxifen 
and ITX, passive diffusion similar to steroids may 
explain both breast tissue and tumour uptake as found 
in the study presented. However, this would not 
readily account for an apparent ability to concentrate 
ITX in tumour tissue relative to normal surrounding 
breast tissue. Currently, there are at least three major 
identified intracelullar binding compartments for 
tamoxifen : partition into cellular membranes, binding 
to high affinity αER’s and binding to low affinity 
antiestrogen binding sites (AEBS), membranous 
protein complexes intimately linked with the 
antiproliferative and antiretroviral effects of certain 
antiestrogenis compounds such as tamoxifen (17). As 
partition into cellular membranes is relatively 
aspecific, a similar degree of accumulation in primary 
breast tumours when compared to surrounding normal 
breast tissue is to be expected. Given the structural 
similarity between ITX and other AEBS binding 
tamoxifen derivatives, some of which 123I labeled, 
retention of ITX in tumour cells may also relate to the 
presence of AEBS. However, AEBS are low to 
moderate  affinity binding sites (18) and depictable 
ITX retention through AEBS binding would require a 
steady state condition and not a bolus injection as 
performed in the series presented. Thus, increased 
tumoural ITX uptake when compared to the 
surrounding normal breast tissue in this series most 
likely reflects functional αER binding, in keeping 
with available animal data.  
 
Metastatic, antiestrogen refractory breast cancer  
 
Evidence in favor of reduced intra-tumoural 
accumulation as a potential pathway for acquired 
resistance to tamoxifen comes from both animal as 
well as human in vivo studies. In MCF-7 xenografts 
in immune-deprived mice which had become resistant 
following 4-6 months prolonged therapy, Osborne et 
al. observed a near 10-fold reduction in intratumoural 
tamoxifen compared with responding tumours in the 
absence of any change in serum concentrations (19). 
In a small clinical study from the same investigators, 
reduced intra-tumoural tamoxifen concentrations 
were found in 8/11 "“non-responsive tumours” treated 
with tamoxifen for between 1 month and 6 years, 
although serum tamoxifen levels were not measured 
to exclude poor compliance (20). Johnston et al. 
studied intra-tumoural tamoxifen accumulation, 
matched to serum concentrations, in a total of 51 
tamoxifen-resistant tumours (21). There was no 
difference in the serum concentrations of tamoxifen 
or N-desmethyltamoxifen in patients who developped 
either acquired tamoxifen resistance after a median of 
24 months, or were de novo resistant to the drug after 
a median of 4 months, or relapsed during adjuvant 
therapy after a median of 28 months. However a 
significant reduction in intra-tumoural concentration 
of tamoxifen in patients with acquired, but not de 
novo, resistance to drugs was found. In some patients 
even a ten-fold reduction in the ratio of tumour to 
serum tamoxifen levels was found, a quantitative 
difference similar to that observed by Osborne et al. 
In keeping with these findings, none of the hormone-
resistant metastasised patients showed depictable 
tumoural ITX uptake when compared to normal 
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breast tissue. Although persistant occupation of 
αER’s by tamoxifen, taking into consideration its 
long half-life in vivo, may partly explain this finding, 
its influence is likely to be low as all of the patients 
included were off antiestrogen treatment for at least 6 
months.  
 
Study Limitations 
 
Due to referral limitations, no patients in 
whom tamoxifen treatment was going to be initiated 
because of metastasis consented to participate in this 
study. In these patients, it would have been interesting 
to  relate the degree of ITX uptake prior to treatment 
initiation to the response to tamoxifen.  
 
Conclusion 
 
The preferential ITX uptake seen in 
αER+ve/PR+ve primary breast carcinoma suggests 
ITX holds potential for predicting response to 
hormonal therapy. The data presented favor decreased 
intra-tumoral tamoxifen accumulation as a  pathway 
for acquired resistance to tamoxifen in patients 
suffering from breast carcinoma.  
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Table 1. 
 
Age  TNMstage Histology      αER  PR     early T/N      late T/N 
______________________________________________________________________________________________ 
65  T4N1M1  ductal ca.     98%    5%     -  - 
54  T3N2M0  ductal ca.       -     -    -  - 
51  T2N1M0  lobular ca.      95%  50% T 3.7             5.0 
          N 2.1             2.4 
66  T3N1M0  lobular ca.     95%  60% T 1.8                     2.0 
          N 1.6             2.7 
56  T3N1M0  lobular ca.    100%  70% T 1.2             1.6 
          N   -  - 
52  T2N1M0  lobular ca.      80%  10%    -  - 
45  T3N1M0  ductal ca.      90%    90% T 1.5              1.5 
          N   -  - 
______________________________________________________________________________________________ 
 
 
 
Clinical, pathological and trans-(iodine-123) iodomethyl-N,N-diethyltamoxifen (ITX) single photon emission 
tomography quantitative  results in patients of group 1.  
TNM stage = clinical Tumour Node Metastases stage, αER = α estrogen receptor, PR = progesteron receptor, early 
T/N = Tumour to Normal tissue ratio’s obtained 30 min post injection, late T/N = Tumour to Normal tissue ratio’s 
obtained 4-5 h post injection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend to the figure  
 
Figure 1 
 
Imaging of breast cancer with trans-(iodine-123) iodomethyl-N,N-diethyltamoxifen (ITX). 
ITX uptake in the primary breast tumour of a 66-old patient  suffering from T3N1Mo breast carcinoma disease as 
visualized by single-photon emission tomography (transaxial,sagittal and coronal slice) performed 30 min after 
injection of ITX. Physiological uptake in homolateral and contralateral non-involved breast tissue as well as 
persisting (intracardiac) bloodpoolactivity is also visualised. 
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PART 2 : GASTRIN RELEASING PEPTIDE RECEPTOR IMAGING IN BREAST 
CARCINOMA 
___________________________________________________________________________ 
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I INTRODUCTION 
 
The largest class of receptors encompasses proteins 
that consist of a single polypeptide chain of variable 
length that traverses the lipid bilayer seven times 
and utilises heterotrimeric GTP-binding proteins to 
govern effector proteins. Unravelling of the role of 
these receptors in proliferative signal transduction, 
their overexpression in carcinoma and their 
oncogenic potential as revealed within the past 
decade has led to the development of novel 
selective anticancer drugs (1,2). Simultaneously, 
several radioligands have been developed for in 
vivo imaging of these G-protein coupled receptors. 
This manuscript reviews the rationale 
behind the development of agonist radioligands for 
visualisation of G-protein coupled gastrin-releasing 
peptide/bombesin receptor expressing tumours. 
 
II BOMBESIN LIKE PEPTIDES AND 
GASTRIN RELEASING PEPTIDE 
 
The tetradecapeptide bombesin was first isolated in 
1971 by Anastasi et al. from the skin of the 
European discoglossid frogs bombina bombina and 
bombina variegata variegata using methanol 
extraction (3). The wide biological activity of 
bombesin and related peptides in rodents and 
amphibia e.g. gastrointestinal, renal and cardiac 
prompted the search for mammal bombesin (4,5) .  
As the first mammal bombesin isolated 
from porcine non-antral stomach stimulated the 
release of gastrin in vivo, in spite of its numerous 
other physiological activities, the peptide was 
termed gastrin releasing peptide (GRP) (6,7). The 
human GRP equivalent was cloned and 
characterised five years later by Spindel et al. in 
1984 (8). Naylor et al. pointed the single human 
GRP gene on chromosome 18 (9). As shown by 
Hildebrand, the biological potency of human GRP 
is similar to that of bombesin (10). 
In humans and other mammals, GRP and 
bombesin are found predominantly in pulmonary 
neuroendocrine cells of foetal lungs, the neurones 
of the central nervous system and gut myenteric 
plexuses and to a lesser extent in prostate, <5 % of 
the total neuroendocrine cells,  breast tissue and 
seminal fluid (8,11,12,13,14). Aside from its 
physiological role, GRP has been shown to be a 
tumour growth stimulating agent for a number of 
normal- and human cancer cell lines, grown in 
culture or as xenografts in nude mice. In these 
tumour models, the tumour growth effect is a direct 
result of binding of GRP to membrane G-protein 
coupled GRP receptors (GRP-R) on the cell 
surface, first isolated in 1990 (15, 
16,17,18,19).Agonist binding to the extra-cellular 
face of the GRP-R results in activation of a guanyl 
nucleotide regulatory binding protein (G-protein) 
due to a change in conformation, resulting 
predominantly in activation of phospholipaseCβ     
and occasionally adenylyl 
cyclase(20,21,22,23,24,25). Similar to  other G-
protein coupled receptors, for GRP-R, both 
homologous or agonist-specific- as well as 
heterologous or non-agonist specific receptor 
desensitisation are discriminated (26,27,28,29). 
Whereas prolonged administration of GRP or 
bombesin to GRP-R expressing cell lines results in 
receptor downregulation, pre-incubation with 1000 
nM cholecystokinin (CCK) or with 1000 nM 
glucose-dependent insulotropic peptide (GIP) 
induce GRP-R upregulation(28,29,30). 
The intracellular distribution of GRP-R is 
determined by four main pathways of movement of 
receptors within cells (31,32,33,34). Newly 
synthesised receptors are delivered to the cell 
surface from the Golgi complex. In unstimulated 
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cells there is a slow endocytosis of receptors from 
the surface into endosomes. In the presence of 
agonist, the rate of endocytosis is increased 
dramatically (35,36,37). The amount of agonist 
ligand endocytosed following receptor binding 
depends on the rates of ligand-receptor dissociation 
and hence ligand affinity and receptor endocytosis. 
Once the receptors reach endosomes, they can 
either be recycled back to the plasma membrane or 
routed to lysosomes for degradation. The ligand 
however remains in the perinuclear space where it 
is trapped in lysosomes (figure 2) (38,39,40,41,42). 
Specifically for high-affinity radiolabelled agonists, 
this entrapment will prolong the residence time of 
radioactivity in the target tissue when compared to 
antagonists, resulting in a higher accumulation of 
radioactivity in GRP-R positive tissues .  
 
IV BOMBESIN-LIKE PEPTIDES AND 
HUMAN CARCINOGENESIS 
 
During the past two decades, the role of GRP and 
its interaction with GRP-R as a tumour growth 
stimulating pathway has been studied in a wide 
variety of human cell lines, either grown in vitro or 
in vivo as xenografts in nude mice. Data on GRP 
expression and specifically GRP-R in human 
tumours however are limited to lung-, prostate-, 
breast-, colorectal- and gastric carcinoma. The latter 
will be discussed. 
 
Lung carcinoma : 
Cell line data: GRP/ bombesin-like 
immunoreactivity has been described in small cell 
lung carcinoma (SCLC)- and carcinoid cell lines 
but not in non-SCLC cell lines (43,44). As shown 
by Moody et al. SCLC cells secrete GRP/bombesin-
like peptide into the surrounding media (45). 
Carney et al. and Weber et al. respectively 
demonstrated that bombesin and GRP act as potent 
mitogens on SCLC but not squamous- or lung 
adenocarcinoma (46,47). High affinity receptors for 
bombesin/GRP like peptides on human small cell 
lung carcinoma cell lines were first demonstrated 
by Moody et al. (48). As shown by several authors, 
the tumour growth stimulating effect of GRP on 
SCLC cell lines can be blocked by a wide variety of 
GRP antagonists (49-55).  
Human data: The first evidence of bombesin-like 
immunoreactivity in human SCLC tumours was 
provided by Wood et al. showing high levels of 
GRP/BLI in a number of human SCLC tumours 
(57). In a larger and more recent series, using a 
broad panel of antibodies, Guinee et al. found 
bombesin like immunoreactivity in 45 % of open 
lung biopsy specimens (9/20)(58). The observation 
that GRP is specifically and actively secreted by 
SCLC cells and present in human SCLC resulted in 
the development of radioimmunoassays (RIA) and 
enzyme linked immunosorbent assays (ELISA) for 
detection of serum pro-GRP from which GRP is 
derived through cleavage (59-60). Pro-GRP levels 
are increased in 76-79% of SCLC patients. 
Additionally, in this patient population proGRP is 
superior to Neuron Specific Enolase in terms of 
sensitivity, specificity and reliability and can be 
used for treatment monitoring and prognosis 
assessment (61,62,63,64,65)).  
Using RT-PCR, Toi-Scott et al. found 
GRP-R expression in 17/20 SCLC cell lines derived 
from patients (66). The presence of GRP-R as well 
as GRP/BLP-like immunoreactivity and GRP 
secretion by human SCLC suggest GRP in these 
tumours may act as an autocrine growth factor. 
Evidence to support this hypothesis was recently 
provided by Kelley et al.  Injection of 2A11, a 
murine monoclonal antibody which binds GRP-R 
with high affinity, at a dose of 250 mg/m2 over 1 h 
three times per week for 4 weeks resulted in a 
complete remission in one and stable disease in 3 
out of 13 previously treated SCLC patients. Of 
interest, human anti mouse antibodies did not 
increase during 2A11 administration in any patient 
and no toxic effects were recorded (67,68).  
 
Prostate carcinoma :  
Cell line data: GRP has been shown to enhance 
tumour growth, either in vitro or in nude mice, and 
invasion into matrigel in vitro of the GRP-R 
expressing prostate carcinoma cell lines PC-3 and 
DU-145. In both models, the GRP tumour growth 
stimulating effect could be blocked effectively by 
GRP-R antagonists such as RC-3095, RC-3095-II 
and RC-3940-II (69,70,71,72,73,74,75,76,77). 
Human data: Using RT-PCR and in situ 
hybridisation (ISH), Bartholdi et al. demonstrated a 
widespread but variable presence of GRP-R mRNA 
expression in fresh frozen specimens of prostate 
carcinoma (12 cases) and benign prostate 
hypertrophy (6 cases)(78). GRP-R mRNA staining 
in cancerous tissue ranged widely from very intense 
to not detectable (about 30 % of cases), while 
normal tissue consistently displayed a low level of 
message staining. In a number of studies, the 
expression of neuroendocrine peptides including 
BLP’s correlated with poor patient prognosis and 
hence associated with advanced metastasised and 
hormone refractory prostate carcinoma. Others, 
however, did not find a prognostic significance 
(79,80,81). 
Data on GRP-R expression in prostate 
carcinoma are variable. Using 125I-Tyr4-bombesin 
as radioligand, Markwalder et al. detected GRP-R 
in 30 of 30 invasive prostate carcinomas and also in 
26 of 26 cases of intraepithelial proliferative 
lesions, corresponding mostly to prostate 
intraepithelial neoplasias (82). Well differentiated 
carcinomas had a higher receptor density than 
poorly differentiated ones. Conversely, GRP 
receptors were identified in only a few hyperplastic 
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prostates and were localised in very low density in 
glandular tissue and, focally, in some stromal 
tissue. On the other hand, of 80 specimens of 
primary prostate cancer examined by Sun et al. 
using receptor binding assays, 50 ( approximately 
63%) showed high affinity, low capacity binding 
sites for bombesin/GRP (83).  
 
Breast carcinoma :  
Cell line data: Vangsted et al. and Yano et al. 
respectively demonstrated that bombesin stimulated 
growth of the human breast cancer cell lines T47D 
and MCF-7 MIII as well as of MDA-MB-231 
(84,85,86). The growth effect in these cell lines 
could be suppressed by RC-3095, RC-3940-II or 
RC-3095-II both in vitro and in vivo in nude mice 
(85,86,87,88). In the MDA-MB231 cell line, 
Miyazaki et al. found a significant decrease in the 
number of binding sites for epidermal growth factor 
as well as for bombesin following chronic 
treatment, an effect which might be related to 
inhibition of tumour growth (87).  
Human data : In a total of 41 human breast 
carcinoma biopsies from different menopausal 
patients, immunoreactivity against GRP was 
detected in 39 % of samples by Vangsted et al.(89). 
Similar results were obtained by Pagani et al. in a 
series of 28 primary breast carcinomas using 
Northern blot analysis with a pre-pro-GRP probe to 
measure GRP mRNA expression (90). In this series, 
moderate to strong expression of GRP mRNA was 
detected in 5 breast carcinomas whereas 4 other 
cases were weakly positive.  
Halmos et al. examined the binding of 
(125I-Tyr4)Bombesin to membranes isolated from 
100 human breast carcinomas (91). Thirthy-three of 
these tumours expressed receptor levels of > 10 
fmol/mg membrane protein, unrelated to patient 
age. Bombesin/GRP receptor expression was 
unrelated to patient age. Gugger et al. using 125I-
Tyr4-Bombesin and (125I)D-Tyr6, beta Ala11, Phe13, 
Nle14-bombesin (6-4) found GRP receptor positivity 
to predominate in invasive ductal carcinoma (29/46 
cases) and ductal carcinoma in situ (11/17) (92). 
Lymph node metastases (n=33) from those primary 
carcinomas expressing GRP receptors were all 
positive. GRP-R’s were also present in high density 
but with heterogeneous distribution in normal ducts 
and lobules from all available breast tissue samples 
(n=23).  
 
Colorectal carcinoma :  
Cell line data: Frucht et al. studied 10 well 
characterised human colon cancer cell lines and 
found membrane bombesin receptors in 30 % (3/10) 
using 125I-Tyr Bombesin (93). Radulovic et al. were 
able to inhibit growth of the human colon cancer 
cell line HT29 when grown as xenografts in nude 
mice using the GRP-R antagonists RC-3095 or RC-
3440. The HT-29 cell line also displayed specific 
binding sites for EGF which were consistently 
down-regulated following efficient treatment. 
Saurin et al. demonstrated that bombesin at a dose 
of 1 nM induced cell spreading and lamellipodia 
formation in the human GRP receptor positive 
coloncarcinoma cell line Isreco 1 (96). Ferris et al. 
provided evidence for a mutation-independent 
heptaspanning receptor constitutive activation 
resulting in cell proliferation of the non-malignant 
human colon epithelial cell line NCM160 and thus 
identified a potential mechanism whereby the GRP-
R may act as an oncogene in humans (97).  
Human data : Data on GRP and GRP-R expression 
in human colorectal cancer are conflicting. Preston 
et al. found 5 out of 21 colorectal cancers, but no 
uninvolved mucosa expressed high affinity, low 
capacity binding sites for GRP. Similarly, in a 
series by Radulovic et al. analysis of 125I-Tyr4-
bombesin binding data revealed the presence of 
specific binding sites in six (40%) of human colon 
cancer specimens (99). Using RT-PCR Saurin et al. 
detected widely variable GRP-R mRNA levels in 
27/29 (93%) of tumour specimens (100). 
Significantly higher levels were found in poorly to 
moderately differentiated tumours (p<0.05) and in 
tumours with lymphatic vessel invasion (p< 0.01). 
Caroll et al. using IHC to detect both GRP and 
GRP-R, found 84 % of 50 randomly selected 
human resected colon cancers aberrantly expressed 
GRP or GRP-R, in ccontrast to only 1 of 37 
metastases. Coexpression of both ligand and 
receptor was only observed in well differentiated 
tumours (62%), independent of disease stage 
suggesting that these proteins primarily act in vivo 
as morphogens. Kaplan-Meier analysis did not 
reveal any difference in patient survival between 
those tumours who did or did not express 
GRP/GRP-R. Finally, Chave et al. using receptor 
and ligand subtype-specific primers for RT-PCR as 
well as expression localisation by ISH, found GRP-
R and ligand expression in colorectal cancer tissue 
as well as adjacent normal mucosa samples from 23 
patients (102). GRP and GRP-R was present in 
greater expression in the tumour samples.  
  
Gastric carcinoma:  
Cell line data : Bold et al. found that bombesin 
stimulated growth of the human gastric cancer cell 
line SIIA could not be blocked with the GRP-R 
antagonists BIM 26189 and BIM 26226, but was 
inhibited by tyrphostin, a blocking agent of 
intracellular tyrosine kinases (103,104). SIIA cells 
possess GRP-R mRNA as measured by reverse 
transcriptase-PCR (105). Furthermore these cells 
possess an 80-kDa cell surface protein that 
specifically binds bombesin. Halmos et al. found 
high affinity 125I-Tyr4-bombesin binding sites on 
crude cell membranes of MKN45 and Hs746T 
human gastric cancer grown in nude mice (106). In 
displacement studies, RC-3095 and RC-3950-II 
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dose-dependently inhibited 125I-Tyr4-bombesin 
binding. Treatment with RC-3095 at a dose of 20 
µg/day decreased significantly the number of 
mitotic cells and serum gastrin levels as well as 
binding sites for epidermal growth factor (EGF) 
(107,108). Preston et al. described the presence of 
functional GRP-R’s in the human gastric cancer cell 
line St42 (109).  
Human data : Ferris et al. determined the normal 
distribution of GRP-R expression as determined by 
RT-PCR on cells lining the human GI tract obtained 
endoscopically by pinch biopsy (110) and found 
only cells lining the gastric antrum showed GRP-R 
expression implicating GI cancers aberrantly 
express GRP receptors. In a series by Preston et al. 
13 of 23 gastric cancers expressed high affinity 
binding sites for GRP/bombesin of which 12 were 
subsequently characterised and found to be of the 
GRP-preferring subtype (111). Finally, Caroll et al. 
looked at the incidence and quality of GRP-R, as 
measured by the presence of GRP- receptor mRNA, 
aberrantly expressed by non-antral gastric 
adenocarcinomas, and evaluated the impact of 
receptor expression on patient survival (112). 
Overall, 8 out of 20 consecutive non-antral gastric 
adenocarcinomas (40%) aberrantly expressed GRP-
R, 6 of which were found to be mutated. 
Pharmacologically, the effect of these mutations 
ranged from rendering the GRP-R non-functional to 
constitutively active. Contrary to expectations, 
survival of patients whose tumour expressed 
functional GRP-R (18.5+9.8 months) was not 
statistically different from those that did not 
(8.3+1.8 months; p=0.24). 
 
DISCUSSION 
 
The GRP/GRP-R interaction is an established 
tumour growth stimulating agent for several 
neoplastic human cell lines either in vitro or grown 
in nude mice. The mechanism by which tumour 
growth stimulation occurs does not appear to be 
unique but in general seems to involve 
transactivation and up-regulation of EGF receptors.  
In human tumours, the role of GRP/GRP-R is less 
clear. Over-expression of GRP-R’s when compared 
to normal surrounding non-cancerous tissue has 
been described in SCLC, prostate-, breast-, 
colorectal- and gastric cancer. In these tumours, 
stimulation of GRP-R’s may occur through 
paracrine produced GRP released by 
neuroendocrine cells present in e.g. human prostate 
and lung, particularly as GRP may diffuse several 
micrometers through tissue to exert it’s effect on 
nearby cells. On the other hand, stimulation of 
GRP-R’s may occur through tumour produced and 
released GRP. At present, simultaneous GRP/GRP-
R co-expression has only been studied and 
described in colorectal carcinoma using both IHC 
and RT-PCR with conflicting results. Whereas 
Caroll et al. using IHC found GRP/GRP-R in 62% 
of samples (31/50), Chave et al. using RT-PCR 
found GRP/GRP-R co-expression in 100% of 
samples studied (23/23) (101,102). Additionally, 
the incidence of GRP and GRP-R expression in 
individual reports looking either at tumour GRP-R 
or GRP also tend to vary significantly e.g. prostate- 
and breast carcinoma (82,83,91,92). Apart from 
differences in patient inclusion, this variation likely 
relates to differences in methodology used for GRP 
or GRP-R estimation, either IHC, mRNA analysis 
(RT-PCR or in situ hybridisation) or membrane 
ligand binding assays. All of these in vitro assays 
have some major drawbacks. Semiquantitative 
visual analysis of immunohistochemically stained 
tissue sections is operator dependent requiring both 
judgement and experience of the observer which 
renders reproducibility suboptimal. Although 
negative controls are generally used for standard 
immunohistochemistry, “specific binding” actually 
represents the “total binding” of the antibody to the 
tissue and non-specific binding cannot be measured 
directly. ISH, blotting and PCR-techniques are 
semiquantitative, labour intensive and require high 
sensitivity of the probes used. Additionally, blotting 
and PCR are applied to bulk tumour homogenates, 
which compromises the distinction of tumour cells 
from normal stromal cells, possibly expressing GRP 
or GRP-R. Importantly, the presence of mRNA for 
GRP or GRP-R is not synonymous to the presence 
of GRP or GRP-R. Lack of correlation between 
mRNA and peptide concentrations of GRP and 
GRP-R, indicating regulation at a post-
transcriptional level has been reported in normal 
gastrointestinal tractus tissue and in vitro on several 
tumour cell lines. As for radioligand binding, 
fixation on prepared membranes does not imply the 
existence of functional receptors that become 
internalised following binding.  Finally, all in vitro 
assays are dependent on sampling of tumour 
material. 
Considering these drawbacks, a non-
invasive, highly sensitive and specific technique to 
detect functional GRP-R and eventually GRP 
expression in vivo would be most welcome. 
Consequently, the development of radiolabelled 
bombesin analogues in nuclear medicine has 
attracted a considerable amount of interest in the 
area of cancer imaging and therapy. Taking into 
consideration the pharmacology of GRP/GRP-R 
interaction, agonists are preferable to antagonists as 
they are internalised, resulting in a higher 
accumulation of radioactivity in GRP-R positive 
tissues. Additionally, provided washout of 
internalised isotope or radioligand e.g. due to 
degradation does not occur, radiolabelled agonists 
may allow depiction of heterologous desensitisation 
through sequential imaging. In this setting, the 
absence of radioligand internalisation implies a 
 54
progressive decrease in membrane binding over 
time and thus an antagonist like behaviour.  
 
V. RADIOLABELLED BOMBESIN 
ANALOGUES 
 
Although radio-iodinated Tyr-containing peptides 
could easily be applied in vivo for receptor targeted 
scintigraphy and radiotherapy, these molecules are 
often rapidly degraded in vivo with release of 
radioiodine hampering their diagnostic and 
therapeutic use. With this regard, degradation of 
125I-Tyr4 Bombesin following internalisation with 
cellular iodine washout has been reported by 
several authors (36,113,114).  
Currently, the most practical radionuclides 
for labelling peptides and other ligands are 111In and 
99mTc, both of which require the conjugation of 
chelating agents to peptides or other ligands. In 
recent years, a number of GRP analogues with 
delayed proteolysis and high potency have been 
developped. Baidoo et al. reported on the synthesis 
and initial evaluation of technetium 
diaminedithiolate analogues derived from the potent 
bombesin analogue Tyr-Gln-Lys-Leu-Gly-Asn-
Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2  (115). 
Results of in vitro competitive binding assays in rat 
brain cortex membranes against (125I-
Tyr4)bombesin showed high affinity for these 
technetium analogues. Karra et al. using a new 
bifunctional chelating agent based on a tetradentate 
dithiadiphosphine framework (P2S2-COOH) 
synthesised 99mTc-P2S2-Bombesin(7-14) (116). 
Pharmacokinetic studies in normal mice showed 
fast and efficient clearance from the blood pool, 
excretion through the renal and hepatobiliary 
pathways and a significant uptake in the GRP-R 
expressing pancreas (pancreas/blood and 
pancreas/muscle ratios at 4 h pi. being ca. 22 and 80 
respectively). Varvarigou et al. reported on the 
synthesis of Cys-Aca-Gln-Arg-Leu-Gly-Asn-Gln-
Trp-Ala-Val-Gly-His-Leu-met-NH2, a ligand that 
showed high lung activity in mice as well as 
hepatobiliary excretion (117). Zinn et al. 
demonstrated specific, high binding affinity of the 
HYNIC chelated peptide Gln-Trp-Ala-Val-Gly-His-
Leu-Met-CONH2 to GRP receptors (118). Breeman 
et al. reported on the synthesis of a number of 
DTPA-bombesin analogues who were studied for 
their binding characteristics to the bombesin/GRP 
receptor on 7315b rat pituitary tumour cell 
membranes in competition with (125I-Tyr4)BN 
(119). Effects of bombesin analogues were 
determined on basal and bombesin-stimulated 
prolactin secretion by 7315b cells to distinguish 
between their agonistic and antagonistic 
characteristics. Of the DTPA complexes studied, 
the antagonist (DTPA-Tyr5,D-Phe6)Bombesin(5-
13)NHEt and the agonist (DTPA-
Pro1,Tyr4)Bombesin showed the highest affinity for 
the bombesin/GRP receptor on 7315b cell 
membranes. Despite similar affinity for the 
receptor, the 111In-labelled agonist, but not the 
antagonist, was internalised by the bombesin/GRP 
receptor-positive tumour cells. Consonant with this 
observation, the agonist  (DTPA-
Pro1,Tyr4)Bombesin showed much higher specific 
uptake in bombesin/GRP receptor positive tissues 
and tumours than the antagonist (DTPA-Tyr5,D-
Phe6)Bombesin(5-13)NHEt, with concordant target 
to background ratios. Biodistribution of this agent 
in rats showed high and specific uptake in tissues of 
the gastrointestinal tract , notably pancreas. Uptake 
of radioactivity was blocked by pre- or co-injection 
of 100 µg (Tyr4)Bombesin, but not when this was 
administered 30 min after the radioligand. This 
finding suggests Bombesin/GRP-R mediated 
internalisation of the radioligand within 30 minutes. 
Specific uptake was found in receptor positive 
CA20948 pancreas tumour and CC531 colon 
carcinoma in tumour bearing rats. The CA20948 
tumour, inoculated in the hindleg, was also 
visualised scintigraphically (120).  
Hofman et al. reported on the synthesis of 
99mTc RP527, a targeting peptide derived from 
bombesin, linked at its N-terminus via a linker 
group to a peptide sequence which chelates 99mTc. 
Both the unlabelled and labelled peptide bind GRP 
receptors with a similar affinity to bombesin (IC 50 
value for displacement of 125I-bombesin : 2-6 nM). 
As 99mTc RP527 is internalised by cells expressing 
the GRP-R it is believed to be an agonist. In SCID 
mice studies, 99mTc RP527 showed an uptake of 
0.2-1.8 (µ), 0.0-0.6(SD) % ID at 4 h with a tumour 
to muscle ratio ranging from 9.8-33.7 at 1h and 6.5-
25.4 at 4 h in human prostate (PC-3), pancreatic 
(CF-PAC-1) and rat pancreatic 5AR42J) tumour 
cells (121). Biodistribution and dosimetry analysis 
of 99mTc RP527 in humans showed rapid 
hepatobiliary excretion, resulting in good imaging 
conditions for the thoracic region, whereas imaging 
of the abdomen was impeded by extensive bowel 
activity. The highest absorbed doses were received 
by the excretory organs, i.e. the urinary bladder and 
gallbladder wall. The average effective dose of 
99mTc RP527 was estimated to be 0.0095m Sv/MBq 
(122). In a small pilot study on ten patients 
suffering from prostate- or breast carcinoma, 99mTc 
RP 527 uptake was seen in 5 patients (123). 
Tumour to background ratios in these patients 
derived from planar and tomographic images 
increased significantly from 1.65 (SD : 1.53) and 
3.35 (SD:3.04) to 2.58 (SD:1.26) and 7.23 
(SD:8.46) at 1 h and 5-6 h pi. (p< 0.01 for both 
planar and tomographic ratios), due to a decrease in 
background activity. SPECT imaging showed 
consistently higher T/N ratios than planar imaging 
(p<0.001). None of the patients suffered from 
adverse or subjective side effects.  
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Safavy et al. reported on the synthesis of tris-
bombesin conjugates with 188Re . The yields of 
chemical syntheses (+ 20 %) and radiolabelling (> 
90 % yield) as well as the positive binding of the 
radiolabelled conjugates to GRPR-positive tumours 
reveal promise in the use of these molecules for 
cancer therapy (124). 
 
VI CONCLUSION 
 
The role of GRP/GRP-R on tumour promotion and 
growth is well established in vitro on human cell 
line cultures and tumour xenografts grown in nude 
mice. However, data on the role of GRP/ GRP-R in 
human malignancies are limited and vary 
significantly according to the in vitro methodology 
used for GRP or GRP-R detection.   In analogy to 
the diagnosis of somatostatin receptor-expressing 
tumours in vivo with somatostatin receptor 
scintigraphy, in vivo GRP-R scintigraphy may be a 
potentially valuable tool to visualise and 
semiquantitate tumour GRP-R expression in a non-
invasive way. As such, GRP-R scintigraphy may be 
helpful to 1) further elucidate the role of GRP/GRP-
R in human malignancies, 2) to determine the 
incidence of functional GRP-R expression in 
various human malignancies in order to define 
diagnostic and staging imaging strategies and 3) to 
allow prediction of therapy responsiveness to 
recently developed bombesin antagonists.  
Finally, the use of Rhenium or Indium labelled 
bombesin analogues may provide a new therapeutic 
approach to GRP/BN expressing tumours. 
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Figure 1 shows the G-protein cycle. 
A. Binding of an agonist to the extracellular domain of its receptor results in the simultaneous dissociation of the 
heterotrimer from the receptor, exchange of GTP for GDP on the α-subunit and dissociation from the βγ-dimer. 
B. Translocation of PhospolipaseC-β (PLC-β) to the cellular membrane. 
C. α.GTP activates PLC-β which hydrolyses phosphatidylinositoldiphosphate (PtdInsP2) to diacylglycerol (DG) and 
inositoltriphosphate (InsP3). The hydrophobic DG remains in the plane of the membrane whereas the hydrophylic InsP3 
is released into the cytoplasm. The soluble cellular and nuclear Protein kinase C’s (c/nPKC) bind to GD and are thus 
translocated to the membrane. This results in their activation with subsequent generation of cellular responses 
characteristic of the agonist.  
D. Epidermal growth factor receptor (EGF-R) transactivation through G-protein coupled receptors can occur through 
activation of the protein kinases src and PYK-2, the latter are activated in the presence of increased intracellular Ca 2+ 
levels.  
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Figure 2.  
Figure 2 shows a schematic representation of endocytosis and recycling of GRP-R. 
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Newly synthesised receptors are delivered to the cell surface from the Golgi complex. In unstimulated cells there is a 
relatively slow endocytosis from the surface into endosomes, which increases dramatically following binding of a receptor 
specific agonist. Once the receptors reach endosomes they can either be recycled back to the plasma membrane or routed to 
lysosomes for degradation. The ligand however remains in the perinuclear space where it is trapped in lysosomes. 
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ABSTRACT 
 
Rationale : To determine the human 
biodistribution and radiation dosimetry of Tc-99m 
RP527, a promising radioligand for the visualization 
of gastrin releasing (GRP) receptor expressing 
human malignancies.  
Methods : Whole body scans were 
performed up to 48 h after intravenous injection of 
555 MBq Tc-99m RP527 in 6 subjects. Blood 
samples were taken at various times up to 48 h after 
injection. Urine was collected up to 48h after 
injection, allowing calculation of renal clearance and 
interpretation of wholebody clearance. Time-activity 
curves were generated for the thyroid, heart, breasts 
in women, testes in men and liver by fitting the 
organ–specific geometric mean counts, obtained 
from regions of interest. The MIRD formulation was 
applied to calculate the absorbed radiation dose for 
various organs.  
Results : The images showed rapid 
hepatobiliary excretion, resulting in good imaging 
conditions for the thoracic region, whereas imaging 
of the abdomen was impeded by extensive bowel 
activity. Tc-99m RP527 was predominantly cleared 
by the kidneys and to a lesser extent by the 
gastrointestinal tract. At 48 h p.i. the mean excretion 
in the urine was 58.3 % ( SD  : 5.4 % ). The highest 
absorbed doses were received by the excretory 
organs, i.e. the urinary bladder and gallbladder wall. 
The average effectve dose of Tc-99m RP527 was 
estimated to be 0.0095 mSv/MBq.  
Conclusions : The biodistribution of Tc-99m 
RP527 demonstrated low lung, myocardial and liver 
uptake allowing early imaging of the 
supradiaphragmatic region and this with a dosimetry 
favourable for clinical SPET imaging. The amount of 
Tc-99m RP527 required for adequate imaging of 
tumoral uptake results in an acceptable effective dose 
to the patient. 
 
Keywords : Tc-99m RP527 – biodistribution - 
dosimetry 
 
 
INTRODUCTION 
 
Gastrin releasing peptide (GRP) belongs to 
the family of bombesin-like peptides (BLP’s) that 
includes the amphibian peptide bombesin as well as 
the mammalian counterpart GRP and neuromedin B 
(1). Aside from their physiological role e.g. secretion 
of gastrin and pancreatic enzymes and gallbladder 
contraction (2,3), BLP’s have been shown to play a 
role in various tumor models and human cancer.  
GRP was first shown to be a mitogen for 
Swiss 3T3 murine embryonal fibroblasts and 
subsequently a growth factor for a number of normal 
cell types and cancers cell lines grown in culture or 
as xenografts in nude mice (4,5,6,7). BLP’s have 
been implicated as autocrine factors promoting 
growth of small cell lung cancer (1). Bologna et al. 
showed that GRP can stimulate proliferation of the 
androgen independent human prostatic carcinoma 
cell line PC3 (8).  Nelson et al. found that both 
bombesin and GRP stimulate proliferation of breast 
cancer cell lines when culture serum was stripped of 
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endogenous GRP-like peptides (9); other workers 
confirmed these findings (10).  
Importantly, the tumour growth stimulating 
effect of BLP’s can be blocked by GRP antagonists. 
Pinski et al. (11), Milovanovic et al. (12) and 
Jungwirth et al. (13) demonstrated the inhibitory 
growth effect of antagonists of the  GRP receptors in 
prostatic carcinoma. The same observation was 
reported by Koppan et al. (14) and Miyazaki et al. 
(15) in small cell lung- and breast carcinoma models 
respectively, either in cancer cells in vitro or 
xenografts grown in syngeneic rats or nude mice.   
GRP and GRP antagonists mediate their 
action through membrane-bound receptors. Three 
structurally and pharmacologically distinct bombesin 
receptor subtypes have been isolated and 
characterized : the gastrin releasing peptide receptor 
(GRP-R), the neuromedin B receptor (NMB-R) and  
bombesin receptor subtype-3 (BRS-3). The three 
receptors are structurally related, sharing about 50 % 
amino acid identity, and are members of the G-
protein coupled receptor superfamily with a seven 
predicted transmembrane segment topology (16). 
GRP receptors have been detected in various types of 
human carcinoma. Markwalder et al. described 
massive GRP receptor overexpression in human 
prostatic tissues that are neoplastically transformed 
or, like prostatic intraepithelial neoplasias, are in the 
process of malignant transformation (17). Gugger et 
al. using in vitro autoradiography showed 
heterogeneous GRP receptor specific expression in 
43 out of 60 (71%) breast carcinomas with all 
involved lymph nodes from primary carcinomas 
expressing GRP receptors being positive (18). Corjay 
et al. confirmed the presence of functional GRP 
receptors in human lung carcinoma (19). The 
presence or absence of receptors as well as their level 
of expression has been correlated with cancer 
prognosis in several settings. The hormone-
responsiveness and improved prognosis related to 
estrogen and progesteron receptor (ER and PR) 
expression in breast cancer is well known ( 20).  In 
laryngeal cancer (21) as well as non small cell lung 
cancer patients (22), the expression of epidermal 
growth factor correlated with a worse prognosis. A 
similar role for GRP receptor expression as 
independent prognosticator was recently suggested 
by Toi-Scott et al in lung carcinoma patients (23). In 
their series, patients from whom cell lines expressed 
GRP receptors versus those whose cell lines did not 
showed a trend towards worse survival (211 + 114 
days vs. 367+ 274 days). A prognostic role for GRP 
was further suggested by Saurin et al. who showed 
that in human colon carcinoma high GRP receptor 
mRNA levels are related to tumour dedifferentiation 
and lymphatic vessel invasion  (24). 
In analogy to the diagnosis of somatostatin 
receptor-expressing tumors in vivo with somatostatin 
receptor scintigraphy, in vivo GRP receptor 
scintigraphy may be a potentially valuable tool to 
visualize and semiquantitate tumoral GRP expression  
in a noninvasive way. This may  allow prediction of 
therapy responsiveness to bombesin antagonists and 
in vivo prognosis stratification. Tc-99m RP527, a 
targeting peptide derived from bombesin linked at its 
N-terminus via a linker group to a peptide sequence 
which chelates Tc-99m, binds GRP receptors with 
similar affinity to bombesin and is taken up by 
prostate-, pancreas- and breast tumour tissue in 
animal models as well as in humans in vivo (25, 26). 
This paper reports on its biodistribution and 
dosimetry in humans.  
 
MATERIALS AND METHODS 
 
Radiopharmaceutical synthesis 
 
Tc-99m RP527 labelling was performed 
using a kit-formulation. 0.1 mL stannous chloride 2 
mM, 0.1 mL sodium gluconate 60 mM, 1850-2035 
MBq 99mTcO4 in 0.3 mL 0.9 % sodium chloride and 
0.5 mL sodium chloride were added to 100 µg of 
RP527. After 35 minutes in a boiling water  bath, the 
reaction mixture was allowed to cool down to room 
temperature and injected on a HPLC system using an 
ethanol: water: acetic acid gradient. The radiolabelled 
peptide was collected at 45 min and the collected 
eluent was diluted with 10 mL 0.9% sodium chloride. 
The overall yield of the radiosynthesis was about 30 
% with a radiochemical purity > 90 % and a specific 
activity > 4.32 TBq/µmol. 
 
Subjects  
 
This study was approved by the Medical 
Ethics Committee of the University Hospital and 
performed according to Good Clinical Practice. Six 
individuals, mean age :  46 yrs, range : 24-73 yrs, 
were included in the study. There were 3 men and 3 
women. All subjects gave their written informed 
consent for participation in the study. All volunteers 
were free from illness on the basis of screening by 
medical history, physical examination, serum 
chemical analysis, complete blood cell count and 
urine analysis. For safety measurements, all chemical 
analysis were repeated during the experiment and 
compared to the baseline (screening) scores. 
 
Imaging 
 
Subjects were positioned supine with their 
arms alongside their body. Whole body images were 
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performed using a triple headed gamma camera (Irix, 
Picker, USA), equipped with low-energy high-
resolution parallel–hole collimators. The energy peak 
was centered at 140 keV with a 15 % window. 
Whole body planar images were acquired 30 min, 1 , 
3, 6, 24 and 48 h post injection. Acquisition was 
performed simultaneously in anterior and posterior 
position with a scan speed of 11.44 cm/min. Matrix 
size was 256x1024 pixels. 
 
Urine sampling 
 
For all subjects, all voided urine from time 
of injection until 48 h following injection was 
collected. The subjects were requested to collect 
urine prior to each emission scan and at home ad 
libitum. For each voidance, the urine was collected in 
a separate container and the volume and time of 
voidance recorded. For each voidance time, two 1 
mL urine aliquots were sampled and radioactivity 
was counted in a NaI (Tl) counter (Cobra Packards 
Instruments Company) after the counting efficiency 
of the system had been determined. The amount of 
radioactivity in the urine at each voidance time was 
expressed as percentage of the injected activity ( % 
IA) of Tc-99m RP527. 
 
Blood sampling 
 
Blood samples were taken at 15sec, 30sec, 
45sec, 1min, 1min15sec,1min30sec, 2min, 5min, 
7.5min, 10min, 12min, 15min, 20min, 30min, 55min, 
2h, 4h, 6h, 24h and 48 h following injection of the 
tracer. From each blood sample duplicate 1 mL 
aliquots were assayed for Tc-99m radioactivity as 
described above. Total blood volume and 
consequently activity was calculated using a total 
blood volume based on body weight and height (27) 
and expressed as a percentage of the injected activity 
( % IA). 
 
Dosimetry 
 
Image analysis 
 
For quantification of radioactivity uptake 
after injection of Tc-99m RP527, regions of interest 
(ROI’s) over the total body and organs of interest 
were drawn on the earliest images and the shapes and 
sizes, i.e. number of pixels, were kept constant over 
all subsequent images. Correction for non-specific 
uptake was performed by using a region over the 
shoulder. For each ROI, i.e. each organ, the 
geometric mean, corrected for physical decay, of 
total anterior and posterior counts was calculated. 
The total body geometric mean activity, calculated 
on the first image ( 1 h p.i.) was taken as total 
injected activity, considering that no urine was 
excreted prior to the first whole body scan. The 
activity in the total body and different organs was 
expressed as the percentage of the injected activity ( 
% IA) calculated by the following equation: 
(geometric mean counts in organ or total 
body)/(geometric mean counts in first total body) x 
100. 
 
Dosimetric calculations 
 
For each individual, time activity curves 
were generated for the thyroid, heart, breasts in 
women, testes in men, liver and whole body. Using 
in house written curve-fitting software, time activity 
curves were generated for these organs by bi-
exponential fits. Two routes of excretion were 
considered, i.e. urinary and faecal excretion. The 
faecal excretion was predicted using data from the 
source organs, the urinary excretion and the material 
excreted by the liver. Of the material excreted by the 
liver, 30  % was assumed to flow directly in the small 
intestine. Activity in the small intestine was assumed 
to follow the gastrointestinal kinetics as adopted in 
the ICRP 30 report (28). Activity in the intestines 
was assumed to pass through the various segments at 
standard rates, the mean transit time being 4 h for the 
small intestine, 13 h for the upper large intestine, and 
24 h for the lower large intestine. The transfer rate 
coefficient from the gallbladder to the small intestine 
was taken to be 1.8 h-1, derived by taking the mean 
of average emptying rates reported by others. 
Source organ residence times were determined from 
integration of the time activity curves. Residence 
times were then used to determine target organ 
radiation doses using the MIRD methodology (29) 
for the normal adult (30) applying the MIRDOSE 
software package (31). 
 
RESULTS 
 
After injection of approximately 555 MBq 
Tc-99m RP527 ( maximum  3 ng/kg per subject), no 
adverse or subjective effects were noticed in any of 
the subjects. Their vital signs remained stable 
throughout the experiment. Moreover, no meaningful 
changes were observed in any of the clinical 
laboratory assays performed on the blood and urine 
specimens obtained at 1 h, 6 h , 24 h and 48 h 
following administration of the radioligand when 
compared to baseline findings. Whole body images 
of a male subject showing the biodistribution of 
radio-activity upon injection of Tc-99m RP527 at 
different time points post-injection are presented in 
figure 1. The whole body images obtained between 
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30 min and 24 h p.i. show most of the activity 
distributed in the bladder, liver, gallbladder and 
intestines, reflecting the known urinary and 
hepatobiliary excretion of peptides. Although the 
kidneys were not visualized in all subjects, there was 
activity in the urinary bladder in all subjects, 
indicating prompt excretion through the renal system. 
Uptake in the brain, myocardium and lungs was low. 
There was a diffuse uptake and retention of 
radioactivity in the normal breast tissue in females as 
well as in the testes in men. Although of low quality 
due to low counting statistics, images at 24 h as well 
as 48 p.i. showed most of the remaining activity 
distributed in the intestines. Averaged ROI data over 
all subjects, expressed as % IA, of the biodistribution 
of 99mTc-RP 527 in the total body and in various 
organs at the different points in time  are presented in 
figure 2. Clearance of radioactivity from blood fitted 
a bi-exponential curve. The assays of blood samples 
showed that the elimination of activity from the 
blood was initially fast, such that by 20 min post 
injection less than 20 % of the injected dose 
remained in the blood . The mean calculated half-life 
was  1.5 min (first exponent). 
The average excretion fractions predicted 
for faeces and measured for urine are given in table 
1. Most of the administered activity was eliminated 
by the renal system. The mean cumulative total 
measured urinary excretion at 48 h post injection was 
58.3 % (SD :  5.4 %) of the administered activity, 
whereas the mean predicted percentage of the 
administered activity excreted in the faeces was  3.9  
% ( SD : 0.8 %) at 48 h post injection.  
The residence time was highest for the 
remainder of the body in all subjects, followed by the 
urinary bladder and the liver (table 2).  
The mean radiation dose estimates ( + 
standard deviation) were  calculated for each subject 
independently, and then averaged ( table  3 ). The 
organs receiving the highest absorbed doses were 
involved in the excretion of Tc-99m RP527 from the 
body. On average, the highest dose was received by 
the urinary bladder ( mean : 9.6E-2 mGy/MBq ; SD 
1.15E-2 mGy/MBq ) followed by the gallbladder wall 
(  mean 1.69E-2 mGy/MBq ; SD :  0.4 mGy/MBq) and 
the testes ( mean 1.22E-2 mGy/MBq  ; SD : 0.3E-02 
mGy/MBq). The estimated mean effective dose for 
the adult subject was   9.5E-03 mSv/MBq ( SD : 1.1E-03 
mSv/MBq). 
 
DISCUSSION 
 
The results of the present study demonstrate 
the favourable biodistribution of Tc-99m RP527 in 
humans. Moreover the results of this study 
demonstrate that Tc-99m RP527 is a 
pharmacologically safe radioligand since it did not 
produce any subjective or objective pharmacological 
effects. The lack of a pharmacological effect was 
expected since the dose injected ( + 3ng/kg) is only 
half of the dose reported of unlabeled bombesin 
inducing side-effects e.g. nausea, vomiting (32). 
In  humans Tc-99m RP527 was cleared rapidly from 
circulation, such that by 20 min post injection, < 20 
% of the injected dose remained in the blood. The 
mean calculated blood clearance half-life of 1.5 min 
of Tc-99m RP527 is comparable to the 2.2 min of 
unlabeled bombesin reported in men (33). Low brain, 
lung and myocardial uptake and rapid hepatobiliary 
excretion of Tc-99m RP527 resulted in excellent 
imaging conditions for the supradiaphragmatic 
region, even at early time points ( 30 min ) p.i. On 
the other hand, in addition to a predominant urinary 
clearance, Tc-99m RP527 was also cleared 
enterohepatically resulting in a high accumulation of  
radioactivity affecting interpretation of the abdominal 
region. 
Of interest is the visualization  of the breasts 
in women and testes in men.  
The visualization of the breasts is in keeping 
with the known bombesin-like immunoreactivity 
demonstrated in mammary glands of various species 
(34,35) indicating that bombesin/GRP similar to ER 
and PR may be involved in the regulation of 
mammary cell proliferation and differentiation. Data 
by Halmos et al. showing  a highly positive 
correlation ( r = 0.671, p< 0.005) between the 
binding capacity of high affinity (Tyr 4)-bombesin 
binding sites and ER levels and between the 
concentration of low affinity (Tyr4)-bombesin 
binding sites and PR levels ( r =0.541, p < 0.005) in 
biopsies of human breast carcinoma suggest a 
possible interaction between both receptor systems 
(36) .  
In primates a bombesin-like peptide 
resulting from alternate splicing of the GRP gene has 
been detected in testis. In vitro, GRP at the 
concentration of 100 nM, added after ionophore 
treatment, enhanced significantly (p<0.05) human 
sperm motility, capacitation, zona binding and 
acrosome reaction thus supporting a role for BLP’s in 
the regulation of sperm cell proliferation and 
differentiation (37). In this regard the visualisation of 
the testes in all 3 male subjects following injection of 
Tc-99m RP527 suggests the presence of a currently 
unidentified human testicular BLP receptor. Since in 
mouse testis the NMB-R gene expression is 
prominent and in rat testis the BRS-3 receptor has 
been shown to be expressed, it is possible that 
different subtypes of bombesin receptors mediate the 
same response in different species (38).  
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The MIRDOSE software provides a 
calculation of the effective dose as defined in the 
 ICRP 60. Based on the mean effective dose 
of 9.5E-03  mSv/MBq obtained in this study, both 
patients and volunteers could easily be investigated 
with  555 MBq Tc-99m RP527 allowing both planar 
and SPECT imaging. The corresponding effective 
dose of 5.27 mSv is equal to the reported average 
effective dose per patient from nuclear medicine 
procedures in Europe (39) and only half of  the 10 
mSv upper limit average effective dose of Category 
II a of the World Health Organisation and Category 
II b of the ICRP report (40). Since the highest dose is 
received by the bladder wall, frequent voiding will 
reduce the absorbed dose to the urinary bladder. 
Given the 1 % probability for severe hereditary 
disorders in the offspring per Sv received by the 
testis, the associated risk related to injection of 555 
MBq Tc-99m RP527 is less than 1/10000. This is 
low when compared to the 1.6 % prevalence of 
naturally occurring genetic disorders (ICRP 60).  
 
CONCLUSION :  The biodistribution of Tc-99m 
RP527 demonstrated low lung, myocardial and liver 
uptake allowing early imaging of the 
supradiaphragmatic region and this with a dosimetry 
favourable for clinical SPET imaging. 
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TABLE 1.  Excretion fractions (% IA) for Tc-99m RP527 
__________________________________________________________________ 
 
Compartment Time p.i. (h)  AVG  SD 
__________________________________________________________________ 
 
Urine  48-measured  58.3  5.4 
Faeces 48-predicted    3.9  0.8 
__________________________________________________________________ 
AVG, average ; SD, standard deviation ; % IA, percentage of the activity injected 
 
 
TABLE 2. Residence times (h) for Tc-99m RP527 for each source organ 
_______________________________________________________________ 
 
Organ   AVG   SD 
________________________________________________________________ 
 
Gall bladder   0.106   0.031 
Lower large intestine  0.031   0.009 
Small intestine   0.048   0.015 
Upper large intestine  0.063   0.019 
Heart wall   0.025   0.004 
Liver    0.264   0.053 
Thyroid   0.012   0.007 
Bladder   1.801   0.206 
Remainder   2.325   0.197 
Breasts*   0.009   0.007 
Testes*   0.028   0.007 
________________________________________________________________ 
AVG, average ; SD, standard deviation, * number of subjects = 3, respectively 
women and men 
 
TABLE 3. Radiation absorbed dose estimates (mGy/MBq) for Tc-99m RP527 
_______________________________________________________________ 
 
Target Organs    AVG  SD 
_______________________________________________________________ 
 
Adrenals    3.27E-03  3.55E-04 
Brain     1.23E-03  1.84E-04 
Gallbladder wall    1.69E-02  4.32E-03 
Lower large intestinal wall   7.27E-03  8.68E-04 
Small intestine    4.53E-03  5.98E-04 
Stomach    2.12E-03  3.20E-04 
Upper large intestinal wall   5.46E-03  9.65E-04 
Heart wall    2.64E-03  5.75E-04 
Kidneys    2.17E-03  3.04E-04 
Liver     4.79E-03  1.13E-03 
Lungs    1.71E-03  3.23E-04 
Muscle    2.40E-03  2.73E-04 
Pancreas    2.57E-03  3.86E-04 
Red marrow    2.18E-03  2.68E-04 
Bone surfaces    3.46E-03  4.07E-04 
Skin     1.25E-03  1.47E-04  
Spleen    1.80E-03  2.74E-04 
Thymus    1.56E-03  2.49E-04 
Thyroid    8.07E-03  3.90E-03 
Urinary bladder wall   9.63E-02  1.16E-02 
Uterus †    1.08E-02  1.15E-03 
Testes †    1.23E-02  2.70E-03 
Ovaries †    6.75E-03  5.17E-04 
Breasts †    9.59E-04  2.28E-04 
Total Body    2.54E-03  3.17E-04 
Effective dose equivalent *   1.13E-02  1.12E-03 
Effective dose *    9.53E-03  1.06E-03 
______________________________________________________________________ 
AVG, average ; SD, standard deviation 
*  Units of the effective dose equivalent and of the effective dose are mSv/MBq 
† gender specific AVG and SD of 3 subjects 
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Figure 1.  
 
The anterior whole body images obtained from a man at 30 min, 1, 3, 6 and 24 h post injection (right to left). 
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Units of the abcis and ordinate are time (h) and % injected activity respectively 
Figure 2. 
 
Time-activity curves for the total body (wb), various organs and blood, calculated from direct measurements of 
counts in organ-specific ROI’s or in blood. The physical decay-corrected data, expressed as % IA are averaged over 
the 6 subjects, except for the breasts (n = 3) and testes (n=3). The error bars represent 1 SD. 
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ABSTRACT 
 
Gastrin releasing peptide (GRP) receptor 
scintigraphy could allow prediction of response to 
GRP receptor targeted treatment options, early non-
invasive diagnosis and in vivo prognosis 
stratification of GRP receptor positive tumours. 
This study reports on the imaging characteristics 
and efficacy for tumour detection of Tc-99m RP527 
a Tc-99m chelated targeting peptide derived from 
bombesin which binds GRP receptors with high 
affinity. 
Ten patients (4 men and 6 women, mean age : 56.4 
years) either suffering from metastasised prostate- 
(n, number of patients = 4) or breast carcinoma 
(n=1) or presenting with a clinical diagnosis highly 
suggestive for breast carcinoma (n=5) were 
included in the study. In the latter 5 patients Tc-
99mRP527 scintigraphy was performed prior to 
diagnostic eg. biopsy and staging examinations. 
Final diagnosis in these patients was breast 
carcinoma in all 5. In all patients whole body planar 
scans and tomographic images were acquired 1 h 
and 5-6 h post-injection of 555 MBq Tc-99m 
RP527 and tumour to normal tissue ratios (T/N) 
determined. 
Tc-99m RP527 showed specific uptake in 4/6 
breast- and 1/4 prostate carcinomas. T/N derived 
from planar and tomographic images increased 
significantly (p<0.01) from 1.65 (SD : 1.53) and 
3.35(SD:3.04) to 2.58(SD:1.26) and 7.23(SD:8.46) 
respectively. T/N derived from tomographic images 
were consistently higher (p<0.01). 
The data presented suggest Tc-99m RP527 results 
in specific tumour localisation and exhibits good 
imaging characteristics with good T/N that may be 
further enhanced by SPECT. 
 
Key words : Tc-99m RP527- GRP receptor-
feasibility 
INTRODUCTION 
 
Gastrin releasing peptide (GRP) belongs to the 
family of bombesin like peptides (BLP’s) which 
include amongst others the amphibian peptide 
bombesin as well as its mammalian counterpart 
GRP (1). Aside from its physiological role (2,3), 
GRP has been shown to play a role in various 
tumour models and human carcinoma. GRP was 
first shown to be a mitogen for Swiss 3T3 murine 
embryonal fibroblasts and subsequently a tumour 
growth factor for a number of normal- and cancer 
cell lines grown in culture or as xenografts in nude 
mice (4,5,6,7,8). In these tumour models, the 
tumour growth stimulating effect of GRP is  a direct 
result of binding of GRP to membrane G-protein 
coupled GRP receptors (GRP-R) on the cell 
surface. The mechanism by which tumour growth 
stimulation occurs does not appear to be constant 
but in general seems to involve trans-activation and 
up-regulation of epidermal growth factor receptors 
(9,10). Importantly, the tumour grwoth stimulating 
effect of GRP can be blocked by a wide variety of 
GRP antagonists ranging from synthetic 
octapeptides, reduced peptide bond analogues of 
GRP, melphalan derivatives, homodimeric forms of 
bombesin, the more promising substance P 
derivatives to anti-bombesin monoclonal antibodies 
eg. 2A11 (11-19). The latter has been used to treat 
small cell lung carcinoma patients (SCLC) and this 
with promising results (19). Over-expression of 
GRP-R when compared to normal surrounding 
tissue has been described in a wide variety of 
human tumours e.g. SCLC, prostate-, breast-, 
colorectal and gastric cancer (20-24). In these 
patient populations, treatment with GRP-R 
antagonists either in mono- or combination therapy, 
radiotherapy with radiolabeled GRP analogues and 
GRP-R targeted cytotoxic peptide conjugates may 
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prove to be new and efficient therapeutic 
approaches.  
 
In analogy to the diagnosis of somatostatin 
receptor-expressing tumours in vivo with 
somatostatin receptor scintigraphy, in vivo GRP-R 
scintigraphy could allow prediction of response to 
these GRP-R targeted treatment options and early 
non-invasive tumour diagnosis. 
This paper reports on a pilot study 
approved by the Ethical Board of the University 
Hospital Ghent, assessing the safety, imaging 
characteristics and efficacy for tumour detection of 
the GRP analogue Tc-99m RP527 developed for 
GRP-R scintigraphy . 
 
METHODS AND PATIENTS 
 
RP 527 synthesis, identification and 
characterisation 
 
The peptide RP527 is synthesised chemically using 
solid phase tBoc chemistry and then purified by 
reverse-phase HPLC at Polypeptide Laboratories 
GmB, Wolfenbuttel, Germany. The peptide is > 97 
% pure, as measured by two differential analytical 
HPLC methods at Polypeptide Laboratories, CA, 
USA. RP527 contains a tripeptide N3S chelator 
(dmgly-L-ser-L-cys(acm)) which forms a stable 
complex with Tc-99m(V)O, losing an 
acetamidomethyl protecting group in the process. 
The chelator sequence is linked to the N-terminus 
of an octapeptide, Gln-Trp-Ala-Val-Gly-His-Leu-
Met-NH2 derived from bombesin, via a gly-5aVa 
linker. The C-terminus is amidated (figure 1). The 
interaction of the chelator with Tc-99m and Re, a 
non-radioactive metal with very similar co-
ordination properties, has been confirmed by NMR 
and X-ray crystallography (25).  
 
Radiolabelling 
 
Tc-99m RP527 labelling was performed using a kit-
formulation provided by Resolution 
Pharmaceuticals and reconstituted according to the 
manufacturer’s guidelines. 0.1 ml stannous chloride 
2 mM, 0.1 ml sodium gluconate 60 mM, 1850-2035 
MBq Tc-99mO4 in 0.3 ml 0.9% sodium chloride 
and 0.5 ml sodium chloride were added to 100 µg 
of RP527. After 35 minutes in a boiling water bath, 
the reaction mixture was allowed to cool down to 
room temperature and injected on a HPLC system 
using an ethanol: water: acetic acid gradient in 
order to separate radiolabelled from unlabelled 
peptide. The radiolabelled peptide was collected at 
45 min and the collected eluent was diluted with 10 
mL 0.9% sodium chloride. The overall yield of the 
radiosynthesis was about 30% with radiochemical 
purity > 90 % and a specific activity > 4.32 
TBq/µmol. The total peptide content of the final 
preparation is < 200 ng. The purified Tc-99m 
RP527 may be stored at 4°C in the dilution vial for 
up to 2 hours.  
For quality control, Re chelated RP527 
(RP720) synthesised by an alternative synthetic 
route is co-injected with the collected Tc-99m 
RP527 on HPLC. Both co-elute, thus confirming 
the identity of the complex. 
 
Patients 
 
Ten patients were included in the study 
following written informed consent. 
Five patients suffered from histologically 
proven and documented bone metastasised 
androgen resistant prostate- (n, number of patients 
=4) or hormonal refractory bone metastasised breast 
carcinoma (n=1). In the latter patient, the primary 
tumour as well as involved lymph nodes were also 
present. 
Another five patients were referred 
because of a clinical diagnosis highly suggestive for 
breast carcinoma (n=5). These patients underwent 
Tc-99m RP527 scintigraphy on the day before 
biopsy and/or fine needle biopsy of the suspected 
mass and/or lymph nodes. Also, in these patients 
routine staging examinations were performed 
within one week following Tc-99m RP527 
scintigraphy. 
For safety measurements, vital signs were 
registered and serum chemical analysis, complete 
blood cell count and urine analysis performed prior 
to injection of 555 MBq Tc-99m RP527 and 
repeated 1, 6 and 24 h pi.  
Whole body scans were performed 1 h and 
5-6 h pi. using a triple headed gamma camera (Irix, 
Picker) in scanning mode (11.3 cm/min) equipped 
with high resolution collimators. Localised SPECT 
acquisitions made of known tumour regions at 1 
and 5-6 h with a 120 x 20 sec acquisition over 360° 
were reconstructed iteratively (Ordered Subset 
Expectation Maximisation  algorithm, 2 iterations, 
6 subsets) and postfiltered using a Butterworth filter 
(cut-off frequency : 0.8 cycles/cm, order 8). 
Tumour to normal tissue ratios (T/N ratio) were 
determined on 1 h and 5-6 h planar and summed 
tomographic slices incorporating the entire 
dimensions of the tumour.  
For comparison of means, paired and 
unpaired two-sided Wilcoxson tests were used. 
 
RESULTS 
 
Patient characteristics and results are 
shown in tables 1 and 2. 
None of the patients suffered from adverse 
or subjective side effects. Vital signs and clinical 
laboratory blood or urine assays remained stable 
throughout the experiment. 
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At 1 h. pi. the distribution of Tc-99m RP527 
activity shows diffuse distribution, minimal 
bloodpool activity and hepatic and renal clearance. 
5-6 h pi. there is significant clearance of activity 
with continued hepatobiliary and renal excretion. In 
general, breast tissue in women and testes in men 
showed a diffuse low tracer uptake and retention. If 
the pancreas was in the field of view of the 
tomographic images pancreatic Tc-99m RP 527 
uptake was clearly depictable (6/10 patients). This 
was not so for planar images due to overlap with 
intestinal activity.  
Out of four bone metastasised androgen 
resistant prostate adenocarcinoma patients, only one 
showed Tc-99m RP527 uptake in + half of the bone 
lesions depicted by bone scintigraphy. In the known 
bone metastasised breast carcinoma patient, neither 
primary tumour site, involved lymph nodes nor 
bone metastases depicted on routine staging 
examinations or confirmed by histology, showed 
Tc-99m RP527 uptake. 
All 5 patients with suspected breast lesions 
were tumour positive on histology. Primary tumour 
Tc-99m RP527 uptake was clearly depictable in 4 
of them (figures 2 and 3). In these 4 patients, all 
involved lymph nodes and part of distant metastases 
(limited to the bone), when present, also showed 
Tc-99m RP527 uptake. No uptake was seen in areas 
of central tumour necrosis if present e.g. patients 6 
and 9. In Tc-99m RP527 positive patients, T/N 
ratios derived from planar and tomographic images 
increased significantly from 1.65 (SD : 1.53) and 
3.35 (SD : 3.04) to 2.58 (SD : 1.26) and 7.23 (SD : 
8.46) at 1 h and 5-6 h pi. (p <0.01 for both planar 
and tomographic T/N ratios), due to a decrease in 
background activity. SPECT imaging showed 
consistently higher T/N ratios than planar imaging 
(p<0.001). 
 
DISCUSSION 
 
The primary actions of RP527 have been previously 
investigated in vitro and in vivo in SCID mice. 
Both unlabelled bombesin, uncomplexed RP527 
and the structural mimic of Tc-99m RP527, RP720 
(ReO-RP527) inhibited binding of I-125 bombesin 
to GRP-R expressing PC-3 and CF-PAC-1 cells 
(human prostate and pancreatic cancer cell lines 
respectively) with similar mean IC50 values ranging 
from 1.6-5.5 nM, suggesting similar affinities for 
the GRP-R. In this in vitro study, the Kd value of I-
125 bombesin was 2.5 nM. Tc-99m RP527 was 
rapidly and specifically bound and internalised by 
both PC-3 and CF-PAC-1 cells. As internalisation 
of G-protein coupled receptor ligands following 
binding to its respective receptor is specific for 
agonists, Tc-99m RP527 is believed to be a GRP-R 
agonist (26).  Internalisation of the GRP/GRP-R 
complex involves coalescence into clathrin-coated 
vesicles and endosomes and migration to the 
perinuclear space. Whereas a portion of GRP-R will 
recycle back to the cell membrane, the ligand 
remains in the perinuclear space where it is trapped 
in lysosomes (27,28). This entrapment prolongs the 
residence time of GRP agonist bound radioactivity 
in the target tissue when compared to antagonists, 
resulting in a higher accumulation of radioactivity 
in GRP-R positive tissues (29-30). Finally, in SCID 
mice studies, Tc-99m RP527 showed tumour 
uptake of 0.2-1.8 (µ), 0.0-0.6 (SD) %/g at 4 h with a 
tumour to muscle ratio ranging from 9.8-33.7 at 1 h 
and 6.25-25.4 at 4 h in humane prostate (PC-3), 
pancreatic (CF-PAC-1) and rat pancreatic (AR42J) 
GRP-R positive tumour cell xenografts (11). 
In the study presented, Tc-99m RP527 
showed selective uptake in 4/6 breast and 1/4 
prostate carcinoma irrespective of lesion size. 
Tumour activity was more easily identified at 5-6 h 
pi. rather than at 1 h pi. due to a decrease in 
background activity, in keeping with the agonist 
character of Tc-99m RP527. The progressive and 
consistent increase in T/N ratios suggests a relative 
difference in clearance rate of bound and unbound 
radioligand from tissue and thus a specific tumour 
uptake mechanism in keeping with in vitro and in 
vivo animal data on Tc-99m RP527. A GRP-R 
mediated uptake is further supported by the 
visualisation of the pancreas, a GRP-R expressing 
organ, in those patients in whom the pancreas was 
in the field of view of the tomographic images.  
The presented findings are concordant with 
data obtained previously using autoradiography in 
breast and prostate carcinoma. Gugger et al. using 
in vitro autoradiography showed heterogeneous 
GRP-R specific expression in 43 out of 60 (71%) 
breast carcinomas with all involved lymph nodes 
from primary cancers expressing GRP-R being 
positive (24). Low grade expression of GRP-R 
proved also ubiquitous in non-neoplastic human 
breast tissue, although heterogeneously distributed. 
Concordingly, Tc-99m RP527 was taken up in both 
primary- and lymph node lesions of 4 out of 6 
(66%) breast cancer patients as well as in bone 
metastases if present. Low physiological uptake of 
Tc-99m RP527 was also seen in normal breast 
tissue but this did not affect tumour depiction. 
Markwalder et al. (15) evaluated the 
expression of GRP-R in neoplastic prostate tissue 
and found a highly variable, high density (dpm/mg 
tissue: 5241+927) bombesin receptor subtype 
expression in 30/30 invasive prostate carcinoma. In 
general undifferentiated primary prostate 
carcinomas expressed low GRP-R levels. However 
poorly differentiated androgen-independent bone 
metastases tended to express GRP-R ( 4 of 7 cases) 
albeit in a highly variable range (dpm/mg tisue : 
3863+2018). In keeping with the large standard 
deviation in this patient group, only one out 4 
androgen independent prostate carcinomas in this 
series took  
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up Tc-99m RP527, and there appeared to be 
variability of uptake between different metastases, 
possibly reflecting different levels of receptor 
expression. As shown by Jiborn et al. 
neuroendocrine differentiation with appearance of 
neurosecretory granules, rich in various peptide 
hormones eg. GRP and biogenic amine , in prostatic 
carcinoma during androgen withdrawal treatment 
occurs in + 40 % of untreated patients. Part of these 
patients might benefit from treatment with GRP 
antagonists e.g. MoAb 2A11 and could be selected 
by means of Tc-99m RP527 scintigraphy. 
In conclusion, the data presented suggest 
Tc-99m RP527 is safe, results in specific tumour 
localisation and exhibits good imaging 
characteristics with good lesion-to-normal tissue 
background ratios. However, additional studies 
clarifying the clinical potential of this agent and 
correlating in vivo Tc-99m RP527 tumour uptake 
with the presence of the tumour GRP receptor 
status as measured, for example, by 
immunohistochemistry or radioligand binding 
assays are mandatory. 
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Table 1 
Patient Gender  Age Diagnosis Planar RP527 SPECT      ∆T/N Nb RP527+/ Nb BSL 
1. M 62 ARBMPA -  -       na  0 /34 
2. M 63 ARBMPA +  +      ↑   14/33 
3. M 74 ARBMPA -  -       na  0 /71 
4. M 59 ARBMPA -  -       na  0 /38 
5.* F 62 HRBMBC -  -       na  0 / 4 
Legends: ARBMPA = androgen resistant bone metastasised prostate adenocarcinoma, HRBMBC : hormone refractory bone metastatised breast carcinoma, na = not applicable, ∆T/N = 
change in tumour-to-normal tissue ratio from 1 h to 5.6 h pi., +  = tumour activity present, - = tumour activity not visualised, ↑ = increase, Nb RP527+ = number of RP527 positive lesions, 
Nb BSL = number of bone scintigraphic metastatic lesions. 
* Primary tumour and axillary lymph nodes in this patient were also Tc-99m RP527 negative. 
 
Table 1 shows the patient characteristics and details of 99mTc RP527 scan results in the subgroup of patients suffering from 
proven and documented bone metastasised androgen resistant prostate – or hormone ablative treatment refractory breast 
carcinoma. 
 
 
Table 2. 
__________________________________________________________________________  
Patient  Age  Final diagnosis Planar RP-527 SPECT ∆T/N Nb RP527+/ Nb BSL 
6. 47 T3N2M0 -  + ↑ na 
7. 37 T3N1M0 -  + ↑ na 
8. 50 T2N3M1 -  - na 0/20  
9. 65 T4N3M1 +  + ↑ 3 /4 
10. 44 T3N1M0 +  + ↑ na 
_________________________________________________________________________ 
Legends : na = not applicable, ∆ T/N = change in tumour-to-normal tissue ratio from 1 h to 5.6 h pi., +  = tumour  
activity present , - = tumour activity not visualised, ↑ = increase, Nb RP527+ = number of Tc-99m RP527 positive  
lesions, Nb BSL = number of bone scintigraphic metastatic lesions 
 
 
Table 2 shows the patient characteristics and details of 99mTc RP527 scan results in the subgroup of patients referred 
because of a clinical diagnosis highly suggestive for breast carcinoma. 
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Figure 1 
Figure 1 shows the structure of Tc-99m RP527. 
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Figure 2 
Figure 2 shows the whole body images (posterior and anterior projection) as well as the corresponding transaxial, coronal and 
sagittal tomographic (top to bottom) Tc-99m RP527 image slices of the thoracic region of patient 9 showing uptake in the 
primary breast tumour (indicated by T), involved axillar, retrosternal and cervical lymph nodes (indicated by N) and bone 
metastases (indicated by M). 
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Figure 3 
Figure 3 shows the transaxial, coronal and sagittal (top to bottom) tomographicTc-99m RP527 image slices of the thoracic 
region of patient 10 showing uptake in the primary breast tumour (indicated by T), a mastitis component (indicated by ma)  
and involved axillary lymph nodes (indicated by N). Bilateral, symmetrical physiological breast uptake (indicated by ph), 
relatively intense when compared to the other breast carcinoma patients, is also seen. Interfering abdominal activity has been 
removed using region growing. 
 
 
 
 
 
 
 
 
 
 
 
 77
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 78
  
 
 
 
 79
Original Article 
______________________________________________________________________________ 
GASTRIN RELEASING PEPTIDE RECEPTOR IMAGING IN HUMAN BREAST 
CARCINOMA USING Tc-99m  RP527 VERSUS IMMUNOHISTOCHEMISTRY 
 
Christophe Van de Wiele*, Rudi VandenBroeke°°, Veronique Cocquyt**, Filip Dumont”, Guido Slegers”, RA. 
Dierckx * 
 
* Division of Nuclear Medicine, Ghent University Hospital, Belgium 
°°  Division of gynaecological oncology, Ghent University Hospital, Belgium 
** Division of Medical Oncology, Ghent University Hospital, Belgium 
“ Department of Radiopharmacy, Ghent University, Belgium 
 
European Journal of Nuclear Medicine, 2001, submitted 
________________________________________________________________________________________
 
 
ABSTRACT 
 
Background : In vivo visualisation of gastrin 
releasing peptide receptor (GRP-R) status by means 
of 99mTc RP527 could predict or rapidly assess 
respons to treatment modalities targeting GRP-R. We 
report on the relationship between breast tumour 
uptake of 99mTc RP527, a 99mTc chelated peptide 
which binds to GRP-R, and GRP-R expression as 
measured by immunohistochemistry (IHC). 
Methods : Nine patients referred because of a clinical 
diagnosis suggestive for breast carcinoma, four 
patients suffering from tamoxifen resistant bone 
mestastasised breast carcinoma and one patient 
presenting with a local breast carcinoma recurrence 
invading the sternum underwent 99mTc RP527 
scintigraphy. Results obtained were compared to 
routine staging examinations in all patients and to 
routine histopathologic analysis and IHC GRP-R 
staining in the first nine patients.  
Findings : All 9 patients with suspected breast lesions 
were tumour positive on histology. Uptake of 99mTc 
RP527 was clearly depictable in the primary tumour 
of 8 out of 9 patients and in involved lymph nodes 
and part of the distant metastasis limited to the bone 
(occurring in only one patient) when present. In none 
of the remaining patients, 99mTc RP527 uptake was 
found. 
In 5 out of 8 99mTc RP527 positive patients, IHC 
was negative whereas the one 99mTcRP527 negative 
tumour was also IHC negative.  
Interpretation : The different incidence GRP-R 
number found between 99mTc RP527 imaging, and 
IHC likely relates to differences in methodology. In 
the near future, 99mTc RP527 imaging might be 
helpful to further elucidate the role of GRP-R in 
human malignancies and to allow prediction or 
monitoring of therapy responsiveness to recently 
developped GRP-R antagonists. 
 
 
INTRODUCTION 
 
The duration of remission of breast cancer 
produced by currently available endocrine treatment 
modalities is varied and eventually all patients with 
advanced breast cancer treated by any modality of 
estrogen deprivation relapse (1). Thus, there exists a 
need for new endocrine treatment modalities that 
improve outcome for hormone unresponsive breast 
tumours. Gastrin releasing peptide/bombesin (GRP) 
has been shown to function as an autocrine growth 
factor in a variety of human tumours, including breast 
carcinoma (2). Its tumour growth stimulating effect is 
a direct consequence of binding to the GRP 
heptaspanning receptor (GRP-R). With the aim of 
inhibiting breast tumour growth, this growth factor 
and its receptor have been evaluated as potential 
targets for various antagonists or blokking agents, e.g. 
the monoclonal antibody 2A11 (3,4,5,6). As these 
blocking agents result in tumour stasis rather than 
regression, alternative techniques to morphological 
imaging, assessing changes in tumour volume, will be 
necessary to monitor there efficacy.   
The success of 111In Octreoscan in 
demonstrating tumours with somatostatin receptors 
(7) and of I123 vasoactive intestinal peptide for 
visualization of tumours overexpressing VIP 
receptors by scintigraphic imaging (8), prompted the 
search for a radiolabelled bombesin/gastrin releasing 
peptide analogue. By virtue of their potential to 
visualise tumour lesion GRP-R status and its effective 
downregulation following efficient treatment, 
radiolabelled gastrin releasing peptide analogues have 
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the potential to predict or rapidly assess respons to 
GRP-R targeted treatment modalities. 
Tc99m RP527 consists of a targeting peptide 
derived from bombesin, linked at its N-terminus via a 
linker group to a peptide sequence which chelates 
99mTc. Both unlabelled bombesin, uncomplexed 
RP527 and the structural mimic of 99mTc RP527, 
RP720 (ReO-RP527) inhibit binding of 125I bombesin 
to GRP-R expressing PC-3 and CF-PAC-1 cells 
(human prostate and pancreatic cancer cell lines 
respectively) with similar mean IC50 values ranging 
from 1.6-5.5 nM. Additionally, 99mTc RP527 was 
rapidly and specifically bound and internalised by 
both PC-3 and CF-PAC-1 cells (9). The ligand has 
been shown to be safe and to exhibit good imaging 
characteristics (10). Data on its uptake as compared to 
GRP-R measurements by other techniques, however, 
are lacking. 
This paper reports on the relationship 
between 99mTc RP527 uptake in tumour lesions of 
patients suffering from breast carcinoma and GRP-R 
expression as measured by immunohistochemistry 
(IHC).   
 
PATIENTS AND METHODS 
 
PATIENTS 
 
This study was approved by the Medical 
Ethics Committee of the University Hospital and 
performed according to Good Clinical Practice. 
Fourteen patients, mean age :  58.6  yrs, range  37-75 
yrs, were included in the study. All patients gave their 
written informed consent for participation in the 
study. Nine patients were referred because of a 
clinical diagnosis highly suggestive for breast 
carcinoma. These patients underwent Tc-99m RP 527 
scintigraphy on the day before biopsy and/or fine 
needle biopsy of the suspected mass and/or lymph 
nodes. In addition to routine histopathologic analysis, 
slides of these patients were stained for GRP-R. Also, 
in these patients, routine staging examinations were 
performed within one week following Tc-99m RP527 
scintigraphy.  
Another four patients suffered from 
histologically proven and documented tamoxifen 
resistant bone metastasised breast carcinoma and one 
patient presented with a local recurrence invading the 
sternum. 
 
METHODS 
 
Radiopharmaceutical synthesis 
 
99mTc-RP 527 labelling was performed 
using a kit-formulation. 0.1 mL stannous chloride 2 
mM, 0.1 mL sodium gluconate 60 mM, 1850-2035 
MBq 99mTcO4 in 0.3 mL 0.9 % sodium chloride and 
0.5 mL sodium chloride were added to 100 µg of 
RP527. After 35 minutes in a boiling water  bath, the 
reaction mixture was allowed to cool down to room 
temperature and injected on a HPLC system using an 
ethanol: water: acetic acid gradient. The radiolabelled 
peptide was collected at 45 min and the collected 
eluent was diluted with 10 mL 0.9% sodium chloride. 
The overall yield of the radiosynthesis was about 30 
% with a radiochemical purity > 90 % and a specific 
activity > 4.32 TBq/µmol. 
 
Scintigraphy 
 
Subjects were positioned supine with their 
arms alongside their body. Whole body images were 
performed using a triple headed gamma camera (Irix, 
Picker, USA), equipped with low-energy high-
resolution parallel–hole collimators. The energy peak 
was centered at 140 keV with a 15 % window. Whole 
body image scans were acquired 1 h and 5-6 h pi. in 
scanning mode (11.3 cm/min). Localised SPECT 
acquisitions made of known tumour regions at 1 h and 
5-6 h with a  120x 20 sec acquisition over 360 ° were 
reconstructed iteratively (Ordered Subset Expectation 
Maximisation algorithm, 2 iterations, 6 subsets) and 
postfiltered using a Butterworth filter (cut-off 
frequency : 0.8 cycles/cm, order 8). Tumour to 
normal tissue ratios (T/N ratio) were determined on 1 
h and 5-6 h planar and summed tomographic slices 
incorporating the entire dimensions of the tumour. 
The normal distribution of early and late T/N ratios 
was assessed using a Chi-square test. Differences 
between T/N ratios obtained 1 h and 5-6 h pi. were 
assessed using a paired t-test. 
 
Immunohistochemistry 
 
Immunohistochemistry was performed on 
formalin-fixed paraffin-embedded samples held by 
the Department of Pathology of the University 
Hospital Ghent. The serie consisted of 7 
diagnostically obtained specimens (6 surgical biopsies 
and 1 needle biopsy) and 2 curative specimens. 5 µm 
thick sections were cut and mounted on poly-L-
lysine-coated slides. No antigen retrieval procedure 
was applied. GRP-R expression was evaluated using a 
polyclonal rabbit anti-peptide antibody (generously 
provided by RV Benya, University of Florida) in a 
standard peroxidase-based three-stage procedure (11). 
In all instances, antibodies were used at a 1:500 
dilution, predetermined as optimal by dilution 
titration using small cell lung carcinoma, GRP-R 
expressing tissue, as a positive control. Adjacent non-
malignant glands served as neagtive controls. 
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Microscopic analysis 
 
All specimens were evaluated using a Nikon 
E600 microscope with Axioplan objectives connected 
to a Microlumina ultraresolution scanning digital 
camera (3,380 x 2,700 pixels (Leaf systems, Fort 
Washington, PA)) 
To allow a more direct comparison with 
99mTc RP527 tumour uptake, reflecting both number 
of GRP-R expressing cells and the intensity of GRP-R 
expression by these cells, slides were analysed for 
geographic extent and intensity of staining. Ten or 
more (10+) high-power fields (hpf) containing tumour 
as well as an equal number of normal mucosal fields 
at x400 magnification were evaluated for each slide. 
For geographic extent determination, fields were 
scored as 1+ = <25%, 2+ = 25-50%, 3+ = 50-75%, 
and 4+ = > 75% cells/hpf positive for chromogen. In 
terms of intensity, cells were scored on a three point 
scoring scale, score 1 = low staining intensity, score 2 
= moderate staining intensity, score 3 = high staining 
intensity. Subsequently, a summed score defined as 
the geographic extent score multiplied by the 
corresponding intensity score was determined for 
each tumour. Only slides with a summed score > 4 
were considered positive for GRP-R. 
 
RESULTS 
 
After injection of approximately 555 MBq 
99mTc RP527 ( maximum 3 ng/kg per subject), no 
adverse or subjective effects were noticed in any of 
the subjects. The whole body and tomographic images 
obtained at 1 and 5 h pi. show a diffuse and 
heterogeneous uptake of radioactivity in the normal 
breast tissue, limited to the central, peri-aureolar 
glandular part of the breast.  
Results of the nine patients referred because 
of a clinical diagnosis highly suggestive for breast 
carcinoma are shown in table 1. All 9 patients with 
suspected breast lesions were tumour positive on 
histology. Primary tumour 99mTc RP527 uptake was 
clearly depictable in 8 out of 9 patients. In these 8 
patients, involved lymph nodes and part of the distant 
metastases limited to the bone (occurring in only one 
patient), when present, also showed 99mTc RP527 
uptake. In 99mTc RP527 positive patients, T/N ratios 
derived from tomographic images increased 
significantly from   3.8 (sd : 2.6)  at 1 h p.i. to 11.3 (sd 
: 10.2) and 5-6 h p.i.(p = 0.0007). In contrast to 
normal breast epithelium, increased receptor 
immunostaining was observed in 3 out of 9 primary 
breast tumours, respectively one ductal and two 
lobular carcinoma. Staining was predominantly 
cytoplasmatic and to a lesser extent membranous and 
limited to the well differentiated areas of the tumours 
(see figure 1). All three patients showed clearly 
depictable 99mTc RP527 uptake. In one patient both 
GRP-R staining and 99mTc RP527 uptake were 
absent. In the 5 remaining patients, tumour GRP-R 
staining was negative whereas 99mTc RP527 uptake 
was positive.  
Finally, in none of the 4 bone metastasized 
breast carcinoma patients, nor in the patient 
presenting with a local recurrence involving the 
sternum, osseous involvement was visualised by 
means of 99mTc RP527 scintigraphy.  
 
DISCUSSION 
 
The data presented show 99mTc RP527 
uptake in untreated primary breast carcinoma and 
related metastases, but not in metastases of previously 
treated patients, as well as ubiquitous and 
heterogenous 99mTc RP527 uptake in non-neoplastic 
breast tissue.  
Expression of GRP-R in primary human 
breast carcinoma has been previously studied by other 
methodologies than scintigraphy or 
immunohistochemistry. Using receptor binding 
techniques on tumour homogenates, Halmos et al. 
found that 33% (33/100) of primary breast carcinoma 
were GRP-R positive (12). Contrarywise, using in 
vitro autoradiography Gugger et al. reported a 62% 
(44/71) incidence of GRP receptors in primary breast 
carcinomas (13). In the series presented, 8 out of 9 
(88%) primary breast carcinoma were GRP-R positive 
as measured by in vivo 99mTc RP527 scintigraphy 
whereas only 3 out of eight scintigraphy positive 
patients proved positive on immunohistochemistry. 
The single scintigraphy-negative patient was also 
negative on IHC.  
The different incidence numbers found by 
these differing techniques likely relate to differences 
in patient inclusion and methodology. GRP receptors 
in primary breast carcinoma are often 
heterogeneously distributed. Thus surgical sections of 
tumour fragments obtained for IHC may contain an 
insufficient or unrepresentative number of tumour 
cells to provide a positive staining result. A similar 
heterogenous distribution has been reported 
previously in breast carcinoma for other receptors, 
e.g. alpha estrogen – (αER), progesterone- (PR) and 
somatostatin receptors (14,15). Furthermore, GRP-R 
are thermolabile proteins, thus sub-optimal storage 
and assay conditions for in vitro analysis may destroy 
binding activity leading to false negative IHC results. 
On the other hand, in terms of imaging, peptide 
bombesin derivatives may also bind to neuromedin-B 
receptors (NMB-R), albeit with much lower affinity 
(16). The latter is structurally related to the GRP-R 
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sharing about 50 % of amino acid identity (17). 
However, there is no evidence for NMB-R expression 
in breast carcinoma (13). Additionally, the blood 
clearance half-life of 99mTc RP527 derived from the 
first exponent of the bi-exponential blood clearance 
clearance curve obtained in healthy volunteers is 1.5 
minutes (18). Consequently, binding of 99mTc RP527 
to its corresponding receptors has to occur very 
rapidly following ligand injection which for low 
affinity receptors would result in a faint and probably 
undiscernable tumour uptake of 99mTc RP527 when 
compared to background activity. 
Similar to the findings by Gugger et al. if the 
primary tumour was GRP-R positive as assessed by 
99mTc RP527 scintigraphy, involved lymph nodes 
were also positive and easily depictable, even if a 
single lymph node was involved (13). This is not 
surprising given the high GRP receptor density and 
homogeneous distribution in axillary lymph node 
metastases compared with the lack of GRP receptors 
in surrounding lymphoreticular tissue (high tumour to 
background ratio).  
In the one patient presenting with a primary 
breast carcinoma and osseous involvement, both 
primary but only half of the metastatic bone lesions 
took up 99mTc RP527 probably reflecting the 
difference in clonal origin, with distinct biological 
parameters, of metastatic lesions. On the other hand, 
in the five patients showing either tumour recurrence 
under adjuvant tamoxifen treatment or formerly 
treated for their osseous disease, none of the known 
sites of osseous involvement were positive on 99mTc 
RP527 scintigraphy. The absence of uptake in these 
less differentiated tumours when compared to 
untreated primary tumours as well as the previously 
reported positive association between GRP-R and 
αER (12) and the preferential expression on well 
differentiated areas of tumour as demonstrated by 
immunohistochemistry in this study supports the 
notion that apart from its known mitogenic and 
growth stimulating activivity (2), GRP-R could also 
act as a morphogen or differentiation factor in breast 
carcinoma. A role for GRP-R as a morphogen has 
been previously reported in colon carcinoma (11). In 
this regard, GRP is known to activate multiple 
different intracellular signaling pathways, including 
those that stimulate cell-growth, cell differentiation 
and cell-to cell attachment (2). Depending on the cell 
type, the GRP-R couples to multiple different G 
proteins, including members of the p21ras superfamily 
(19). GRP-R activation of these proteins, including 
p21rho, alters p125fak phosphorylation and influences the 
integrity of focal cell-cell adhesions (20). Because in 
normal development many morphogens act via 
heptaspanning receptors, it is not surprising that some 
have recently been shown to perform this role in 
cancer, e.g. vasoactive intestinal peptide (21,22,23).  
Finally, Gugger et al. described a ubiquitous 
heterogeneous GRP-R expression in normal breast 
ductules and lobules, possibly related to a 
heterogenous innervation pattern of the glands and 
lobules, assuming that GRP plays a neurotransmitter 
role in the breast, as it does in the gastro-intestinal 
tract (13). As the sample size containing non-
neoplastic breast tissue was often small, the authors 
suggested that the percentage of receptor 
heterogeneity may not be representative for the whole 
breast. The 99mTc RP527 images show the 
heterogeneous GRP-R expression to be limited to the 
central, glandular part of the breast.  The reason for 
this heterogeneity and the relative high incidence 
when compared to other hormone receptors e.g. αER 
and PR, warrants further investigation. Possibly GRP-
R, similar to αER and PR may be involved in the 
regulation of mammary cell proliferation and 
differentiation. 
In the direct future, traditional objective end 
points such as simple tumor cell killing or growth 
delay will no longer by themselves be sufficient for 
evaluating response to treatment of novel developed 
anti-cancer treatment modalities (24). The opportunity 
presented is to replace such blunt instruments with 
more specific end-points that are tailor-made for any 
particular molecular target. One of these surrogate 
end-points is the use of nucleic acid microassays and 
related proteomics on tumour biopsy tissue (25,26). 
However, as it will be impossible to obtain 
information on all lesions by these techniques, tumor 
heterogeneity will need to be addressed by alternative 
methodologies. In this regard, the development of 
non-invasive whole body molecular imaging 
approaches is extremely attractive. As companies are 
further reducing the time scale from potential new 
targets to development candidates, these imaging 
techniques will need to be developed simultaneously. 
Over the last few years, potent and selective 
bombesin antagonists have been developed. These 
compounds have shown strong inhibition in both 
animal tumour models and human cell lines and more 
recently also in patients suffering from small cell lung 
carcinoma (2,3,4,5). Therefore, the application of this 
type of compound as a long-term treatment of breast 
cancer may be considered as a future therapeutic goal 
for which the appropriate imaging technique could be 
99mTC RP527 scintigraphy. As shown in the series 
presented, in a subset of patients, 99mTc RP527 
scintigraphy allows visualization of primary breast 
carcinoma as well as involved lymph nodes and 
metastases. These patients may ultimately prove more 
amenable for GRP-R targeted treatments. In this 
regard, the presence of GRP-R was shown to correlate 
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with growth inhibition by an anti-bombesin antibody 
in small cell lung cancer cell lines (27). Additionally 
99mTc RP527 scintigraphy has the potential to 
rapidly (sequential imaging) and non-invasively 
monitor effective dowregulation or blockage by GRP-
R targeted treatments. 
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Figure 1 shows GRP-R staining, using a liquid DAB substrate-chromogen, in breast tumour areas with a more glandular 
structure of a 44-year-old patient presenting with an invasive ductal carcinoma. Corresponding scintigraphic images showing 
99mTc RP527 uptake in the primary tumour as well as in involved lymph node tissue are displayed on page 77. 
 
 
 
 
 
 
table 1. Clinical, pathological and scintigraphic findings in patients presenting with a primary untreated breast carcinoma. 
____________________________________________________________________________________________________ 
Age Histology TNM stage αER PR GRP-R (SS) Imaging  
(yrs)     IHC IHC IHC  ( T/N ratios primary , early/late) 
____________________________________________________________________________________________________ 
37 Inv.Lob.  TxN1M0  0 0 negative  positive (2.1/9.5) 
72 Inv.Lob.  T3N+M0  0 0 negative  positive (1.8/2.1)  
63 Inv.Lob.  T1N0M0  90 90 negative  positive (4.3/12.3) 
69 Inv.Duct.  T2N1M0  75 60 negative  positive  (3.6/4.5) 
44 Inv.Duct.  T3N1M0  0 0 positive (12) positive (3.6/4.6) 
41 Inv.Lob.  TxNxM0  90 80 positive (6) positive (3.4/8.2) 
75 Inv.Duct.  T4N1M0  95 0 negative  positive (8.5/32.7) 
51 Inv.Lob.  TxNxM0  90 50 negative  negative (-/-) 
65 Inv.Lob.  T4N1M1  98 5 positive(6) positive (11.9/39) 
____________________________________________________________________________________________________ 
TNM, Tumour Node Metastases stage, IHC = immunohistochemistry, αER = α estrogen receptor , PR = progesterone receptor, T/N = 
Tumour to normal tissue ratios obtained 1(early) and 4-5 h(late) post injection for the primary tumour, GRP-R = gastrin releasing peptide 
receptor. 
For αER and PR, IHC results are expressed as the percentage of positive tumour cells. For GRP-R, IHC is expressed as a sum score (SS), 
taking into account both intensity and the number of GRP-R positive cells. 
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DISCUSSION 
 
Part I 
 
In part I of the thesis the available 
literature on radiolabelled estradiol derivatives to 
predict response to hormonal treatment in breast 
cancer is reviewed and the human biodistribution, 
dosimetry and metabolisation of trans–1-(4-(2-
diethylaminoethoxy)phenyl)-1,2-diphenyl-5mesyl-
1-pentene (iodomethyl-N,N-diethyltamoxifen ( 
ITX) in healthy volunteers as well as preliminary 
findings on ITX uptake in patients suffering from 
breast carcinoma described.  
It was shown that available data fail to 
substantiate a direct relationship between tumour 
uptake of radiolabelled estradiol derivatives and 
αER (alpha estrogen receptor) status in keeping 
with recent pathophysiological findings 
demonstrating 1) estradiol sequestration and 
retention through other than αER mediated, either 
membrane or non-membrane related, mechanisms 
and 2) an inverse relationship between estradiol 
uptake and local biosynthesis through aromatisation 
and interconversion in αER positive tumours (1). 
Additionally, given the discovery of very high 
affinity αER-like binding sites (Kd, dissociation 
constant < 0.1 nM) (2) and the potential for 
underestimation of αER Kd when using ligand 
binding assays (3), at least part of radiolabelled 
estradiol derivative uptake reflects tumoral 
perfusion rather than the ligand-receptor binding 
process. However, the reduction in cellular uptake, 
membrane sequestration and local biosynthesis of 
estradiol following tamoxifen treatment in αER 
responsive tumours, should allow for early therapy 
respons prediction through rapid sequential 
radiolabeled estradiol scintigraphy (1). The need for 
two scanning episodes however may be considered 
a relative drawback. Consequently an imaging 
technique that could give the same information in 
only one scanning episode is of interest. In this 
regard, assessment of uptake of radiolabelled 
tamoxifen, the mainstay of adjuvant- as well as 
palliative hormonal treatment for breast cancer 
patients, seems a plausible alternative. Not only 
could in vivo imaging of radiolabelled tamoxifen 
tumour uptake, retention and eventually efflux help 
to increase our understanding of tamoxifen’s action, 
it could also help to increase our knowledge of the 
mechanisms involved in resistance to the drug. This 
in turn could provide new targets for the design of 
therapeutic agents which can both effectively 
antagonise the αER-dependent growth pathway, as 
well as circumvent or prevent the emergence of 
inevitable resistance to the drug in vivo.  
Yang et al. previously introduced trans–1-
(4-(2-diethylaminoethoxy)phenyl)-1,2-diphenyl-
5mesyl-1-pentene(iodmethyl-N,N-diethyltamoxifen, 
ITX) as an αER specific anti-oestrogen for breast 
cancer imaging (4). ITX was shown to actively 
reduce the growth of MCF-7 human breast cancer 
cells grown in nude mice, displaying similar growth 
inhibitory activity when compared to tamoxifen. 
Furthermore, in gamma scintigraphic imaging 
studies with ITX, the rabbit uterus uptake could be 
blocked by pretreatment with diethylstilbestrol, 
suggesting the uptake in uterus is via an αER-
mediated process. In terms of biodistribution, 
injection of ITX in Sprague-Dawley and Fisher 344 
rats showed high liver ( 6.764 % + 0.056% injected 
dose/g tissue at 1 h) and lung (2.835% + 0.1596% 
injected dose/g tissue at 1 h) uptake as well as 
progressively increasing tumour to blood ratios 
reaching an optimum at 24h p.i. These findings 
implied that delayed imaging may be required in 
order to increase the ITX tumour to tissue ratio and 
clear the high amounts of drug taken up by the liver 
and lung, allowing better depiction of ITX uptake 
by tumours. The human biodistribution and 
dosimetry study however showed low lung 
retention and rapid hepatobiliary excretion of the 
radiopharmaceutical, resulting in excellent imaging 
conditions for the thoracic region even at early time 
points (1 h ) post injection (5). On the other hand, 
enterohepatic clearance resulted in high 
accumulation of radioactivity in the abdominal 
region, impeding image interpretation. In particular, 
expected physiological uptake in normal uterine 
tissue was difficult to discern from bowel or urinary 
bladder activity. Differences in clearance between 
rats and humans may be due to species differences 
in metabolism, e.g; a more rapid biliary clearance in 
man. Based on an effective dose of 8.44E-04 (SD: 
1.51E-03 mSv/MBq) as calculated by the 
MIRDOSE software (6,7), it was shown that both 
patients and volunteers could easily be investigated 
with 185 MBq ITX, allowing both planar and 
single-photon emission tomography (SPECT) 
imaging.  
As labeled metabolites not only could 
complicate quantitative analysis but also provide an 
image background that could make it difficult to 
identify ITX binding lesions that are small or 
display low ITX binding, the clearance properties 
and metabolite formation of ITX in human plasma 
were studied. ITX was rapidly cleared from human 
plasma according to a two-compartmental model 
with polar metabolites appearing as early as 7.5 min 
p.i., dominating by 20-90 min p.i., in keeping with 
the rapid liver uptake seen in the human 
biodistribution and dosimetry study. As shown by 
Jacolot et al., the metabolisation of tamoxifen 
occurs predominantly in the liver via cytochrome P-
450 enzymes located in the microsomes (8), the 
major metabolite being N-demethyltamoxifen 
accounting for 95-100% of all tamoxifen serum 
metabolites (9). Although N-desmethyltamoxifen  
is an active metabolite, its binding affinity for the 
αER is much lower than the parent compound. It 
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has also been noted to be much less potent than 
tamoxifen at blocking estrogen-induced increases in 
uterine weight. 4-Hydroxylation is another primary 
metabolic pathway for tamoxifen. Although the 
anti-estrogen 4-hydroxytamoxifen is present in 
much smaller concentrations than the N-desmethyl 
metabolite it has a much higher binding affinity to 
the αER. Finally, a number of other metabolites e.g. 
metabolite E, formed by cleavage of the 
dimethylaminoethane basic side chain of tamoxifen 
with subsequent conversion to a hydroxyl group, 
and bisphenol, both eliciting estrogen activity have 
been reported. ITX is structurally similar to 
tamoxifen and the CH3I group does not interfere 
with the demethylation, hydroxylation nor 
deamination proces. Thus, N-desmethyl-ITX as 
well as hydroxylated or deaminated ITX derivatives 
could contribute to a certain extent to human breast 
carcinoma visualisation through direct binding to 
the αER. Yet the radioactive metabolite found in 
man can not be N-demethyl ITX, 4-OH-ITX nor 
any other anticipated metabolic derivative. As N-
dimethyl ITX, 4-OH-ITX or deaminated ITX 
derivatives are more polar than ITX, their HPLC 
retention time should be reduced to a certain degree 
when compared to ITX which was not subtantiated 
by our findings. Rather, the metabolite formed 
eluted with the deadtime of the HPLC column 
suggesting the presence of a very small, highly 
polar metabolite excluding any of the 
abovementionned metabolites. In this regard, the 
biodistribution data in humans showing 
visualisation of the thyroid over time point towards 
free iodine. As iodine is polar and negatively 
charged, with the exception of the thyroid, it has 
only limited access to the intracellular space. 
However, it will increase background activity 
owing to its presence in blood and extracellular 
space. Given the early blood disappearance of ITX 
and the slow decline of metabolites, from the 
standpoint of imaging and quantifying ITX tumour 
uptake, it could be concluded that delayed imaging 
is unlikely to yield better results than imaging 
starting at 15-30 min p.i. 
The feasibility of ITX imaging was 
assessed in patients suffering from primary- and 
known metastatic breast carcinoma, either resistant 
or non-resistant to hormonal treatment. In 
previously untreated patients, ITX uptake was 
related to tumor αER and PR receptor status as 
assessed by immunohistochemistry. In primary 
breast carcinoma patients, increased uptake when 
compared to normal anticipated physiological αER 
expressing breast uptake was seen in αER+ve/PR 
+ve tumours but not in αER+ve/PR-ve and αER-
ve/PR-ve tumours. As shown in the Early Breast 
cancer Trialists meta-analysis, wherease αER 
positivity confers a 50 % response rate to front-line 
endocrine therapy, associated PR positivity, 
reflecting αER functionality, increases the 
likelihood of favorable response to endocrine 
treatment by 20-30% (10). In contrast, patients who 
are αER and PR negative have a less than 5% 
response rate to endocrine treatment. Consequently, 
the lack of discernible ITX uptake when compared 
to background activity in αER+ve/PR-ve tumours 
may prove advantageous for patient response 
prediction to tamoxifen treatment. Johnston et al. 
previously reported that both αER+ve and αER-ve 
tumours progressively accumulate tamoxifen but 
αER+ve tumours do so much more rapidly (11). 
Thus, higher ITX uptake in αER+ve tumours when 
compared to αER-ve tumours was expected. 
Hypothetically, the lack of rapid ITX uptake in 
αER+ve/PR-ve tumours may be explained by a 
lower affinity of tamoxifen to non-functional αER. 
Most breast tumours that acquire resistance 
to tamoxifen in the clinic do so in the face of a 
continued expression of αER. Although a variety of 
mechanisms for acquired tamoxifen resistance in 
the presence of functional αER have been put 
forward (12), available data in humans favor 
reduced intra-tumoural accumulation, possibly due 
to the presence of a currently unknown efflux 
pump. In this regard, Johnston et al. studied intra-
tumoural tamoxifen accumulation matched to serum 
concentrations, in a total of 51 tamoxifen-resistant 
tumours. There was no difference in the serum 
concentrations of tamoxifen or N-
desmethyltamoxifen in patients who developped 
either acquired tamoxifen resistance after a median 
duration of 24 months or were de novo resistant to 
the drug after a median of 4 months, or relapsed 
during adjuvant therapy after a median of 28 
months. However, a significant reduction in intra-
tumoural concentration of tamoxifen in patients 
with acquired, but not de novo, resistance was 
found. In some patients even a ten-fold reduction in 
the ratio of tumour to serum tamoxifen levels was 
found (13). In keeping with these findings, none of 
the hormone resistant metastasised patients studied 
showed depictable tumor ITX uptake when 
compared to normal breast tissue. Data from 
patients who have undergone serial tumour αER 
and PR determinations while undergoing hormonal 
therapy show that immunoreactive αER content 
does not change significantly, while PR postitivity 
rates drop significantly over time, in keeping with 
the fact that induction of PR expression requires 
functional αER. Thus , the findings presented again 
favor a lower affinity of tamoxifen to non-
functional αER. Although persistant occupation of 
αER’s by tamoxifen, taking into conisderation its 
long half-life in vivo, may partly explain these 
findings, its influence is likely to be low as all of 
the patients included were off antiestrogen 
treatment for at leats 6 months.  
Due to referral limitations, no patients in 
whom tamoxifen treatment was going to be initiated 
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because of metastasis consented to participate in 
this study. In these patients, it would have been 
interesting to relate the degree of ITX uptake prior 
to treatment initiation to treatment outcome.  
 
Part 2 
 
In part 2 the rationale behind the 
development of agonist radioligands for 
visualisation of G-protein coupled gastrin-releasing 
peptide/bombesin receptor expressing tumours is 
reviewed and the human biodistribution and 
dosimetry in healthy volunteers of 99mTc RP527, a 
GRP-R agonist, as well as phase I and II studies 
with this ligand in patients suffering from breast 
carcinoma described.  
It was shown that GRP receptor 
scintigraphy could serve several purposes, 
respectively : 1) to further elucidate the role of 
GRP/GRP-R in human maligancies, 2) to determine 
the incidence of functional GRP-R expression in 
various human maligancies in order to define 
diagnostic and staging imaging strategies and 3) to 
allow prediction of therapy responsiveness to 
recently developped bombesin antagonists (14). 
The GRP-R agonist radioligand 99mTc-
RP527 consists of a targeting peptide derived from 
bombesin, linked at its N-terminus via a linker 
group to a peptide sequence which chelates 99mTc 
(15). Both the unlabelled and labelled peptide bind 
GRP receptors with similar affinity as bombesin (IC 
50 value for displacement of 125I-bombesin : 2-6 
nM) and are internalized by GRP-R expressing 
tumours. The human biodistribution of 99mTc 
RP527 demonstrated low lung, myocardial and liver 
uptake allowing early imaging of the 
supradiaphragmatic region and this with a 
dosimetry favorable for clinical SPECT imaging ( 
mean effective dose : 9.5E-03 mSv/MBq) (16). 
Importantly, none of the subjects studied suffered 
from side effects or adverse events. 
Phase I/II studies showed 99mTc RP527 
uptake in untreated primary breast carcinoma and 
related metastases, but not in metastases of 
previously treated patients, as well as ubiquitous 
and heterogeneous 99mTc RP527 uptake in non-
neoplastic breast tisue. The latter finding is in 
keeping with available data on GRP-R expression 
in healthy breast tissue. Tumour activity was more 
easily identified on delayed images (5-6 h p.i.) 
rather than at 1 h p.i. due to a decrease in 
background activity, in keeping with the agonist 
character of 99mTc RP527 (17). Internalisation of 
the GRP/GRP-R complex involves coalescence into 
clathrin coated vesicles and migration to the 
perinuclear space. Whereas a portion of GRP-R will 
recycle back to the cell membrane, the ligand 
remains in the perinuclear space where it is trapped 
in lysosomes. This entrapment prolongs the 
residence time of GRP agonist bound radioactivity 
when compared to antagonists, resulting in a higher 
accumulation of radioactivity in GRP-R positive 
tissues. The progressive and consistent increase in 
tumour to normal tissue ratios suggests a relative 
difference in clearance rate of bound and unbound 
radioligand from tissue and thus a specific tumour 
uptake mechanism in keeping with in vitro and in 
vivo animal data on 99mTc RP527. A GRP-R 
mediated uptake is further supported by the 
visualisation of the pancreas, a GRP-R expressing 
organ, in those patients in whom the pancreas was 
in the field of view of the tomographic images.  
The different incidence numbers for GRP-
R expression found by immunohistochemistry 
(IHC) (33%) and 99mTc RP527 imaging (88%) in 
the studies presented as compared to the 62% and 
33% incidence respectively obtained using 123I-Tyr-
bombesin binding on respectively tumour 
homogenates and in vitro-autoradiography likely 
relate to differences in patient inclusion and 
methodology (17,18,19,20). For example, sampling 
errors and sub-optimal storage and assay conditions 
for in vitro analysis, destroying binding activity, 
may result in false negative IHC staining. On the 
other hand, with regard to imaging, peptide 
bombesin derivatives may also bind to neuromedin-
B receptors, albeit with a much lower affinity. The 
latter is structurally related to the GRP-R sharing 
about 50 % of amino acid identity. However, there 
is no evidence for NMB-R expression in breast 
carcinoma. Additionally, the blood clearance half-
life of 99mTc RP527 derived from the first 
exponent of the bi-exponential blood clearance 
curve obtained in healthy volunteers is 1.5 minutes. 
Consequently, binding of 99mTc RP527 to its 
corresponding receptors has to occur very rapidly 
following ligand injection which for low affinity 
receptors would result in a faint and probably 
undiscernable tumour uptake of 99mTc RP527 
when compared to background activity. Future 
studies addressing the potential of 99mTc RP527 to 
visualise blockage of GRP-R following 
administration of a GRP-R specific targeting 
monoclonal antibody such as 2A11 may further 
confirm the presumed specific binding of 99mTc 
RP527 to GRP-R derived from human tumour cell 
line binding- and internalisation studies in vitro as 
well as from imaging studies in vivo in xenografted 
animals. 
Our findings presented further suggest that 
in breast carcinoma GRP-R is likely expressed early 
in the course of disease and disappears as disease 
progresses, supporting a role for GRP-R as 
differentiation factor or morphogen. A role for GRP-
R as morphogen has been previously also reported in 
colon carcinoma (21). In this regard, GRP is known 
to activate multiple different intracellular signaling 
pathways, including those that stimulate cell-growth, 
cell differentiation and cell-to cell attachment. 
Because in normal development many morphogens 
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act via heptaspanning receptors, it is not surprising 
that some have recently been shown to perform this 
role in cancer, e.g. vasoactive intestinal peptide. 
Larger series, however, are mandatory to confirm this 
finding. If correct though, bombesin antagonists e.g. 
MoAb 2a11 aimed at antagonising the growth 
stimulatory effect of the GRP/GRP-R pathway (22) 
are likely to be only efficacious early in the course of 
breast carcinoma disease.  
 
Future prospects 
 
The relatively low tumour to background 
ratios of ITX,  likely related to the high volume of 
distribution of anti-estrogenic ligands, obviating the 
need for SPECT imaging may be considered a 
relative drawback. Hypothetically, this drawback 
might be overcome by pretreatment with unlabelled 
tamoxifen saturating the low affinity, high capacity 
anti-estrogenic tissue and serum binding sites 
thereby increasing the in-vivo availability of the 
radiopharmaceutical for intratumoural high affinity 
low capacity binding sites.  In addition to testing 
this hypothesis, studies assessing the value of breast 
tumour ITX uptake for predicting response to 
hormonal treatment in both an adjuvant as well as 
palliative setting need to be carried out.  
The favorable breast tumour to background 
ratios and incidence of 99mTc RP527 positive 
primary breast tumour as evidenced by the pilot 
study carried out warrants a comparative study with 
99mTc sestamibi for scintimammography.  
Provided that the preliminary findings 
presented, suggesting GRP-R is a differentiation 
factor, are confirmed, the potential usefulness of 
99mTc RP527 as in vivo prognostic marker e.g. for 
dividing node negative breast carcinoma patients in 
low- or high-risk categories for recurrence, is 
worthy of investigation.  
Finally, the predictive value of 99mTc 
RP527 breast tumour uptake for response to GRP-R 
targeted treatment options e.g. in a neo-adjuvant 
setting comparing chemotherapy alone versus 
chemotherapy plus the GRP-R treatment option 
could be addressed.   
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SUMMARY 
 
To maximize the benefit from routinely 
used e.g. triphenylethylenes and novel hormonal 
treatment modalities e.g. farnesyltransferase 
inhibitors in patients suffering from breast 
carcinoma , objective markers of therapeutic succes 
are mandatory. This could be achieved through in 
vivo characterization of intracellular alpha estrogen 
receptor (αER) and cell surface receptor status. 
This thesis describes both methodological and 
initial clinical studies with 123I-dimethyl-N,N-
tamoxifen (ITX) and 99mTc RP527, radioligands 
for single photon emission tomographic imaging 
(SPECT) of human breast cancer, respectively 
targeted against αER and the G-protein coupled 
Gastrin-releasing peptide cell surface receptor 
(GRP-R ). Results obtained with ITX are described 
in part I, results obtained with 99mTc RP527 are 
described in part II 
 
Part I 
 
First, it was shown that whereas available 
data fail to substantiate a direct relationship 
between breast tumour uptake of radiolabelled 
estradiol derivatives and αER status, in keeping 
with recent pathophysiological findings, sequential 
radiolabelled estradiol scintigraphy has the potential 
for early therapy response prediction to hormonal 
treatrment. However, as this would require two 
scanning episodes, an imaging technique yielding 
the same information in only one scanning episode 
is of major interest. In this regard, assessment of 
uptake of radiolabelled 123I-dimethyl-N,N-
tamoxifen (ITX) seemed a plausible alternative.  
Yang et al. previously reported high liver 
and lung uptake as well as progressively increasing 
tumour to blood ratios of ITX reaching an optimum 
at 24 h p.i. in breast tumour xenografts in Sprague-
Dawley and Fisher 344 rats. This implied that 
delayed imaging may be a prerequisite to allow 
better depiction of ITX uptake. The human 
biodistribution and dosimetry study however 
showed low lung retention and rapid hepatobiliary 
excretion of ITX, resulting in excellent imaging 
conditions for the thoracic region even at early time 
points (1 h) post injection. Based on an effective 
dose of 8.44E-04 (SD : 1.51E-03 mSv/MBq), it was 
shown that both patients and volunteers could easily 
be investigated with 185 MBq ITX.  
As radiolabelled metabolites not only 
could complicate quantitative analysis but also 
provide an image background that could make it 
difficult to identify ITX binding lesions that are 
small or display low ITX binding, we also studied 
the clearance properties and metabolite formation 
of ITX in human plasma. ITX was found to  rapidly 
clear from human plasma according to a two-
compartmental model with polar metabolites 
appearing as early as 7.5 min p.i., dominating by 
20-90 min p.i. As ITX is structurally similar to 
tamoxifen and the CH3I group does not interfere 
with the demethylation proces, the expected 
metabolite was N-demethyl ITX. However 
discordingly, the metabolite found did not display a 
reduction in HPLC retention time as expected. 
Although deaminated and hydroxylated ITX 
derivatives are theoretically possible, the 
biodistribution data in humans showing 
visualisation of the thyroid over time pointed 
towards free iodine. Given the early blood 
disappearance of ITX and the slow decline of 
metabolites, from the standpoint of imaging and 
quantifying ITX uptake, it could be concluded that 
delayed imaging is unlikely to yield better results 
than imaging starting at 15-30 min p.i. 
Subsequently we asssessed the feasibility 
of ITX imaging in patients suffering from primary- 
and known metastatic breast carcinoma, either 
resistant (acquired) or non-resistant to hormonal 
treatment. The preferential uptake of ITX found in 
patients with αER and progesteron receptor (PR) 
positive tumours suggest that ITX imaging may 
prove advantageous for predicting response to 
tamoxifen treatment. On the other hand, the absence 
of ITX uptake in metastatic lesions in the setting of 
acguired resistance favor decreased intra-tumoural 
tamoxifen accumulation as a pathway for acquired 
resistance to tamoxifen in patients suffering from 
breast carcinoma. On the basis of these findings, a 
more extensive study examining the relationship 
between ITX uptake and clinical response and 
resistance to endocrine treatment will be initiated. 
 
Part II 
 
First, it was shown that GRP receptor 
scintigraphy could serve several purposes, 
respectively : 1) to further elucidate the role of 
GRP/GRP-R in human malignancies, 2) to 
determine the incidence of functional GRP-R 
expression in various human malignancies e.g. 
breast carcinoma in order to define diagnostic and 
staging imaging strategies and 3) to allow 
prediction of therapy responsiveness to recently 
developped bombesin antagonists. 
Second, we studied the human 
biodistribution and dosimetry of the GRP-R agonist 
radioligand 99mTc RP527. 99mTc RP527 consists 
of a targeting peptide derived from bombesin, 
linked at its N-terminus via a linker group to a 
peptide sequence which chelates 99mTc. It was 
previously shown that both the unlabelled and 
labelled peptide bind GRP receptors with similar 
affinity as bombesin (IC 50 value for displacement 
of bombesin : 2-6 nM) and that both are 
internalized by GRP-R expressing tumours. The 
human biodistribution of 99mTc RP527 
demonstrated low lung, myocardial and liver uptake 
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allowing early imaging of the supradiaphragmatic 
region and this with a dosimetry favorable for 
clinical SPECT imaging (mean effective dose : 
9.5E-03 mSv/MBq) 
Third, phaseI/II studies with this ligand 
were performed in patients suffering from breast 
carcinoma. In keeping with previous in vitro 
autoradiography studies, 99mTc RP527 was taken 
up in primary-, and lymph node lesions as well as in  
involved bone metastases of de novo diagnosed 
patients. Low  physiological uptake of 99mTc 
RP527 was also seen in normal breast tissue but this 
did not affect tumour depiction. In contrast, patients 
suffering from   hormone resistant breast carcinoma 
failed to take up 99mTc RP527. These findings 
suggested that in breast carcinoma GRP-R is 
expressed early in the course of disease and 
subsequently disappears. Based on these findings, a 
role as morphogen for GRP-R can not be excluded. 
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SAMENVATTING 
 
Ten einde onnodige en niet-efficiënte 
hormonale behandelingen, dit zowel voor wat 
gevalideerde als nieuwere medicaties betreft, te 
vermijden bij borstkanker patiënten zijn objectieve 
merkers van therapeutisch succes noodzakelijk. 
Potentiële kandidaat-merkers zijn radioliganden die 
in vivo karakterisatie van de tumorale α-estrogeen 
receptor (αER) en cel-oppervlak receptoren 
toelaten. Desbetreffende worden in deze thesis 
methodologische en prelimair-klinische studies 
beschreven met 123I-dimethyl-N,N-tamoxifen 
(ITX) en 99mTc RP527, SPET (single photon 
emission tomography) radioliganden gericht tegen 
respektievelijk αER en de G-proteine gekoppelde 
gastrin-releasing peptide receptor (GRP-R). De 
resultaten bekomen met ITX worden beschreven in 
deel I, de resulaten bekomen met 99mTc RP527 
worden beschreven in deel II. 
 
Deel I 
 
Vooreerst wordt aangetoond dat de 
beschikbare literatuurgegevens een direct verband 
tussen tumorale opname van radioactief gemerkte 
estradiol-derivaten, gemeten bij middel van 
scintigrafie, voor beeldvorming en tumor αER 
status (bekomen via immunohistochemie of ligand-
binding studies) niet ondersteunen. Evenwel, in 
overeenstemming met recente pathophysiologische 
bevindingen zou respons predictie op hormonale 
therapiëen mogelijks gerealiseerd kunnen worden 
door middel van sequentiële radioactief gemerkte 
estradiol scintigrafie. Echter dit vergt twee 
opeenvolgende scanning-epsioden en voor klinisch 
gebruik is een éénmalig onderzoek dat dezelfde 
informatie kan verschaffen te prefereren. In deze 
context leek het gebruik van radioactief gemerkt 
tamoxifen (ITX), een courant gebruikt anti-
oestrogeen, een voor de hand liggend alternatief. 
Eerder rapporteerden Yang et al. een hoge 
lever- en longopname evenals een progressieve 
toename in tumor tot bloed ITX ratios, optimaal 24 
ur na radioligand injectie, na injectie van ITX in 
borst-tumor xenograft-bevattende Sprague-Dawley 
and Fisher 344 ratten. Deze bevindingen 
suggereerden dat laattijdige beeldvorming, teneinde 
ITX tumor opname beter in beeld te kunnen 
brengen, noodzakelijk kon zijn. Evenwel de 
humane biodistributie- en dosimetriestudie toonde 
een beperkte retentie in de longen en een snelle 
hepatobiliaire klaring van ITX, resulterend in 
excellente beeldvormingscondities voor de 
thoracale regio vanaf 1 uur na tracer injectie. De 
berekende gemiddelde effectieve dosis betrof 8.44E-
04 (SD 1.51E-03) mSv/MBq. De vooropgestelde 
dosis voor injectie bij patiënten aan de hand van de 
voorvermelde waarde is 185 MBq.  
Radioactieve ITX metabolieten kunnen 
niet enkel de kwantitatieve analyse van ITX tumor 
opname bemoeilijken maar tevens een verhoging 
van de achtergrondactiviteit in de hand werken 
waardoor kleine letsels moeilijker kunnen 
gevisualiseerd worden. Derhalve werden de 
bloedklaringseigenschappen en metaboliet-vorming 
in humaan plasma van ITX bestudeerd. ITX werd 
snel geklaard uit de bloedbaan volgens een twee-
compartimenteel-model waarbij polaire 
metabolieten verschenen in het plasma vanaf 7.5 
min p.i., dominerend rond 20-90 min p.i. Aangezien 
ITX structureel verwant is aan tamoxifen en de 
CH3I groep niet interfereert met demethylering was 
de meest voor de hand liggende metaboliet N-
demethyl ITX. Echter, de gevormde metabolieten 
vertoonden niet de verwachte reductie in HPLC 
(high performance liquid chromatography) retentie 
tijd. Alhoewel gedeamineerde en gehydroxyleerde 
ITX derivaten theoretisch tot de mogelijkheden 
behoren, dient in eerste instantie gedacht te worden 
aan vrij iodide, mede gezien de visualisatie van de 
schildklier bij de gezonde vrijwilligers ondanks 
voorbereiding met lugol (cfr. humane 
biodistributie- en dosimetriestudie). Gezien de 
snelle bloedklaring van ITX en de trage afname van 
plasma ITX metabolieten kon geconcludeerd 
worden dat laattijdige beeldvorming géén 
meerwaarde zou bieden ten opzichte van 
vroegtijdige beeldvorming p.i. 
Vervolgens werden patiënten gescand 
lijdend aan primair of gemetastaseerd 
borstcarcinoma. ITX toonde een preferentiële 
opname in αER en progesteron receptor (PR) 
positieve primaire tumor letsels dewelke een hogere 
respons op hormonale therapie vertonen. Verder 
werd er bij gemetastaseerde, tamoxifen resistente 
patiënten géén ITX opname in tumorletsels 
gevisualiseerd in overeenstemming met andere 
studies die efflux of sterk gereduceerde opname van 
tamoxifen als resistentie-mechanisme opwerpen. 
Deze hoopgevende bevindingen nopen tot verdere 
exploratie van het klinisch potentieel van ITX. 
 
Deel II 
 
In deel II werd eerst ingegaan op de 
potentiële mogelijkheden van GRP-R scintigrafie, 
met name : 1) verdere opheldering van de rol van 
de GRP/GRP-R pathway in humane tumoren, 2) het 
bepalen van de incidentie van GRP-R expressie in 
verschillende humane tumoren teneinde 
diagnostische en follow-up strategiëen met behulp 
van GRP-R radioliganden te ontwikkelen en 3) het 
voorspellen van respons op GRP-R antagonisten, in 
preklinische en klinische evaluatie. 
Vervolgens werd de humane biodistributie en 
dosimetrie van de GRP-R agonist 99mTc RP527 
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beschreven. 99mTc RP527 bestaat uit een merker -
eiwit afgeleid van bombesine, gekoppeld via een 
linker groep aan een eiwitsequentie dewelke 99mTc 
cheleert. Zowel het getechnetieerde als ongemerkt 
RP527 binden GRP-R met een vergelijkbare 
affiniteit als bombesine (IC50 waarden voor 
verdringing van bombesine : 2-6 nM) en worden 
geïnternaliseerd door GRP-R exprimerende 
tumoren. De humane biodistributie en dosimetrie 
van 99mTc RP527 toonde een lage long-, myocard- 
en lever opname, wat visualisatie van 
supradiaphragmatische tumorlokalisaties ten goede 
komt. De berekende gemiddelde effectieve dosis 
bedroeg 9.5E-03 mSv/MBq 
Finaal werden faze I/II studies verricht bij 
borstkankerpatiënten. In overeenstemming met 
beschikbare in vitro-autoradiografie studies werd 
een duidelijke 99mTc RP527 opname vastgesteld in 
primaire- en metastatische letsels van de novo 
gediagnosticeerde patiënten. 99mTc RP527 werd 
ook opgenomen in normaal borstweefsel, evenwel 
zonder dat hierdoor de detecteerbaarheid van de 
primaire tumor bemoeilijkt werd. Opvallend was 
een afwezige opname in tumor letsels van 
gemetastaseerde, tamoxifen resistente tumoren. 
Deze bevindingen sluiten een rol van GRP-R als 
morfogeen, waarbij in de loop van 
tumordedifferentiatie GRP-R verdwijnt, niet uit. 
Verdere exploratie evenals uitbreiding van deze 
bevindingen op een grotere reeks patiënten is 
evenwel aangewezen. 
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RESUME 
 
 
Afin d’éviter des traitements hormonaux 
inutiles et inefficaces du cancer du sain, aussi bien 
dans l’emploi de médications validées que dans 
celui de nouveaux agents thérapeutiques, il nous 
faut rechercher des traceurs démontrant 
objectivement l’efficacité de l’agent thérapeutique. 
Des candidats traceurs potentiels sont les radio-
ligands qui permettent la caractérisation in vivo des 
récepteurs tumoraux α-œstrogène(α-ER) et ceux de 
la membrane cellulaire. A cet effet nous décrivons 
dans cette thèse des études méthodologiques et 
cliniques préliminaires utilisant le 123I-dimethyl-
N,N-tamoxifen (ITX) ainsi que le 99mTc-RP527, 
des radio-ligand SPET dirigés respectivement 
contre le αER et le gastrin releasing 
peptide récepteur (GRP-R). Les résultats obtenus 
avec le ITX sont décrits dans la partie I, ceux 
obtenus avec le 99mTc-RP527 dans la partie II. 
 
Partie I 
 
D’abord nous démontrons que les données 
de la littérature ne soutiennent pas la thèse d’un 
rapport direct entre la captation d’un traceur dérivé 
de l’estradiol (démontré par scintigraphie) et le 
nombre de αER (obtenus via l’immuno-histochimie 
ou via l’étude des liaison ligand). Cependant, 
conformément à de récentes constatations patho-
physiologiques la prédiction de réponse à la 
thérapie hormonale pourrait etre réalisée au moyen 
de scintigraphie séquentielle de captation de 
l’estradiol radioactif. Cette procédure a cependant 
l’inconvénient de requérir deux scans consécutifs et 
pour l’emploi clinique un seul examen pouvant 
fournir les mêmes données est à préférer. Dans ce 
contexte l’utilisation de tamoxifen radioactif semble 
etre une alternative indiquée, le tamoxifen étant un 
anti-œstrogène d’emploi courant. 
Jadis Yang et al. ont rapporté une captation 
élevée à hauteur du foi et des poumons ainsi qu’une 
augmentation progressive du rapport tumeur/sang 
atteignant son maximum 24h après injection du 
radio-ligand. L’injection du ITX fut appliquée dans 
un modèle de tumeur mammaire dans des rats du 
type Sprague-Dawley et Fisher 344. Ces constats 
suggéraient qu’une scintigraphie retardée pourrait 
etre nécessaire pour mettre en évidence la captation 
de l’ITX par la tumeur. Chez l’homme, par contre, 
l’étude de la bio-distribution et de la dosimétrie 
démontrèrent une rétention restreinte dans les 
poumons et une rapide clairance hépato-biliaire de 
l’ITX, avec comme effet d’excellentes images de la 
région thoracique dès 1 h après l’injection du 
traceur 
La dose effective moyenne calculée 
s’élevait à : 8.44E – 04 (DS 1.51E – 03) mSv/MBq. 
Se basant sur cette donnée la dose conseillée, 
injectable au patient,  est de 185 MBq.    
Les métabolites radioactifs de l’ITX 
nuisent à l’analyse quantitative de la captation 
tumorale et car ils procurent une augmentation du 
bruit de fond, ce qui rend plus difficile la 
visualisation de petites lésions. A cet effet nous 
avons étudié la clairance sanguine et la présence de 
métabolites de l’ITX dans le plasma sanguin. La 
clairance de l’ITX dans le sang est rapide et se 
passe selon un modèle bi-compartimental. Des 
métabolites polaires apparaissent dès 7.5 min après 
injection avec un maximum entre 20 et 90 min. 
L’ITX étant analogue au tamoxifen et le groupe 
CH3I n’interférant point dans la déméthylation, le 
métabolite le plus logique est le N-démethyl ITX. 
Cependant, les métabolites en présence ne 
montraient pas la réduction escomptée du temps de 
rétention par HPLC (high performance liquid 
chromatography). Bien que les dérivés dés-aminés 
et hydroxylés du ITX sont théoriquement possible, 
il faut en premier lieu penser à l’iode libre, vu la 
constatation chez les volontaires sains d’une 
visualisation de la glande thyroïde malgré la 
préparation au lugol (cfr : étude de la bio-
distribution et dosimétrie chez l’homme). Vu la 
clairance rapide du ITX et la lente décroissance de 
ses métabolites dans le plasma, une scintigraphie 
retardée ne présenterait pas d’avantage sur la 
scintigraphie précoce. 
Ensuite des scintigraphies furent exécutées 
sur des malades souffrant d’un cancer mammaire 
primaire ou métastasé. Ici l’ITX montrait une 
captation préférentielle sur les récepteurs 
oestrogène et de la progestérone des tumeurs 
primaires ayant une réponse prononcée à la thérapie 
hormonale. De plus, chez les patients métastasés 
résistants au tamoxifen aucune captation de l’ITX 
dans les lésions ne put être visualisée, ce qui est en 
concordance avec d’autres études qui font état 
d’une captation fort réduite du tamoxifen 
qu’expliquerait un mécanisme de rejet. 
Ces constatations prometteuses invitent à 
l’exploration du potentiel clinique du ITX. 
 
Partie II 
 
Dans la seconde partie nous examinons 
d’abord les possibilités potentielles de la 
scintigraphie du GPR-R, notamment :1) éclaircir 
d’avantage le rôle du système GRP/GRP-R dans les 
tumeurs humaines , 2) déterminer l’incidence de 
l’expression GRP-R dans différents types de 
tumeurs humaines afin de développer des stratégies 
diagnostiques et de follow-up au moyen de radio-
ligands du GRP-R et 3) prédire la réponse aux 
antagonistes du GRP-R dans l’évaluation pré-
clinique et clinique. 
Ensuite, nous décrivons la bio-distribution 
et la dosimétrie du 99mTc-RP527, agoniste du 
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GRP-R. Le 99mTc-RP527 consiste en une protéine 
traceuse dérivée de la bombésine ou le 99mTc est 
fixé par chélation. Aussi bien la forme froide du 
RP527 que celle technetiée se fixent au GRP-R 
avec une affinité comparable à celle de la 
bombésine (valeur de supplantation de la 
bombésine IC50 = 2-6 nM) et sont incorporées dans 
les tumeurs à expression GRP-R. La bio-
distribution et la dosimétrie du 99mTcRP527 chez 
l’homme montrent une faible captation dans les 
poumons, le myocarde et le foie, ce qui favorise la 
localisation de tumeurs supra-diaphragmale. La 
dose effective moyenne calculée s’élevait à 9.5E – 
03 mSv/MBq. 
Pour finir, des examens furent fait sur des 
patients en phase I/II de tumeurs mammaire. En 
concordance avec les données d’autoradiographie in 
vitro une nette captation du 99mTcRP527 fut 
constatée dans les lésions primaires et métastasées 
des patients non-traités  ultérieurement? Le 
99mTcRP527 est également capté par le tissu 
mammaire sain, ceci ne gênant pas cependant la 
détection de la tumeur primaire. Ce qui est frappant 
c’est l’absence de captation dans les lésions de 
tumeurs métastasées résistantes au tamoxifen. Ces 
constatations n’excluent point un rôle de 
morphogène du GRP-R par lequel le GRP-R 
disparaîtrait au cours de la différentiation tumorale. 
Une plus ample exploration de ces constatations est 
indiquée sur une série élargie de patients. 
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ADDENDUM 1
 
 
Brief explanation of the techniques used or 
referred to in the thesis. 
 
Planar and tomographic scintigraphy (nuclear 
medicine imaging) 
 
The gamma camera is a camera that allows 
detection of scintillations (flashes of light) 
produced when gamma rays interact with a sodium 
iodide crystal located at the front of the camera. 
The scintillations are detected by photomultiplier 
tubes, and whilst the areas of crystal seen by the 
tubes overlap, the location of each scintillation can 
be computed from the relative responses of each 
tube. The energy of each scintillation is also 
measured from the response of the tubes, and the 
electrical signal to the imaging computer consists of 
the location and the photon energy. In front of the 
crystal is a collimator which is made of lead with 
multiple elongated holes. The holes allow only 
gamma rays that are traveling perpendicularly to the 
crystal face to enter. The gamma photons absorbed 
by the crystal therefore form an image of the 
distribution of radionuclide in front of the camera. 
Aside from generating planar images by aquiring 
data with the head(s) of the camera in fixed 
position, the camera can also rotate around the 
patient to perform emission tomography. This 
technique relies on the acquisition of a number of 
equally spaced planar views (typically 32 or 64) as 
the camera rotates around the patient. These images 
are then reconstructed into tomograms using either 
backprojection algorithms or iterative 
reconstruction algorithms which estimate the 
original three-dimensional distribution of activity 
that would have resulted in the planar views 
actually obtained. When compared to planar 
imaging, tomography has a number of technical 
advantages which include improved image contrast 
because of elimination of overlying structures, and 
the potential for quantification of the tracer uptake. 
 
In situ Hybridisation 
 
In this technique, cloned DNA is labeled in vitro 
using nucleoside triphosphates that are conjugated 
to biotin (a naturally occurring prosthetic group that 
can be used as a molecular tag) or contain a 
fluorescent nucleoside derivative. The labeled DNA 
is placed on a microscopic slide to which 
chromosomes are attached; the sample is then 
treated to allow visualization by light microscopy of 
regions where the labeled DNA probes hybridizes 
to the chromosomes.  
 
Polymerase Chain reaction (PCR) 
 
PCR is a technique that uses genomic DNA that is 
digested into large fragments using a restriction 
enzyme and then is heat-denatured into single 
strands. Two synthetic oligonucleotides 
complementary to the 3’ends of the DNA segment 
of interest are added in great excess to the 
denatured DNA, and the temperature is lowered to 
50-60°C. The genomic DNA remains denatured 
because the complementary strands are too low a 
concentration to encounter each other during the 
period of incubation, but the specific 
oligonucleotides, which are at a very high 
concentration, hybridize with their complementary 
sequences in the genomic DNA. The hybridized 
oligonucleotides then serve as primers for DNA 
chain synthesis, which begins upon addition of a 
supply of deoxynucleotides and a temperature-
resistant DNA polymerase such as that from 
Thermus aquaticus ( a bacterium that lives in hot 
springs). This enzyme, called Taq polymerase, can 
extend the primers at temperatures up to 72°C. 
When synthesis is complete, the whole mixture is 
further heated (to 95°C) to melt the newly formed 
DNA duplexes. When the temperature is lowered 
again, another round of synthesis takes place 
because excess primer is still present. Repeated 
cycles of synthesis (cooling) and melting (heating) 
quickly amplify the sequence of interest. At each 
round, the number of copies of the sequence 
between the primer is doubled; therefore the desired 
sequence increases exponentially.  
 
Southern blotting 
 
Southern blotting is a technique that can identify 
specific restriction fragments in a complex mixture 
of restriction fragments. First, the DNA to be 
analyzed is digested to completion with a restriction 
enzyme. The complex mixture of DNA fragments 
obtained as such is subjected to gel electrophoresis 
to separate the fragments according to size. 
However, many different fragments are of exactly 
the same length and these do not separate from each 
other. The restriction fragments present in the gel 
are subsequently denatured with alkali and 
transferred onto a nitrocellulose filter or nylon 
membrane by blotting. This procedure preserves the 
distribution of the fragments in the gel. The filter is 
then incubated under hybridization conditions with 
a specific radiolabeled DNA probe usually 
generated from a cloned restriction fragment. The 
DNA restriction fragment that is complementary to 
the probe hybridizes, and its location on the filter 
can be revealed by autoradiography.  
 
Northern blotting 
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Northern blotting is a technique used to detect a 
particular RNA in a mixture of RNA’s. A RNA 
sample, often the total cellular RNA content, is 
denatured by treatment with an agent (e.g., 
formaldehyde) that prevents hydrogen bonding 
between base pairs, ensuring that all the RNA 
molecules have an unfolded, linear conformation. 
The individual RNAs then are separated according 
to size by gel electrophoresis and transferred to a 
nitrocellulose filter to which the extended denatured 
RNAs adhere. The filter then is exposed to a 
labeled DNA probe and subjected to 
autoradiography. Because the amount of a specific 
RNA in a sample can be estimated from a Northern 
blot, the procedure is widely used to compare the 
amounts of a particular mRNA in cells under 
different conditions.  
 
Western blotting 
 
Western blotting or immunoblotting is a three-step 
procedure technique commonly used to separate 
proteins and then identify a specific protein of 
interest. The first step in an immunoblot assay is to 
separate a protein mixture on an SDS-
polyacrylamide gel. Then, a paper-thin membrane 
made from nitrocellulose, which tenaciously binds 
most proteins, is applied to the face of the gel. 
When an electric field is applied, proteins are 
driven out of the gel and transferred to the 
membrane. This process is called blotting because 
the membrane picks up the proteins as if it were a 
blot impression of the gel. In the second step, the 
membrane is soaked in a solution of an antibody 
specific for the protein of interest. Only the band 
containing this protein binds to the antibody, 
forming a layer of antibody molecules. In the final 
step, the membrane is “developed” with an enzyme-
linked antibody to identify the band containing the 
protein of interest.  
 
Immunohistochemistry 
 
Immunohistochemistry is a technique that allows 
visualization and identification of molecules in 
sectionned and mounted tissues through the usage 
of specific monoclonal antibodies. In general, fixed 
tissue sections mounted on slides are rehydrated in 
graded alcohols and then rinsed in a running water 
bath. To quench endogenous peroxidase activity, 
slides are preincubated in a hydrogen 
peroxidesolution in a light impermeable chamber. 
After washing and preincubation in blocking 
solution, a primary antibody is applied followed by 
tissue incubation. Subsequently, after washing, 
tissues are then incubated with a biotinylated anti-
rabbit or ant-mouse IgG, washed and incubated 
again, this time with streptavidin conjugated to a 
peroxidase. After washing, slides are incubated 
with a liquid substrate chromogen system for a 
number of minutes allowing for identification of 
bound antibody.  
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ADDENDUM 2 
 
 
 
 
 
 
 
 
Metabolism of tamoxifen (TAM). 
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Structure of iodotamoxifen as compared to tamoxifen. 
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